<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD003875.pub3" GROUP_ID="ORAL" ID="361702070812164387" MERGED_FROM="" MODIFIED="2010-11-30 13:13:44 +0100" MODIFIED_BY="Philip Riley" REVIEW_NO="0076" REVMAN_SUB_VERSION="5.0.25" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="8.3">
<COVER_SHEET MODIFIED="2010-11-30 12:08:09 +0000" MODIFIED_BY="[Empty name]">
<TITLE>Enamel matrix derivative (Emdogain®) for periodontal tissue regeneration in intrabony defects</TITLE>
<CONTACT>
<PERSON ID="15497" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Marco</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Esposito</LAST_NAME>
<SUFFIX/>
<POSITION>Senior Lecturer</POSITION>
<EMAIL_1>espositomarco@hotmail.com</EMAIL_1>
<EMAIL_2>marco.esposito@manchester.ac.uk</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Oral and Maxillofacial Surgery</DEPARTMENT>
<ORGANISATION>School of Dentistry, The University of Manchester</ORGANISATION>
<ADDRESS_1>Coupland 3 Building, Oxford Road</ADDRESS_1>
<ADDRESS_2/>
<CITY>Manchester</CITY>
<ZIP>M13 9PL</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 161 275 6714</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2010-11-30 12:02:51 +0000" MODIFIED_BY="Luisa Fernandez Mauleffinch">
<PERSON ID="15497" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Marco</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Esposito</LAST_NAME>
<SUFFIX/>
<POSITION>Senior Lecturer</POSITION>
<EMAIL_1>espositomarco@hotmail.com</EMAIL_1>
<EMAIL_2>marco.esposito@manchester.ac.uk</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Oral and Maxillofacial Surgery</DEPARTMENT>
<ORGANISATION>School of Dentistry, The University of Manchester</ORGANISATION>
<ADDRESS_1>Coupland 3 Building, Oxford Road</ADDRESS_1>
<ADDRESS_2/>
<CITY>Manchester</CITY>
<ZIP>M13 9PL</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 161 275 6714</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="DDD35C2F82E26AA200BB9F5B869D39C4" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Maria Gabriella</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Grusovin</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>gabri.grusovin@tiscali.it</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Oral and Maxillofacial Surgery</DEPARTMENT>
<ORGANISATION>School of Dentistry, The University of Manchester</ORGANISATION>
<ADDRESS_1>Higher Cambridge Street</ADDRESS_1>
<ADDRESS_2/>
<CITY>Manchester</CITY>
<ZIP>M15 6FH</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="CD0C9A8F82E26AA2008044A21E25219F" ROLE="AUTHOR">
<PREFIX>Mr</PREFIX>
<FIRST_NAME>Nikolaos</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Papanikolaou</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>Nikolaos.Papanikolaou@postgrad.manchester.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Oral and Maxillofacial Surgery</DEPARTMENT>
<ORGANISATION>School of Dentistry, The University of Manchester</ORGANISATION>
<ADDRESS_1>Higher Cambridge Street</ADDRESS_1>
<ADDRESS_2/>
<CITY>Manchester</CITY>
<ZIP>M15 6FH</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="15484" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Paul</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Coulthard</LAST_NAME>
<SUFFIX/>
<POSITION>Professor in Oral and Maxillofacial Surgery</POSITION>
<EMAIL_1>paul.coulthard@manchester.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Oral and Maxillofacial Surgery</DEPARTMENT>
<ORGANISATION>School of Dentistry, The University of Manchester</ORGANISATION>
<ADDRESS_1>Coupland III Building, Oxford Road</ADDRESS_1>
<ADDRESS_2/>
<CITY>Manchester</CITY>
<ZIP>M13 9PL</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="8328" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Helen</FIRST_NAME>
<MIDDLE_INITIALS>V</MIDDLE_INITIALS>
<LAST_NAME>Worthington</LAST_NAME>
<SUFFIX/>
<POSITION>Co-ordinating Editor</POSITION>
<EMAIL_1>helen.worthington@manchester.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Cochrane Oral Health Group</DEPARTMENT>
<ORGANISATION>School of Dentistry, The University of Manchester</ORGANISATION>
<ADDRESS_1>Coupland III Building, Oxford Road</ADDRESS_1>
<ADDRESS_2/>
<CITY>Manchester</CITY>
<ZIP>M13 9PL</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 161 306 0237</PHONE_1>
<PHONE_2>+44 161 275 7819</PHONE_2>
<FAX_1>+44 161 275 7815</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2009-11-05 16:23:09 +0000" MODIFIED_BY="Luisa Fernandez Mauleffinch">
<UP_TO_DATE>
<DATE DAY="27" MONTH="5" YEAR="2009"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="4" MONTH="2" YEAR="2009"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="7" MONTH="10" YEAR="2011"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="2002"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2003"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2009"/>
</DATES>
<WHATS_NEW MODIFIED="2010-11-30 12:08:09 +0000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-11-30 12:08:09 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="30" MONTH="11" YEAR="2010"/>
<DESCRIPTION>
<P>Minor edits to figures to ensure greater clarity.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2010-11-16 16:54:26 +0000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-11-16 16:54:26 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="5" MONTH="11" YEAR="2009"/>
<DESCRIPTION>
<P>Minor edit.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2009-11-05 16:27:57 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="27" MONTH="5" YEAR="2009"/>
<DESCRIPTION>
<P>Change in review authors. Three new included studies.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2009-11-05 16:28:00 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="27" MONTH="5" YEAR="2009"/>
<DESCRIPTION>
<P>Searches updated February 2009.<BR/>
</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-05-27 13:59:17 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="20" MONTH="6" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_MAJOR" MODIFIED="2008-06-20 10:03:33 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="5" MONTH="8" YEAR="2005"/>
<DESCRIPTION>
<P>Substantive amendment. Changes from the first version: Two additional trials were included, and two previously included studies were excluded, but no significant changes in the results and conclusions occurred. Numerous pending and new trials were excluded. Quality assessment was slightly simplified. Data from split-mouth trials were entered in the MetaView. Heterogeneity is now also assessed by I<SUP>2</SUP>. One additional post hoc subgroup analysis evaluating the effects of study design (parallel group versus split-mouth trials) was evaluated. Several previous post hoc subgroup analyses were excluded. Outcome endpoints are now measured at 1, 5 and 10 years. We have added the dichotomous outcome PAL &lt; 2 mm, and calculated NNT.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2009-03-18 09:40:35 +0000" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES>
<SOURCE>
<NAME>School of Dentistry, The University of Manchester</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2010-11-16 15:02:02 +0000" MODIFIED_BY="Helen Worthington">
<SUMMARY MODIFIED="2009-06-28 17:23:41 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-06-20 10:08:38 +0100" MODIFIED_BY="[Empty name]">Enamel matrix derivative (Emdogain®) for periodontal tissue regeneration in intrabony defects</TITLE>
<SUMMARY_BODY MODIFIED="2009-06-28 17:23:41 +0100" MODIFIED_BY="[Empty name]">
<P>Emdogain might have some advantages over other methods of regenerating the tissue<B> </B>supporting teeth lost by gum disease, such as less postoperative complications, but has not been shown to save more compromised teeth or that patients noticed any aesthetic improvement 1 year after its application.<BR/>Bacteria in plaque can cause gum disease (periodontitis) that breaks down tissue supporting teeth. Surgical cleaning tries to stop the disease to save loose teeth. Bone grafting, guided tissue regeneration and enamel matrix derivatives (such as Emdogain) aim to regenerate support tissues. Emdogain contains proteins (derived from developing pig teeth) believed to regenerate tooth attachment. The review found that adjunctive application of Emdogain regenerates about 1 mm more tissue than surgical cleaning alone, although it is unclear to which extent such improvement is noticeable since patients did not find any difference in the aesthetic results. Emdogain showed similar clinical results to guided tissue regeneration, but is simpler to use and determines less complications. Bone substitutes may induce less gum retraction than Emdogain. No serious adverse reactions to Emdogain were reported in trials. </P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2009-07-15 17:00:06 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND>
<P>Periodontitis is a chronic infective disease of the gums caused by bacteria present in dental plaque. This condition induces the breakdown of the tooth supporting apparatus until teeth are lost. Surgery may be indicated to arrest disease progression and regenerate lost tissues. Several surgical techniques have been developed to regenerate periodontal tissues including guided tissue regeneration (GTR), bone grafting (BG) and the use of enamel matrix derivative (EMD). EMD is an extract of enamel matrix and contains amelogenins of various molecular weights. Amelogenins are involved in the formation of enamel and periodontal attachment formation during tooth development.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To test whether EMD is effective, and to compare EMD versus GTR, and various BG procedures for the treatment of intrabony defects.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2009-03-18 10:40:24 +0000" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Oral Health Group Trials Register, CENTRAL, MEDLINE and EMBASE. Several journals were handsearched. No language restrictions were applied. Authors of randomised controlled trials (RCTs) identified, personal contacts and the manufacturer were contacted to identify unpublished trials. Most recent search: February 2009.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>RCTs on patients affected by periodontitis having intrabony defects of at least 3 mm treated with EMD compared with open flap debridement, GTR and various BG procedures with at least 1 year follow up. The outcome measures considered were: tooth loss, changes in probing attachment levels (PAL), pocket depths (PPD), gingival recessions (REC), bone levels from the bottom of the defects on intraoral radiographs, aesthetics and adverse events. The following time-points were to be evaluated: 1, 5 and 10 years.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Screening of eligible studies, assessment of the methodological quality of the trials and data extraction were conducted in duplicate and independently by two authors. Results were expressed as random-effects models using mean differences for continuous outcomes and risk ratios (RR) for dichotomous outcomes with 95% confidence intervals (CI). It was decided not to investigate heterogeneity, but a sensitivity analysis for the risk of bias of the trials was performed.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2009-07-15 16:59:44 +0100" MODIFIED_BY="[Empty name]">
<P>Thirteen trials were included out of 35 potentially eligible trials. No included trial presented data after 5 years of follow up, therefore all data refer to the 1-year time point. A meta-analysis including nine trials showed that EMD treated sites displayed statistically significant PAL improvements (mean difference 1.1 mm, 95% CI 0.61 to 1.55) and PPD reduction (0.9 mm, 95% CI 0.44 to 1.31) when compared to placebo or control treated sites, though a high degree of heterogeneity was found. Significantly more sites had &lt; 2 mm PAL gain in the control group, with RR 0.53 (95% CI 0.34 to 0.82). Approximately nine patients needed to be treated (NNT) to have one patient gaining 2 mm or more PAL over the control group, based on a prevalence in the control group of 25%. No differences in tooth loss or aesthetic appearance as judged by the patients were observed. When evaluating only trials at a low risk of bias in a sensitivity analysis (four trials), the effect size for PAL was 0.62 mm (95% CI 0.28 to 0.96), which was less than 1.1 mm for the overall result. Comparing EMD with GTR (five trials), GTR showed statistically significant more postoperative complications (three trials, RR 0.12, 95% CI 0.02 to 0.85) and more REC (0.4 mm 95% CI 0.15 to 0.66). The only<B> </B>trial comparing EMD with a bioactive ceramic filler found statistically significant more REC (-1.60 mm, 95% CI -2.74 to -0.46) at the EMG treated sites.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2009-07-15 17:00:06 +0100" MODIFIED_BY="[Empty name]">
<P>One year after its application, EMD significantly improved PAL levels (1.1 mm) and PPD reduction (0.9 mm) when compared to a placebo or control, however, the high degree of heterogeneity observed among trials suggests that results have to be interpreted with great caution. In addition, a sensitivity analysis indicated that the overall treatment effect might be overestimated. The actual clinical advantages of using EMD are unknown. With the exception of significantly more postoperative complications in the GTR group, there was no evidence of clinically important differences between GTR and EMD. Bone substitutes may be associated with less REC than EMD.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2010-11-16 15:02:02 +0000" MODIFIED_BY="Helen Worthington">
<BACKGROUND MODIFIED="2009-07-15 17:03:49 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Evaluating the quality of active-control trials in periodontal research. &lt;/p&gt;&lt;p&gt;Tu YK. Maddick I. Kellett M. Clerehugh V. Gilthorpe MS. &lt;/p&gt;&lt;p&gt;Journal of Clinical Periodontology. 33(2):151-6, 2006 Feb.&lt;/p&gt;" NOTES_MODIFIED="2009-07-15 17:03:49 +0100" NOTES_MODIFIED_BY="[Empty name]">
<P>Periodontitis is a chronic infective disease of the gums with severe forms affecting 10% to 30% of the adult population. Periodontitis rarely affects children and young adults but its prevalence increases steadily with advancing age. Periodontitis is caused by bacteria present in the dental plaque that induce an inflammatory response of the periodontal tissues. In susceptible individuals, this chronic inflammation will induce the breakdown of the periodontal ligament and the surrounding alveolar bone resulting in the formation of periodontal pockets around the roots. Such pockets constitute an ideal protected environment for bacteria and allow the proliferation of more aggressive anaerobic species. The symptoms of periodontitis are often underestimated and may include bleeding and recession of the gums. Painful periodontal abscesses may also form. At a more advanced stage teeth may drift and become increasingly mobile. The end result of the disease is tooth loss.</P>
<P>The treatment of periodontitis is cause-related. The role of the patient's home plaque control is crucial for the success of the therapy, since pockets can be re-colonised by bacteria in a few weeks. Periodontal pockets and root surfaces have to be mechanically cleaned from bacteria (debridement). In the presence of deep pockets surgery may also be indicated to get access to the deepest parts of the pockets to properly clean them and to reduce the depth of the pockets (pocket elimination). The goal of this treatment approach is to stop the progression of periodontal disease. Following treatment, healing occurs by repair without the formation of new periodontal attachment (<LINK REF="REF-Bowers-1989a" TYPE="REFERENCE">Bowers 1989a</LINK>). One of the main concerns for many patients is that after periodontal treatment, the gum recession is increased and may cause aesthetic problems.</P>
<P>The ideal treatment would be to recover the periodontal tissues that have been lost (periodontal tissue regeneration). Several surgical techniques have been developed in an attempt to regenerate periodontal tissues including guided tissue regeneration (GTR), bone grafting (BG) and the use of enamel matrix derivative (EMD). All these treatments have been shown to have the potential to regenerate at least some periodontal attachment in humans (<LINK REF="REF-Bosshardt-2005" TYPE="REFERENCE">Bosshardt 2005</LINK>; <LINK REF="REF-Bowers-1989b" TYPE="REFERENCE">Bowers 1989b</LINK>; <LINK REF="STD-Sculean-1999" TYPE="STUDY">Sculean 1999</LINK>). With GTR, a biocompatible barrier (either resorbable or non-resorbable) is surgically positioned around the root to seal the bone defect and protect the blood clot. A Cochrane review (<LINK REF="REF-Needleman-2006" TYPE="REFERENCE">Needleman 2006</LINK>) has shown that GTR is a little more effective than open flap debridement (1.2 mm in probing attachment levels (PAL) gain and 1.2 mm in probing pocket depths (PPD) reduction), however it was also observed that there was a marked variability of results (heterogeneity) with GTR among various randomised clinical trials. Grafting techniques may include autogenous bone grafting, demineralised freeze-dried bone allografts (DFDBA), animal derived graft materials (xenografts) and synthetic bone graft materials (alloplasts such as hydroxyapatite). The effectiveness of bone grafting for periodontal regeneration in intrabony defects was assessed in two systematic reviews (<LINK REF="REF-Reynolds-2003" TYPE="REFERENCE">Reynolds 2003</LINK>; <LINK REF="REF-Trombelli-2002" TYPE="REFERENCE">Trombelli 2002</LINK>). Both reviews showed improved probing attachment levels when grafts were used when compared to open flap debridement. However, in one review the gain varied considerably with respect to the different materials used (<LINK REF="REF-Trombelli-2002" TYPE="REFERENCE">Trombelli 2002</LINK>). The authors remarked that due to a significant heterogeneity in results between studies, general conclusions need to be drawn with caution (<LINK REF="REF-Trombelli-2002" TYPE="REFERENCE">Trombelli 2002</LINK>). The other review (<LINK REF="REF-Reynolds-2003" TYPE="REFERENCE">Reynolds 2003</LINK>) concluded that there were no differences in clinical outcome measures among various graft types. The results of both these reviews have to be carefully evaluated since the methodological standards were not similar, therefore further research is needed to confirm these findings. Both GTR and grafting procedures are based on the concept of selective exclusion of epithelial cells from colonizing the wound and space maintaining for the blood clot to regenerate the periodontal tissues. In addition, bone grafts may possess osteoinductive and osteoconductive properties.</P>
<P>Periodontal regeneration mediated by EMD is based on a different concept. It is believed that EMD used in periodontal lesions mimics the development of the tooth supporting apparatus during tooth formation (<LINK REF="REF-Hammarstr_x00f6_m-1997a" TYPE="REFERENCE">Hammarström 1997a</LINK>). The enamel matrix is composed of a number of proteins, 90% of which are amelogenins. Such proteins are thought to induce the formation of the periodontal attachment during tooth formation. The only commercially available product using EMD is called Emdogain® and is produced by Biora (Malmö, Sweden). The company has been incorporated into Straumann Biologics Division since 1 April 2004. Originally the product consisted of EMD and a vehicle solution (propylene glycol alginate) that had to be mixed before use. In order to save time and simplify the procedures a ready-to-use Emdogain gel was developed. A large multicentre randomised controlled trial (RCT) showed no differences between the original EMD and the new ready-to-use Emdogain gel formulation (<LINK REF="REF-Bratthall-2001" TYPE="REFERENCE">Bratthall 2001</LINK>). EMD is derived from the developing teeth germs of 6-month old piglets (<LINK REF="REF-Hammarstr_x00f6_m-1997b" TYPE="REFERENCE">Hammarström 1997b</LINK>). Since EMD is a porcine-derived material, it might have the potential of stimulating immune reactions in humans. However, EMDs are quite similar among mammalian species (<LINK REF="REF-Brookes-1995" TYPE="REFERENCE">Brookes 1995</LINK>), thus are less likely to be antigenic. Multiple exposures to EMD during periodontal therapy have been shown to be safe for the patient (<LINK REF="REF-Froum-2004" TYPE="REFERENCE">Froum 2004</LINK>; <LINK REF="REF-Heard-2000" TYPE="REFERENCE">Heard 2000</LINK>; <LINK REF="REF-Zetterstr_x00f6_m-1997" TYPE="REFERENCE">Zetterström 1997</LINK>). It is of interest to note that the vehicle solution (propylene glycol alginate abbreviated in PGA) of the EMD has significant antimicrobial effects on periodontal pathogens (<LINK REF="REF-Arweiler-2002" TYPE="REFERENCE">Arweiler 2002</LINK>; <LINK REF="REF-Sculean-2001c" TYPE="REFERENCE">Sculean 2001c</LINK>; <LINK REF="REF-Spahr-2002" TYPE="REFERENCE">Spahr 2002</LINK>). However, these authors interpreted their findings as Emdogain having antimicrobial properties.</P>
<P>Another issue was whether EMD could improve periodontal wound healing. Despite that EMD was not marketed or approved for non-surgical use, an RCT of 3-week duration suggested that EMD treated sites healed better than contralateral sites treated with the vehicle-control after non surgical root-planing and curettage (<LINK REF="REF-Wennstr_x00f6_m-2002" TYPE="REFERENCE">Wennström 2002</LINK>). However, such findings were not confirmed by two non-placebo controlled RCTs using masked examiners for evaluating the early postsurgical healing events (<LINK REF="STD-Hagenaars-2004" TYPE="STUDY">Hagenaars 2004</LINK>; <LINK REF="STD-Wachtel-2003" TYPE="STUDY">Wachtel 2003</LINK>). A third placebo-controlled RCT (<LINK REF="STD-Grusovin-2009" TYPE="STUDY">Grusovin 2009</LINK>) also failed to show any improved healing at the EMD treated sites.</P>
<P>Two RCTs compared the effect of postoperative antibiotics and no antibiotics in combination with EMD (<LINK REF="STD-Mombelli-2005" TYPE="STUDY">Mombelli 2005</LINK>; <LINK REF="REF-Sculean-2001d" TYPE="REFERENCE">Sculean 2001d</LINK>). Results were contradictory: while one study suggested no advantages in using postoperative antibiotics (<LINK REF="REF-Sculean-2001d" TYPE="REFERENCE">Sculean 2001d</LINK>), the other suggested that additional benefits may be expected using systemic antibiotics (<LINK REF="STD-Mombelli-2005" TYPE="STUDY">Mombelli 2005</LINK>). However, patients of the latter trial were subjected to non-surgical interventions for which EMD is not marketed or approved.</P>
<P>Prior to the application of EMD, most authors 'condition' the root surface after mechanical debridement for gently removing the 'smear layer' (the residual of the debridement procedure). Various 'conditioning agents' have been used and the manufacturer of EMD produces one root conditioner called PrefGel® composed of 24% ethylenediaminetetra-acetic acid (EDTA) at neutral pH. There is no evidence that this procedure is effective (<LINK REF="REF-Sculean-2006" TYPE="REFERENCE">Sculean 2006</LINK>). Traditionally such root conditioners were used to chemically modify the root surface in order to stimulate periodontal regeneration. A systematic review (<LINK REF="REF-Mariotti-2003" TYPE="REFERENCE">Mariotti 2003</LINK>) failed to show the efficacy of such procedures.</P>
<P>EMD is also currently used in many other clinical situations such as the treatment of furcation defects of periodontally compromised teeth, recession, in combinations with GTR, BG, etc. A new recent application, for which EMD was not marketed or approved for, is to promote periodontal attachment regeneration around reimplanted traumatically avulsed teeth or reimplanted ankylotic teeth. However, contradictory results were reported (<LINK REF="REF-Filippi-2001" TYPE="REFERENCE">Filippi 2001</LINK>; <LINK REF="REF-Filippi-2002" TYPE="REFERENCE">Filippi 2002</LINK>; <LINK REF="REF-Schj_x00f8_tt-2005" TYPE="REFERENCE">Schjøtt 2005</LINK>).</P>
<P>In conclusion, there is conflicting evidence on the efficacy of EMD, and a comprehensive high-quality systematic review could be one way to investigate whether EMD is effective or not, and whether there are relevant clinical advantages for the patients in the treatment of intrabony defects.</P>
<P>After the publication of the first version of the present review, four different systematic reviews were published on the efficacy of EMD in the treatment of intrabony defects (<LINK REF="REF-Giannobile-2003" TYPE="REFERENCE">Giannobile 2003</LINK>; <LINK REF="REF-Kalpidis-2002" TYPE="REFERENCE">Kalpidis 2002</LINK>; <LINK REF="REF-Trombelli-2002" TYPE="REFERENCE">Trombelli 2002</LINK>; <LINK REF="REF-Venezia-2004" TYPE="REFERENCE">Venezia 2004</LINK>), reaching, in some cases, rather different conclusions. Many more systematic reviews were published from 2006.</P>
</BACKGROUND>
<OBJECTIVES MODIFIED="2009-07-15 17:04:37 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="2">Primary</HEADING>
<P>To test the null hypothesis of no difference in outcomes using enamel matrix derivative (EMD) versus a placebo or not for the treatment of intrabony defects.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Secondary</HEADING>
<P>To test the null hypothesis of no difference in outcomes between EMD versus guided tissue regeneration (GTR) for the treatment of intrabony defects.<BR/>To test the null hypothesis of no difference in outcomes between EMD versus various 'bone' grafting procedures (BG) for the treatment of intrabony defects.</P>
</SUBSECTION>
</OBJECTIVES>
<METHODS MODIFIED="2009-11-05 16:34:39 +0000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2009-07-15 17:05:17 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES>
<P>Randomised controlled clinical trials (RCTs) testing the efficacy of EMD with at least 1 year follow up. The following time-points were to be evaluated: 1, 5 and 10 years.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Patients affected by chronic, aggressive, or early onset periodontitis with intrabony defects having an intrabony component of at least 3 mm to be treated. The depths of intrabony component could be assessed on intraoral radiographs, but intrasurgical measurements were preferred. Trials clearly including patients with shallower intrabony defects were excluded.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2009-07-15 17:05:17 +0100" MODIFIED_BY="[Empty name]">
<P>(1) Interventions comparing the use of EMD versus a placebo or not. Both the test and the control sites had to undergo the same intervention, surgical or not, the only difference being the use of EMD for the treatment of intrabony defects.<BR/>(2) Interventions comparing the use of EMD versus GTR with barriers for the treatment of intrabony defects.<BR/>(3) Interventions comparing the use of EMD versus various types of BG, including animal-derived and synthetic bone, for the treatment of intrabony defects.<BR/>Trials describing the combined used of EMD, GTR, BG or other growth factors were not included in the present review.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2009-03-22 16:29:29 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Primary</HEADING>
<P>(1) Tooth loss<BR/>(2) Changes in probing attachment level (PAL)<BR/>(3) Aesthetics (better, no change or worse according to patient opinion)<BR/>(4) Postoperative complications and other adverse events.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary</HEADING>
<P>(1) PAL gain &lt; 2 mm (dichotomous outcome only for Emdogain versus control)<BR/>(2) Changes in probing pocket depth (PPD)<BR/>(3) Changes in gingival recession (REC)<BR/>(4) Changes in bone level from the bottom of the defect (BD) in relation to cemento-enamel junction (CEJ) on intraoral radiographs taken with a parallel technique.</P>
</SUBSECTION>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2009-07-15 17:10:21 +0100" MODIFIED_BY="[Empty name]">
<P>For the identification of studies included or considered for this review we developed detailed search strategies for each database searched. These were based on the search strategy developed for MEDLINE via OVID but revised appropriately for each database. The search strategy used a combination of controlled vocabulary and free text terms. The subject search for MEDLINE was combined with the Cochrane Highly Sensitive Search Strategy for identifying reports of randomised controlled trials (RCTs) (as published in Box 6.4.c in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> version 5.0.1 updated September 2008 (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>)). </P>
<SUBSECTION>
<HEADING LEVEL="3">Databases searched</HEADING>
<UL>
<LI>The Cochrane Oral Health Group Trials Register (to 4 February 2009) (<I>see</I> <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>)</LI>
<LI>The Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I> 2009, Issue 1) (<I>see</I> <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>)</LI>
<LI>MEDLINE (1966 to 4 February 2009) (<I>see</I> <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>)</LI>
<LI>EMBASE (1980 to 4 February 2009) (<I>see</I> <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>).</LI>
</UL>
<P>The most recent electronic search was carried out 4 February 2009.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Handsearching</HEADING>
<P>We identified the following journals as being important to be handsearched for this review: <I>European Journal of Oral Implantology,</I> <I>International Journal of Periodontics and Restorative Dentistry, Journal of Clinical Periodontology, Journal of Dental Research, Journal of Periodontal Research, Journal of Periodontology</I>. For further information about the journals being handsearched consult the Cochrane Oral Health Group website <A HREF="http://www.ohg.cochrane.org">www.ohg.cochrane.org</A>. Where these journals had not already been searched as part of the Cochrane Journal Handsearching Programme, the journals were handsearched by one of the review authors.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Language</HEADING>
<P>Non-English papers were included. The Cochrane Oral Health Group had non-English language trials translated.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Unpublished trials</HEADING>
<P>The bibliographies of papers and review articles were checked for studies outside the handsearched journals. Authors of RCTs identified, personal contacts, the old and the new manufacturers were written to in an attempt to identify unpublished or ongoing trials.</P>
</SUBSECTION>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2009-11-05 16:34:39 +0000" MODIFIED_BY="[Empty name]">
<P>The titles and abstracts (when available) of all reports identified were scanned independently by two review authors. For studies appearing to meet the inclusion criteria, or for which there were insufficient data in the title and abstract to make a clear decision, the full report was obtained and was assessed independently by two review authors to establish whether the studies met the inclusion criteria or not. Disagreements were resolved by discussion. Where resolution was not possible, a third author was consulted. All studies meeting the inclusion criteria then underwent validity assessment and data were extracted. Studies rejected at this or subsequent stages were recorded in the table of excluded studies, and reasons for exclusion recorded.</P>
<SUBSECTION>
<HEADING LEVEL="3">Data extraction</HEADING>
<P>Data were extracted by two review authors independently using specially designed data extraction forms. Any disagreement was discussed and a third review author consulted where necessary. Authors of the RCTs were contacted for clarification or missing information. Data were excluded until further clarification was available if agreement could not be reached.<BR/>For each trial the following data were recorded.<BR/>
</P>
<UL>
<LI>Year of publication, country of origin, setting and source of study funding.</LI>
<LI>Details of the participants including demographic characteristics and criteria for inclusion.</LI>
<LI>Details on the study design (parallel group or split mouth).</LI>
<LI>Details on the type of intervention.</LI>
<LI>Details of the outcomes reported, including method of assessment and time intervals.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Risk of bias in included studies</HEADING>
<P>An assessment of the risk of bias in included studies was undertaken following the recommendations as described in Chapter 8 of the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> 5.0.1 (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>). Two review authors independently and in duplicate assessed the risk of bias of all included studies. Any disagreement was discussed and where necessary a third review author was consulted to achieve consensus. Authors were contacted directly for clarification.</P>
<P>A specific tool for assessing risk of bias in each included study was adopted. This comprised a description and a judgement for each entry in a risk of bias table, where each entry addressed a specific feature of the study:</P>
<UL>
<LI>Adequate sequence generation</LI>
<LI>Allocation concealment</LI>
<LI>Blinding (of outcome assessor)</LI>
<LI>Incomplete outcome data addressed</LI>
<LI>Free of selective reporting</LI>
<LI>Free of other bias.</LI>
</UL>
<P>The judgement for each entry involved answering a question, with answers 'Yes' indicating low risk of bias, 'No' indicating high risk of bias, and 'Unclear' indicating either lack of information or uncertainty over the potential for bias.</P>
<P>Allocation concealment was considered adequate if it was centralised (e.g. allocation by a central office unaware of subject characteristics); pharmacy-controlled randomisation; pre-numbered or coded identical containers which were administered serially to participants; on-site computer system combined with allocation kept in a locked unreadable computer file that can be accessed only after the characteristics of an enrolled patient have been entered; sequentially numbered, sealed, opaque envelopes; and other approaches similar to those listed above, along with the reassurance that the person who generated the allocation scheme did not administer it. Some schemes may be innovative and not fit any of the approaches above, but still provide adequate concealment. Approaches to allocation concealment which were considered clearly inadequate included: alternation, use of case record numbers, dates of birth or day of the week, and any procedure that was entirely transparent before allocation, such as an open list of random numbers. Ideally the surgeon should have known the group allocation only after having elevated the flap and debrided the root surface. Those articles or authors stating that allocation concealment procedures were implemented but did not provide details on how this was accomplished, were coded as 'unclear'.</P>
<P>After taking into account the additional information provided by the authors of the trials, the overall risk of bias in included studies was assessed using three key domains: allocation concealment, blinding of outcome assessor (where applicable) and completeness of follow up. Studies were graded into the following categories.</P>
<UL>
<LI>Low risk of bias (plausible bias unlikely to seriously alter the results) if all three key domains were met.</LI>
<LI>High risk of bias (plausible bias that seriously weakens confidence in the results) if one or more key domains were not met.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Data synthesis</HEADING>
<P>For dichotomous outcomes, the estimates of effects of an intervention were expressed as risk ratios together with 95% confidence intervals. For continuous outcomes, mean differences and 95% confidence intervals were used to summarise the data for each group. The statistical unit was the patient and not the treated sites. Numbers needed to treat (NNT) were calculated for PAL gain &lt; 2 mm.</P>
<P>Meta-analyses were done only with studies of similar comparisons reporting the same outcome measures. Risk ratios were combined for dichotomous data, and mean differences for continuous data, using random-effects models. Data from split-mouth and parallel group studies were combined using the procedures outlined in <LINK REF="REF-Elbourne-2002" TYPE="REFERENCE">Elbourne 2002</LINK>. It was necessary to estimate the appropriate standard errors where these were not presented in the trial reports using the methods presented by <LINK REF="REF-Follmann-1992" TYPE="REFERENCE">Follmann 1992</LINK>. We did not have the paired standard deviations for one split-mouth study and we imputed this from the standard deviations of the two groups assuming an intraclass correlation coefficient (icc) of 0.25 as this was the median icc found in a review using the same outcomes from similar studies (<LINK REF="REF-Needleman-2006" TYPE="REFERENCE">Needleman 2006</LINK>). The generic inverse variance procedure in Review Manager (RevMan) 5 was used to combine these two subgroups in the analyses.</P>
<P>The significance of any discrepancies in the estimates of the treatment effects from the different trials was assessed by means of Cochran's test for heterogeneity and the I<SUB>
<SUP>2</SUP>
</SUB> statistic, which describes the percentage total variation across studies that is due to heterogeneity rather than chance. However, it was decided not to try to explain the heterogeneity. The motivation for this choice is the following: in general, subgroup analyses are exploratory investigations to generate hypotheses to be tested in future studies. The results from these are only tentative and need to be confirmed in studies designed specifically for this purpose. Unfortunately, too much weight is often put on the results from subgroup analyses in this area, and too often such tentatively explanations are misused. We have therefore decided not to undertake any subgroup analyses apart from for study design, with subgroups for split-mouth and parallel group studies. Random-effects metaregression analysis was used to investigate whether the effect of study design (post hoc comparison) could explain heterogeneity for PAL, PPD and REC changes in the various comparisons.</P>
<P>Sensitivity analyses were undertaken to examine the effect size in PAL, PPD and REC changes, excluding trials at high risk of bias on the assessment of the overall estimates of effect. In addition, the effect of including unpublished literature on the review's findings was to be examined.</P>
</SUBSECTION>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2010-11-16 14:59:25 +0000" MODIFIED_BY="Helen Worthington">
<STUDY_DESCRIPTION MODIFIED="2009-07-15 18:10:39 +0100" MODIFIED_BY="[Empty name]">
<P>Of the 35 potentially eligible trials, 13 were included in this review (<LINK REF="STD-Crea-2008" TYPE="STUDY">Crea 2008</LINK>; <LINK REF="STD-Francetti-2004" TYPE="STUDY">Francetti 2004</LINK>; <LINK REF="STD-Grusovin-2009" TYPE="STUDY">Grusovin 2009</LINK>; <LINK REF="STD-Heijl-1997" TYPE="STUDY">Heijl 1997</LINK>; <LINK REF="STD-Leknes-2009" TYPE="STUDY">Leknes 2009</LINK>; <LINK REF="STD-Okuda-2000" TYPE="STUDY">Okuda 2000</LINK>; <LINK REF="STD-Pontoriero-1999" TYPE="STUDY">Pontoriero 1999</LINK>; <LINK REF="STD-R_x00f6_sing-2005" TYPE="STUDY">Rösing 2005</LINK>; <LINK REF="STD-Sanz-2004" TYPE="STUDY">Sanz 2004</LINK>; <LINK REF="STD-Silvestri-2000" TYPE="STUDY">Silvestri 2000</LINK>; <LINK REF="STD-Silvestri-2003" TYPE="STUDY">Silvestri 2003</LINK>; <LINK REF="STD-Tonetti-2002" TYPE="STUDY">Tonetti 2002</LINK>; <LINK REF="STD-Zucchelli-2002" TYPE="STUDY">Zucchelli 2002</LINK>) and 22 trials (<LINK REF="STD-Bokan-2006" TYPE="STUDY">Bokan 2006</LINK>; <LINK REF="STD-Chambrone-2007" TYPE="STUDY">Chambrone 2007</LINK>; <LINK REF="STD-Doertbudak-2000" TYPE="STUDY">Doertbudak 2000</LINK>; <LINK REF="STD-Eger-1998" TYPE="STUDY">Eger 1998</LINK>; <LINK REF="STD-Francetti-2005" TYPE="STUDY">Francetti 2005</LINK>; <LINK REF="STD-Froum-2001" TYPE="STUDY">Froum 2001</LINK>; <LINK REF="STD-Ghaffar-2001" TYPE="STUDY">Ghaffar 2001</LINK>; <LINK REF="STD-Hagenaars-2004" TYPE="STUDY">Hagenaars 2004</LINK>; <LINK REF="STD-Lombardo--2000" TYPE="STUDY">Lombardo 2000</LINK>; <LINK REF="STD-Martinez-2001" TYPE="STUDY">Martinez 2001</LINK>; <LINK REF="STD-Martu-2000a" TYPE="STUDY">Martu 2000a</LINK>; <LINK REF="STD-Martu-2000b" TYPE="STUDY">Martu 2000b</LINK>; <LINK REF="STD-Minabe-2002" TYPE="STUDY">Minabe 2002</LINK>; <LINK REF="STD-Mombelli-2005" TYPE="STUDY">Mombelli 2005</LINK>; <LINK REF="STD-Ozcelik-2007" TYPE="STUDY">Ozcelik 2007</LINK>; <LINK REF="STD-Parashis-2004" TYPE="STUDY">Parashis 2004</LINK>; <LINK REF="STD-Sculean-1999" TYPE="STUDY">Sculean 1999</LINK>; <LINK REF="STD-Sculean-2001a" TYPE="STUDY">Sculean 2001a</LINK>; <LINK REF="STD-Sculean-2001b" TYPE="STUDY">Sculean 2001b</LINK>; <LINK REF="STD-Vandana-2004" TYPE="STUDY">Vandana 2004</LINK>; <LINK REF="STD-Wachtel-2003" TYPE="STUDY">Wachtel 2003</LINK>; <LINK REF="STD-Windisch-2002" TYPE="STUDY">Windisch 2002</LINK>) were excluded for the following reasons: not an RCT (<LINK REF="STD-Doertbudak-2000" TYPE="STUDY">Doertbudak 2000</LINK>; <LINK REF="STD-Eger-1998" TYPE="STUDY">Eger 1998</LINK>; <LINK REF="STD-Lombardo--2000" TYPE="STUDY">Lombardo 2000</LINK>; <LINK REF="STD-Martu-2000a" TYPE="STUDY">Martu 2000a</LINK>; <LINK REF="STD-Martu-2000b" TYPE="STUDY">Martu 2000b</LINK>; <LINK REF="STD-Parashis-2004" TYPE="STUDY">Parashis 2004</LINK>), teeth extracted after 6 months (<LINK REF="STD-Sculean-1999" TYPE="STUDY">Sculean 1999</LINK>; <LINK REF="STD-Windisch-2002" TYPE="STUDY">Windisch 2002</LINK>), insufficient data presented (<LINK REF="STD-Ghaffar-2001" TYPE="STUDY">Ghaffar 2001</LINK>; <LINK REF="STD-Martinez-2001" TYPE="STUDY">Martinez 2001</LINK>), data in an inappropriate form (<LINK REF="STD-Francetti-2005" TYPE="STUDY">Francetti 2005</LINK>), data presented in a way that we could not use (<LINK REF="STD-Froum-2001" TYPE="STUDY">Froum 2001</LINK>; <LINK REF="STD-Minabe-2002" TYPE="STUDY">Minabe 2002</LINK>; <LINK REF="STD-Wachtel-2003" TYPE="STUDY">Wachtel 2003</LINK>), too short follow up (<LINK REF="STD-Hagenaars-2004" TYPE="STUDY">Hagenaars 2004</LINK>; <LINK REF="STD-Ozcelik-2007" TYPE="STUDY">Ozcelik 2007</LINK>), included intrabony defects less than 3 mm deep (<LINK REF="STD-Chambrone-2007" TYPE="STUDY">Chambrone 2007</LINK>; <LINK REF="STD-Mombelli-2005" TYPE="STUDY">Mombelli 2005</LINK>; <LINK REF="STD-Sculean-2001a" TYPE="STUDY">Sculean 2001a</LINK>; <LINK REF="STD-Sculean-2001b" TYPE="STUDY">Sculean 2001b</LINK>; <LINK REF="STD-Vandana-2004" TYPE="STUDY">Vandana 2004</LINK>) and different flap techniques were used (<LINK REF="STD-Bokan-2006" TYPE="STUDY">Bokan 2006</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="3">Characteristics of the trial setting and investigators</HEADING>
<P>Nine trials had a parallel group design (<LINK REF="STD-Crea-2008" TYPE="STUDY">Crea 2008</LINK>; <LINK REF="STD-Francetti-2004" TYPE="STUDY">Francetti 2004</LINK>; <LINK REF="STD-Grusovin-2009" TYPE="STUDY">Grusovin 2009</LINK>; <LINK REF="STD-Pontoriero-1999" TYPE="STUDY">Pontoriero 1999</LINK>; <LINK REF="STD-Sanz-2004" TYPE="STUDY">Sanz 2004</LINK>; <LINK REF="STD-Silvestri-2000" TYPE="STUDY">Silvestri 2000</LINK>; <LINK REF="STD-Silvestri-2003" TYPE="STUDY">Silvestri 2003</LINK>; <LINK REF="STD-Tonetti-2002" TYPE="STUDY">Tonetti 2002</LINK>; <LINK REF="STD-Zucchelli-2002" TYPE="STUDY">Zucchelli 2002</LINK>) and five studies were designed as split-mouth trials (<LINK REF="STD-Heijl-1997" TYPE="STUDY">Heijl 1997</LINK>; <LINK REF="STD-Leknes-2009" TYPE="STUDY">Leknes 2009</LINK>; <LINK REF="STD-Okuda-2000" TYPE="STUDY">Okuda 2000</LINK>; <LINK REF="STD-Pontoriero-1999" TYPE="STUDY">Pontoriero 1999</LINK>; <LINK REF="STD-R_x00f6_sing-2005" TYPE="STUDY">Rösing 2005</LINK>). The comparisons made in one trial (<LINK REF="STD-Pontoriero-1999" TYPE="STUDY">Pontoriero 1999</LINK>) were both within patients and between patients. Seven trials were conducted in Italy (<LINK REF="STD-Crea-2008" TYPE="STUDY">Crea 2008</LINK>; <LINK REF="STD-Francetti-2004" TYPE="STUDY">Francetti 2004</LINK>; <LINK REF="STD-Grusovin-2009" TYPE="STUDY">Grusovin 2009</LINK>; <LINK REF="STD-Pontoriero-1999" TYPE="STUDY">Pontoriero 1999</LINK>; <LINK REF="STD-Silvestri-2000" TYPE="STUDY">Silvestri 2000</LINK>; <LINK REF="STD-Silvestri-2003" TYPE="STUDY">Silvestri 2003</LINK>; <LINK REF="STD-Zucchelli-2002" TYPE="STUDY">Zucchelli 2002</LINK>), two in Norway (<LINK REF="STD-Leknes-2009" TYPE="STUDY">Leknes 2009</LINK>; <LINK REF="STD-R_x00f6_sing-2005" TYPE="STUDY">Rösing 2005</LINK>), one in Japan (<LINK REF="STD-Okuda-2000" TYPE="STUDY">Okuda 2000</LINK>), one in Sweden (<LINK REF="STD-Heijl-1997" TYPE="STUDY">Heijl 1997</LINK>), and two trials were conducted in several countries (<LINK REF="STD-Sanz-2004" TYPE="STUDY">Sanz 2004</LINK>; <LINK REF="STD-Tonetti-2002" TYPE="STUDY">Tonetti 2002</LINK>). Six trials were multicentre (<LINK REF="STD-Heijl-1997" TYPE="STUDY">Heijl 1997</LINK>; <LINK REF="STD-Sanz-2004" TYPE="STUDY">Sanz 2004</LINK>; <LINK REF="STD-Silvestri-2000" TYPE="STUDY">Silvestri 2000</LINK>; <LINK REF="STD-Silvestri-2003" TYPE="STUDY">Silvestri 2003</LINK>; <LINK REF="STD-Tonetti-2002" TYPE="STUDY">Tonetti 2002</LINK>; <LINK REF="STD-Zucchelli-2002" TYPE="STUDY">Zucchelli 2002</LINK>). Five trials were conducted in university dental clinics (<LINK REF="STD-Crea-2008" TYPE="STUDY">Crea 2008</LINK>; <LINK REF="STD-Francetti-2004" TYPE="STUDY">Francetti 2004</LINK>; <LINK REF="STD-Leknes-2009" TYPE="STUDY">Leknes 2009</LINK>; <LINK REF="STD-Okuda-2000" TYPE="STUDY">Okuda 2000</LINK>; <LINK REF="STD-R_x00f6_sing-2005" TYPE="STUDY">Rösing 2005</LINK>), five were conducted both in university dental clinics and private practices (<LINK REF="STD-Sanz-2004" TYPE="STUDY">Sanz 2004</LINK>; <LINK REF="STD-Silvestri-2000" TYPE="STUDY">Silvestri 2000</LINK>; <LINK REF="STD-Silvestri-2003" TYPE="STUDY">Silvestri 2003</LINK>; <LINK REF="STD-Tonetti-2002" TYPE="STUDY">Tonetti 2002</LINK>; <LINK REF="STD-Zucchelli-2002" TYPE="STUDY">Zucchelli 2002</LINK>), two studies in private practices (<LINK REF="STD-Grusovin-2009" TYPE="STUDY">Grusovin 2009</LINK>; <LINK REF="STD-Pontoriero-1999" TYPE="STUDY">Pontoriero 1999</LINK>) and one trial in a public specialist clinic of periodontology (<LINK REF="STD-Heijl-1997" TYPE="STUDY">Heijl 1997</LINK>). Nine trials were funded or partially supported by manufacturers (<LINK REF="STD-Francetti-2004" TYPE="STUDY">Francetti 2004</LINK>; <LINK REF="STD-Grusovin-2009" TYPE="STUDY">Grusovin 2009</LINK>; <LINK REF="STD-Heijl-1997" TYPE="STUDY">Heijl 1997</LINK>; <LINK REF="STD-Pontoriero-1999" TYPE="STUDY">Pontoriero 1999</LINK>; <LINK REF="STD-R_x00f6_sing-2005" TYPE="STUDY">Rösing 2005</LINK>; <LINK REF="STD-Sanz-2004" TYPE="STUDY">Sanz 2004</LINK>; <LINK REF="STD-Silvestri-2000" TYPE="STUDY">Silvestri 2000</LINK>; <LINK REF="STD-Silvestri-2003" TYPE="STUDY">Silvestri 2003</LINK>; <LINK REF="STD-Tonetti-2002" TYPE="STUDY">Tonetti 2002</LINK>), such information was explicit only in four trials (<LINK REF="STD-Grusovin-2009" TYPE="STUDY">Grusovin 2009</LINK>; <LINK REF="STD-Heijl-1997" TYPE="STUDY">Heijl 1997</LINK>; <LINK REF="STD-Sanz-2004" TYPE="STUDY">Sanz 2004</LINK>; <LINK REF="STD-Tonetti-2002" TYPE="STUDY">Tonetti 2002</LINK>). Four trials were not supported by manufacturers (<LINK REF="STD-Crea-2008" TYPE="STUDY">Crea 2008</LINK>; <LINK REF="STD-Leknes-2009" TYPE="STUDY">Leknes 2009</LINK>; <LINK REF="STD-Okuda-2000" TYPE="STUDY">Okuda 2000</LINK>; <LINK REF="STD-Zucchelli-2002" TYPE="STUDY">Zucchelli 2002</LINK>).</P>
<P>In total 653 patients were treated in the 13 included trials.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Characteristics of the interventions</HEADING>
<P>Nine trials (<LINK REF="STD-Francetti-2004" TYPE="STUDY">Francetti 2004</LINK>; <LINK REF="STD-Grusovin-2009" TYPE="STUDY">Grusovin 2009</LINK>; <LINK REF="STD-Heijl-1997" TYPE="STUDY">Heijl 1997</LINK>; <LINK REF="STD-Okuda-2000" TYPE="STUDY">Okuda 2000</LINK>; <LINK REF="STD-Pontoriero-1999" TYPE="STUDY">Pontoriero 1999</LINK>; <LINK REF="STD-R_x00f6_sing-2005" TYPE="STUDY">Rösing 2005</LINK>; <LINK REF="STD-Silvestri-2000" TYPE="STUDY">Silvestri 2000</LINK>; <LINK REF="STD-Tonetti-2002" TYPE="STUDY">Tonetti 2002</LINK>; <LINK REF="STD-Zucchelli-2002" TYPE="STUDY">Zucchelli 2002</LINK>) compared EMD versus control flap surgery. The surgical techniques for the control flaps were: the modified Widman flap in four trials (<LINK REF="STD-Heijl-1997" TYPE="STUDY">Heijl 1997</LINK>; <LINK REF="STD-Okuda-2000" TYPE="STUDY">Okuda 2000</LINK>; <LINK REF="STD-Pontoriero-1999" TYPE="STUDY">Pontoriero 1999</LINK>; <LINK REF="STD-Silvestri-2000" TYPE="STUDY">Silvestri 2000</LINK>) whereas in the other five trials (<LINK REF="STD-Francetti-2004" TYPE="STUDY">Francetti 2004</LINK>; <LINK REF="STD-Grusovin-2009" TYPE="STUDY">Grusovin 2009</LINK>; <LINK REF="STD-R_x00f6_sing-2005" TYPE="STUDY">Rösing 2005</LINK>; <LINK REF="STD-Tonetti-2002" TYPE="STUDY">Tonetti 2002</LINK>; <LINK REF="STD-Zucchelli-2002" TYPE="STUDY">Zucchelli 2002</LINK>) the simplified or the modified papilla preservation techniques were used. In five trials (<LINK REF="STD-Grusovin-2009" TYPE="STUDY">Grusovin 2009</LINK>; <LINK REF="STD-Heijl-1997" TYPE="STUDY">Heijl 1997</LINK>; <LINK REF="STD-Okuda-2000" TYPE="STUDY">Okuda 2000</LINK>; <LINK REF="STD-Pontoriero-1999" TYPE="STUDY">Pontoriero 1999</LINK>; <LINK REF="STD-R_x00f6_sing-2005" TYPE="STUDY">Rösing 2005</LINK>) a placebo (the propylene glycol alginate vehicle gel solution) was used in the control flaps.</P>
<P>Six trials (<LINK REF="STD-Crea-2008" TYPE="STUDY">Crea 2008</LINK>; <LINK REF="STD-Pontoriero-1999" TYPE="STUDY">Pontoriero 1999</LINK>; <LINK REF="STD-Sanz-2004" TYPE="STUDY">Sanz 2004</LINK>; <LINK REF="STD-Silvestri-2000" TYPE="STUDY">Silvestri 2000</LINK>; <LINK REF="STD-Silvestri-2003" TYPE="STUDY">Silvestri 2003</LINK>; <LINK REF="STD-Zucchelli-2002" TYPE="STUDY">Zucchelli 2002</LINK>) compared EMD versus guided tissue regeneration (GTR). In four trials non-resorbable barriers were used (<LINK REF="STD-Crea-2008" TYPE="STUDY">Crea 2008</LINK>; <LINK REF="STD-Silvestri-2000" TYPE="STUDY">Silvestri 2000</LINK>; <LINK REF="STD-Silvestri-2003" TYPE="STUDY">Silvestri 2003</LINK>; <LINK REF="STD-Zucchelli-2002" TYPE="STUDY">Zucchelli 2002</LINK>), in one trial resorbable barriers were used (<LINK REF="STD-Sanz-2004" TYPE="STUDY">Sanz 2004</LINK>), and in one trial (<LINK REF="STD-Pontoriero-1999" TYPE="STUDY">Pontoriero 1999</LINK>) both resorbable and non-resorbable barriers were used, however we used data only from the non-resorbable barrier group since defects shallower than 3 mm were included in the two groups in which resorbable barriers were used. Non-resorbable barriers were removed 6 weeks after their insertion with the exception of one trial (<LINK REF="STD-Pontoriero-1999" TYPE="STUDY">Pontoriero 1999</LINK>) in which they were removed after 4 weeks. For one trial it is unclear when the barriers were removed (<LINK REF="STD-Sanz-2004" TYPE="STUDY">Sanz 2004</LINK>). In one study connective tissue grafts were placed in six patients after barrier removal (<LINK REF="STD-Silvestri-2000" TYPE="STUDY">Silvestri 2000</LINK>).</P>
<P>One trial (<LINK REF="STD-Leknes-2009" TYPE="STUDY">Leknes 2009</LINK>) compared EMD versus a bone graft (BG). A bone substitute made of granulated ceramic (PerioGlas, US Biomaterials, Alachua, FL, USA) was used (<LINK REF="STD-Leknes-2009" TYPE="STUDY">Leknes 2009</LINK>).</P>
<P>The following root-conditioning procedures before EMD application were implemented in all trials.<BR/>
</P>
<UL>
<LI>36% ortho-phosphoric acid for 15 seconds, also to the controls (<LINK REF="STD-Heijl-1997" TYPE="STUDY">Heijl 1997</LINK>; <LINK REF="STD-Okuda-2000" TYPE="STUDY">Okuda 2000</LINK>).</LI>
<LI>24% ethylenediaminetetra-acetic acid (EDTA) gel for 2 minutes only in the EMD treated sites (<LINK REF="STD-Crea-2008" TYPE="STUDY">Crea 2008</LINK>; <LINK REF="STD-Francetti-2004" TYPE="STUDY">Francetti 2004</LINK>; <LINK REF="STD-Leknes-2009" TYPE="STUDY">Leknes 2009</LINK>; <LINK REF="STD-Sanz-2004" TYPE="STUDY">Sanz 2004</LINK>) and also to the open flap debridement control sites (<LINK REF="STD-Grusovin-2009" TYPE="STUDY">Grusovin 2009</LINK>; <LINK REF="STD-Pontoriero-1999" TYPE="STUDY">Pontoriero 1999</LINK>; <LINK REF="STD-R_x00f6_sing-2005" TYPE="STUDY">Rösing 2005</LINK>; <LINK REF="STD-Tonetti-2002" TYPE="STUDY">Tonetti 2002</LINK>; <LINK REF="STD-Zucchelli-2002" TYPE="STUDY">Zucchelli 2002</LINK>) and the GTR sites (<LINK REF="STD-Silvestri-2003" TYPE="STUDY">Silvestri 2003</LINK>; <LINK REF="STD-Zucchelli-2002" TYPE="STUDY">Zucchelli 2002</LINK>).</LI>
<LI>17% EDTA solution for 20 seconds only for the EMD group (<LINK REF="STD-Silvestri-2000" TYPE="STUDY">Silvestri 2000</LINK>).</LI>
</UL>
<P>The following postoperative systemic antibiotics and hygiene procedures were prescribed.<BR/>
</P>
<UL>
<LI>Doxycycline (Vibramycin, Pfizer) 200 mg day 1 and 100 mg for 3 weeks; 0.2% chlorhexidine rinsing for 4 to 6 weeks and no mechanical cleaning in operated areas for 6 weeks (<LINK REF="STD-Heijl-1997" TYPE="STUDY">Heijl 1997</LINK>).</LI>
<LI>Amoxicillin 3 grams 1 hour before surgery; 0.12% chlorhexidine rinsing twice a day for 6 weeks (<LINK REF="STD-Pontoriero-1999" TYPE="STUDY">Pontoriero 1999</LINK>).</LI>
<LI>Cefaclor 750 mg per day for 5 days; 0.12% chlorhexidine rinsing three times a day for 6 weeks and no mechanical cleaning for the first postoperative week (<LINK REF="STD-Okuda-2000" TYPE="STUDY">Okuda 2000</LINK>).</LI>
<LI>Amoxicillin and clavulanic acid (Augmentin, Smith Klein Beecham) 2 grams per day for 6 days; 0.2% chlorhexidine rinsing twice a day for 8 weeks and no mechanical cleaning in operated areas for 2 months (<LINK REF="STD-Silvestri-2000" TYPE="STUDY">Silvestri 2000</LINK>; <LINK REF="STD-Silvestri-2003" TYPE="STUDY">Silvestri 2003</LINK>).</LI>
<LI>Amoxicillin 500 mg three per day for 10 days; chlorhexidine rinsing twice a day for the initial healing period (<LINK REF="STD-R_x00f6_sing-2005" TYPE="STUDY">Rösing 2005</LINK>).</LI>
<LI>In the published article the use of antibiotics was not mentioned but the authors informed us that antibiotics were used in five patients of the Emdogain group and seven control patients; 0.12% chlorhexidine rinsing twice a day for 4 weeks and gentle sweeping of operated areas with a postsurgical toothbrush starting from the third postoperative day without interdental cleaning for 4 weeks (<LINK REF="STD-Tonetti-2002" TYPE="STUDY">Tonetti 2002</LINK>).</LI>
<LI>Amoxicillin and clavulanic acid (Augmentin, Smith Klein Beecham) 1 gram per day starting 1 day before surgery for 6 days thereafter; 0.2% chlorhexidine rinsing twice a day for 11 weeks without interdental cleaning in the operated areas (<LINK REF="STD-Zucchelli-2002" TYPE="STUDY">Zucchelli 2002</LINK>).</LI>
<LI>Amoxicillin and clavulanic acid (Augmentin, Smith Klein Beecham) 1 gram per day for 7 days; 0.2% chlorhexidine rinsing twice a day for 6 weeks without mechanical cleaning in the operated areas (<LINK REF="STD-Francetti-2004" TYPE="STUDY">Francetti 2004</LINK>).</LI>
<LI>In the published article the use of antibiotics was not mentioned but the authors informed us that amoxicillin 500 mg for 4 days was prescribed; 0.12% chlorhexidine rinsing twice a day for 4 weeks and gentle sweeping of operated areas with a postsurgical toothbrush starting from the third postoperative day without interdental cleaning for 4 weeks (<LINK REF="STD-Sanz-2004" TYPE="STUDY">Sanz 2004</LINK>).</LI>
<LI>Amoxicillin 500 grams twice daily starting 1 day before surgery for 6 days; 1% chlorhexidine gel twice daily for 4 weeks (<LINK REF="STD-Crea-2008" TYPE="STUDY">Crea 2008</LINK>).</LI>
<LI>No antibiotics; 0.12% chlorhexidine rinsing twice a day for 3 weeks and gentle sweeping of operated areas with a postsurgical toothbrush starting from the second postoperative week without interdental cleaning for 4 weeks (<LINK REF="STD-Grusovin-2009" TYPE="STUDY">Grusovin 2009</LINK>).</LI>
<LI>No antibiotics; 0.2% chlorhexidine rinsing twice a day for 2 weeks (<LINK REF="STD-Leknes-2009" TYPE="STUDY">Leknes 2009</LINK>).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Characteristics of outcome measures</HEADING>
<UL>
<LI>After contacting the authors, postoperative complications (infection) were available for all trials.</LI>
<LI>Tooth loss was not described in one trial (<LINK REF="STD-Sanz-2004" TYPE="STUDY">Sanz 2004</LINK>).</LI>
<LI>Changes in PAL and PPD were described in all trials.</LI>
<LI>PAL gain &lt; 2 mm was described in six trials (<LINK REF="STD-Francetti-2004" TYPE="STUDY">Francetti 2004</LINK>; <LINK REF="STD-Grusovin-2009" TYPE="STUDY">Grusovin 2009</LINK>; <LINK REF="STD-Heijl-1997" TYPE="STUDY">Heijl 1997</LINK>; <LINK REF="STD-Silvestri-2000" TYPE="STUDY">Silvestri 2000</LINK>; <LINK REF="STD-Tonetti-2002" TYPE="STUDY">Tonetti 2002</LINK>; <LINK REF="STD-Zucchelli-2002" TYPE="STUDY">Zucchelli 2002</LINK>).</LI>
<LI>Four trials did not describe changes in REC (<LINK REF="STD-Francetti-2004" TYPE="STUDY">Francetti 2004</LINK>; <LINK REF="STD-Heijl-1997" TYPE="STUDY">Heijl 1997</LINK>; <LINK REF="STD-R_x00f6_sing-2005" TYPE="STUDY">Rösing 2005</LINK>; <LINK REF="STD-Silvestri-2003" TYPE="STUDY">Silvestri 2003</LINK>).</LI>
<LI>Bone level measurements from the bottom of the defect to the CEJ on intraoral radiographs taken with a paralleling technique were performed in six trials (<LINK REF="STD-Crea-2008" TYPE="STUDY">Crea 2008</LINK>; <LINK REF="STD-Francetti-2004" TYPE="STUDY">Francetti 2004</LINK>; <LINK REF="STD-Grusovin-2009" TYPE="STUDY">Grusovin 2009</LINK>; <LINK REF="STD-Heijl-1997" TYPE="STUDY">Heijl 1997</LINK>; <LINK REF="STD-Okuda-2000" TYPE="STUDY">Okuda 2000</LINK>; <LINK REF="STD-R_x00f6_sing-2005" TYPE="STUDY">Rösing 2005</LINK>). Radiographic data from two studies were not used (<LINK REF="STD-Francetti-2004" TYPE="STUDY">Francetti 2004</LINK>; <LINK REF="STD-Okuda-2000" TYPE="STUDY">Okuda 2000</LINK>) because of data presented as per cent relative area of bone density and not as linear measurements (<LINK REF="STD-Okuda-2000" TYPE="STUDY">Okuda 2000</LINK>) and for not having used a fixed reference mark to assess changes over time (<LINK REF="STD-Francetti-2004" TYPE="STUDY">Francetti 2004</LINK>).</LI>
<LI>Aesthetics according to the patient's opinion was measured in two trials (<LINK REF="STD-Grusovin-2009" TYPE="STUDY">Grusovin 2009</LINK>; <LINK REF="STD-Tonetti-2002" TYPE="STUDY">Tonetti 2002</LINK>). Data could not be combined in a meta-analysis because were presented as continuous data (<LINK REF="STD-Tonetti-2002" TYPE="STUDY">Tonetti 2002</LINK>) or ordinal data (<LINK REF="STD-Grusovin-2009" TYPE="STUDY">Grusovin 2009</LINK>). Patients' opinion from one trial (<LINK REF="STD-Grusovin-2009" TYPE="STUDY">Grusovin 2009</LINK>) was dichotomised into patients not satisfied or patients moderately and highly satisfied with the aesthetics outcome.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Baseline characteristics</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Specific exclusion criteria</HEADING>
<UL>
<LI>None in particular (<LINK REF="STD-Heijl-1997" TYPE="STUDY">Heijl 1997</LINK>; <LINK REF="STD-Leknes-2009" TYPE="STUDY">Leknes 2009</LINK>; <LINK REF="STD-Pontoriero-1999" TYPE="STUDY">Pontoriero 1999</LINK>).</LI>
<LI>Smokers (<LINK REF="STD-Crea-2008" TYPE="STUDY">Crea 2008</LINK>; <LINK REF="STD-Okuda-2000" TYPE="STUDY">Okuda 2000</LINK>; <LINK REF="STD-Silvestri-2000" TYPE="STUDY">Silvestri 2000</LINK>).</LI>
<LI>Medium smokers, i.e. more than 10 cigarettes per day (<LINK REF="STD-Silvestri-2003" TYPE="STUDY">Silvestri 2003</LINK>).</LI>
<LI>Heavy smokers, i.e. more than 20 cigarettes per day (<LINK REF="STD-Sanz-2004" TYPE="STUDY">Sanz 2004</LINK>; <LINK REF="STD-Tonetti-2002" TYPE="STUDY">Tonetti 2002</LINK>; <LINK REF="STD-Zucchelli-2002" TYPE="STUDY">Zucchelli 2002</LINK>).</LI>
<LI>Any periodontal treatment in the previous 2 years (<LINK REF="STD-Okuda-2000" TYPE="STUDY">Okuda 2000</LINK>).</LI>
<LI>Any periodontal treatment in the previous 3 years (<LINK REF="STD-Francetti-2004" TYPE="STUDY">Francetti 2004</LINK>).</LI>
<LI>Antibiotics in the previous 6 months (<LINK REF="STD-Okuda-2000" TYPE="STUDY">Okuda 2000</LINK>; <LINK REF="STD-R_x00f6_sing-2005" TYPE="STUDY">Rösing 2005</LINK>; <LINK REF="STD-Zucchelli-2002" TYPE="STUDY">Zucchelli 2002</LINK>) or 3 months (<LINK REF="STD-Grusovin-2009" TYPE="STUDY">Grusovin 2009</LINK>).</LI>
<LI>Less than 2 mm of attached gingiva (<LINK REF="STD-Francetti-2004" TYPE="STUDY">Francetti 2004</LINK>; <LINK REF="STD-Okuda-2000" TYPE="STUDY">Okuda 2000</LINK>; <LINK REF="STD-Tonetti-2002" TYPE="STUDY">Tonetti 2002</LINK>).</LI>
<LI>Teeth with crowns or supporting fixed partial bridges (<LINK REF="STD-Crea-2008" TYPE="STUDY">Crea 2008</LINK>).</LI>
<LI>Endodontically treated teeth (<LINK REF="STD-Crea-2008" TYPE="STUDY">Crea 2008</LINK>).</LI>
</UL>
<P>In all trials defects did not extend into furcations (in one study, <LINK REF="STD-Grusovin-2009" TYPE="STUDY">Grusovin 2009</LINK>, only teeth with furcation degree 3 were excluded) and patients were selected because they were motivated and had good oral hygiene.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Presurgical treatments</HEADING>
<UL>
<LI>All patients treated with repeated mechanical debridement and some with antimicrobials and surgical interventions over long time periods (<LINK REF="STD-Heijl-1997" TYPE="STUDY">Heijl 1997</LINK>).</LI>
<LI>All patients treated with mechanical debridement and antiseptics and/or antibiotics when indicated (<LINK REF="STD-Tonetti-2002" TYPE="STUDY">Tonetti 2002</LINK>).</LI>
<LI>All patients treated with mechanical debridement (<LINK REF="STD-Crea-2008" TYPE="STUDY">Crea 2008</LINK>; <LINK REF="STD-Francetti-2004" TYPE="STUDY">Francetti 2004</LINK>; <LINK REF="STD-Leknes-2009" TYPE="STUDY">Leknes 2009</LINK>; <LINK REF="STD-Okuda-2000" TYPE="STUDY">Okuda 2000</LINK>; <LINK REF="STD-Pontoriero-1999" TYPE="STUDY">Pontoriero 1999</LINK>; <LINK REF="STD-R_x00f6_sing-2005" TYPE="STUDY">Rösing 2005</LINK>; <LINK REF="STD-Sanz-2004" TYPE="STUDY">Sanz 2004</LINK>; <LINK REF="STD-Silvestri-2000" TYPE="STUDY">Silvestri 2000</LINK>; <LINK REF="STD-Silvestri-2003" TYPE="STUDY">Silvestri 2003</LINK>; <LINK REF="STD-Zucchelli-2002" TYPE="STUDY">Zucchelli 2002</LINK>).</LI>
<LI>All patients treated with mechanical debridement and, when indicated, with surgery (<LINK REF="STD-Grusovin-2009" TYPE="STUDY">Grusovin 2009</LINK>).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Characteristics of the defects</HEADING>
<UL>
<LI>PPD greater or equal to 6 mm and intrabony defects with a depth greater or equal to 4 mm (<LINK REF="STD-Francetti-2004" TYPE="STUDY">Francetti 2004</LINK>; <LINK REF="STD-Heijl-1997" TYPE="STUDY">Heijl 1997</LINK>; <LINK REF="STD-Okuda-2000" TYPE="STUDY">Okuda 2000</LINK>; <LINK REF="STD-Silvestri-2000" TYPE="STUDY">Silvestri 2000</LINK>).</LI>
<LI>PPD greater or equal to 6 mm and intrabony defects with a depth greater or equal to 3 mm (<LINK REF="STD-Pontoriero-1999" TYPE="STUDY">Pontoriero 1999</LINK>).</LI>
<LI>PPD greater or equal to 7 mm and intrabony defects with a depth greater or equal to 3 mm (<LINK REF="STD-Leknes-2009" TYPE="STUDY">Leknes 2009</LINK>; <LINK REF="STD-Zucchelli-2002" TYPE="STUDY">Zucchelli 2002</LINK>).</LI>
<LI>Intrabony defects with a depth greater or equal to 3 mm (<LINK REF="STD-R_x00f6_sing-2005" TYPE="STUDY">Rösing 2005</LINK>; <LINK REF="STD-Sanz-2004" TYPE="STUDY">Sanz 2004</LINK>; <LINK REF="STD-Tonetti-2002" TYPE="STUDY">Tonetti 2002</LINK>).</LI>
<LI>Intrabony defects with a depth greater or equal to 4 mm (<LINK REF="STD-Crea-2008" TYPE="STUDY">Crea 2008</LINK>; <LINK REF="STD-Grusovin-2009" TYPE="STUDY">Grusovin 2009</LINK>; <LINK REF="STD-Silvestri-2003" TYPE="STUDY">Silvestri 2003</LINK>) and wider than 2 mm (<LINK REF="STD-Grusovin-2009" TYPE="STUDY">Grusovin 2009</LINK>).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Baseline comparisons among groups</HEADING>
<UL>
<LI>No statistically significant differences among test and control groups for PAL, PPD and radiographic bone levels (<LINK REF="STD-Heijl-1997" TYPE="STUDY">Heijl 1997</LINK>; <LINK REF="STD-R_x00f6_sing-2005" TYPE="STUDY">Rösing 2005</LINK>).</LI>
<LI>No statistically significant differences among test and control groups for full mouth plaque score (FMPS), full mouth bleeding score (FMBS), PAL, PPD, REC and intrabony components (<LINK REF="STD-Okuda-2000" TYPE="STUDY">Okuda 2000</LINK>; <LINK REF="STD-Pontoriero-1999" TYPE="STUDY">Pontoriero 1999</LINK>; <LINK REF="STD-Sculean-2001a" TYPE="STUDY">Sculean 2001a</LINK>; <LINK REF="STD-Zucchelli-2002" TYPE="STUDY">Zucchelli 2002</LINK>) and distribution of number of walls of the bony defects (<LINK REF="STD-Tonetti-2002" TYPE="STUDY">Tonetti 2002</LINK>) and smokers (<LINK REF="STD-Sanz-2004" TYPE="STUDY">Sanz 2004</LINK>).</LI>
<LI>No statistically significant differences among test and control groups for FMPS, PAL, PPD, REC and intrabony components (<LINK REF="STD-Sculean-2001b" TYPE="STUDY">Sculean 2001b</LINK>).</LI>
<LI>No statistically significant differences among test and control groups for PAL, PPD, REC and intrabony components (<LINK REF="STD-Silvestri-2003" TYPE="STUDY">Silvestri 2003</LINK>).</LI>
<LI>No statistically significant differences among test and control groups for intrabony components (<LINK REF="STD-Francetti-2004" TYPE="STUDY">Francetti 2004</LINK>; <LINK REF="STD-Silvestri-2000" TYPE="STUDY">Silvestri 2000</LINK>).</LI>
<LI>Slightly more compromised periodontal situation in the group treated with GTR than in the EMD group (<LINK REF="STD-Crea-2008" TYPE="STUDY">Crea 2008</LINK>).</LI>
<LI>1 mm deeper and wider circumferential defects in the EMD group than in the placebo group (<LINK REF="STD-Grusovin-2009" TYPE="STUDY">Grusovin 2009</LINK>).</LI>
<LI>More recession (1.3 mm) in the BG group than in the EMD group (<LINK REF="STD-Leknes-2009" TYPE="STUDY">Leknes 2009</LINK>), no data provided on the depth of the infrabony defect component.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Type of maintenance and frequency during the postoperative phase and the follow up of the trials</HEADING>
<UL>
<LI>Supragingival professional tooth cleaning at weeks 2, 4, 6 and thereafter, depending on the level of plaque control, at 3, 6, 9 and 12 months or at 4, 8 and 12 months. At 1 year an individual recall programme was decided and patients were recalled at least every 6 months (<LINK REF="STD-Heijl-1997" TYPE="STUDY">Heijl 1997</LINK>).</LI>
<LI>Supragingival professional tooth cleaning every 15 days; 1 year (<LINK REF="STD-Pontoriero-1999" TYPE="STUDY">Pontoriero 1999</LINK>).</LI>
<LI>Supragingival professional cleaning weekly for the first 6 weeks and thereafter once a month; 1 year (<LINK REF="STD-Okuda-2000" TYPE="STUDY">Okuda 2000</LINK>).</LI>
<LI>Supragingival professional cleaning weekly for the first month and thereafter every 3 months; 1 year (<LINK REF="STD-Leknes-2009" TYPE="STUDY">Leknes 2009</LINK>).</LI>
<LI>Supragingival professional cleaning weekly for the first 6 weeks and thereafter every 3 months; 3 years (<LINK REF="STD-Crea-2008" TYPE="STUDY">Crea 2008</LINK>).</LI>
<LI>Supragingival professional cleaning weekly for the first 8 weeks and thereafter every 3 months; 1 year (<LINK REF="STD-Silvestri-2000" TYPE="STUDY">Silvestri 2000</LINK>; <LINK REF="STD-Silvestri-2003" TYPE="STUDY">Silvestri 2003</LINK>).</LI>
<LI>Supragingival professional tooth cleaning at weeks 1, 2, 3, 4, 6 and thereafter every 3 months; 1 year (<LINK REF="STD-Grusovin-2009" TYPE="STUDY">Grusovin 2009</LINK>; <LINK REF="STD-Sanz-2004" TYPE="STUDY">Sanz 2004</LINK>; <LINK REF="STD-Tonetti-2002" TYPE="STUDY">Tonetti 2002</LINK>).</LI>
<LI>Supragingival professional tooth cleaning once a month; 1 year (<LINK REF="STD-Francetti-2004" TYPE="STUDY">Francetti 2004</LINK>; <LINK REF="STD-Zucchelli-2002" TYPE="STUDY">Zucchelli 2002</LINK>).</LI>
<LI>Supragingival professional tooth cleaning once every 2 weeks for 8 weeks and thereafter every 3 months (<LINK REF="STD-R_x00f6_sing-2005" TYPE="STUDY">Rösing 2005</LINK>).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Duration of follow up</HEADING>
<UL>
<LI>3 years (<LINK REF="STD-Crea-2008" TYPE="STUDY">Crea 2008</LINK>; <LINK REF="STD-Grusovin-2009" TYPE="STUDY">Grusovin 2009</LINK>; <LINK REF="STD-Heijl-1997" TYPE="STUDY">Heijl 1997</LINK>). Data analysed only at 1 year in one study (<LINK REF="STD-Grusovin-2009" TYPE="STUDY">Grusovin 2009</LINK>).</LI>
<LI>2 years (<LINK REF="STD-Francetti-2004" TYPE="STUDY">Francetti 2004</LINK>).</LI>
<LI>1 year (<LINK REF="STD-Leknes-2009" TYPE="STUDY">Leknes 2009</LINK>; <LINK REF="STD-Okuda-2000" TYPE="STUDY">Okuda 2000</LINK>; <LINK REF="STD-Pontoriero-1999" TYPE="STUDY">Pontoriero 1999</LINK>; <LINK REF="STD-R_x00f6_sing-2005" TYPE="STUDY">Rösing 2005</LINK>; <LINK REF="STD-Sanz-2004" TYPE="STUDY">Sanz 2004</LINK>; <LINK REF="STD-Silvestri-2000" TYPE="STUDY">Silvestri 2000</LINK>; <LINK REF="STD-Silvestri-2003" TYPE="STUDY">Silvestri 2003</LINK>; <LINK REF="STD-Tonetti-2002" TYPE="STUDY">Tonetti 2002</LINK>; <LINK REF="STD-Zucchelli-2002" TYPE="STUDY">Zucchelli 2002</LINK>).</LI>
</UL>
<P>In the present review only 1-year data were used with the exception of one trial (<LINK REF="STD-Heijl-1997" TYPE="STUDY">Heijl 1997</LINK>) for which 16-month data were used.</P>
</SUBSECTION>
</SUBSECTION>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2009-07-15 18:23:36 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Allocation concealment</HEADING>
<P>Six papers described clearly the procedure for allocation concealment (<LINK REF="STD-Crea-2008" TYPE="STUDY">Crea 2008</LINK>; <LINK REF="STD-Grusovin-2009" TYPE="STUDY">Grusovin 2009</LINK>; <LINK REF="STD-Heijl-1997" TYPE="STUDY">Heijl 1997</LINK>; <LINK REF="STD-Leknes-2009" TYPE="STUDY">Leknes 2009</LINK>; <LINK REF="STD-R_x00f6_sing-2005" TYPE="STUDY">Rösing 2005</LINK>; <LINK REF="STD-Sanz-2004" TYPE="STUDY">Sanz 2004</LINK>). All the other trials were marked as unclear. All authors replied to our request for additional clarification. With three exceptions, they replied that allocation was concealed without providing any description of the concealment procedures. Thus all those trials were still scored as 'unclear' (<LINK REF="STD-Pontoriero-1999" TYPE="STUDY">Pontoriero 1999</LINK>; <LINK REF="STD-Zucchelli-2002" TYPE="STUDY">Zucchelli 2002</LINK>), as additional information on the method of allocation concealment was not provided. The authors of four trials (<LINK REF="STD-Francetti-2004" TYPE="STUDY">Francetti 2004</LINK>; <LINK REF="STD-Okuda-2000" TYPE="STUDY">Okuda 2000</LINK>; <LINK REF="STD-Silvestri-2003" TYPE="STUDY">Silvestri 2003</LINK>; <LINK REF="STD-Tonetti-2002" TYPE="STUDY">Tonetti 2002</LINK>) described the allocation concealment procedure which was then judged to be adequate. Allocation was not concealed and was scored as 'No' for one trial (<LINK REF="STD-Silvestri-2000" TYPE="STUDY">Silvestri 2000</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Blinding</HEADING>
<P>Outcome assessors were considered to be blinded in seven trials (<LINK REF="STD-Crea-2008" TYPE="STUDY">Crea 2008</LINK>; <LINK REF="STD-Grusovin-2009" TYPE="STUDY">Grusovin 2009</LINK>; <LINK REF="STD-Heijl-1997" TYPE="STUDY">Heijl 1997</LINK>; <LINK REF="STD-Leknes-2009" TYPE="STUDY">Leknes 2009</LINK>; <LINK REF="STD-Okuda-2000" TYPE="STUDY">Okuda 2000</LINK>; <LINK REF="STD-R_x00f6_sing-2005" TYPE="STUDY">Rösing 2005</LINK>; <LINK REF="STD-Zucchelli-2002" TYPE="STUDY">Zucchelli 2002</LINK>), unclear in three cases (<LINK REF="STD-Pontoriero-1999" TYPE="STUDY">Pontoriero 1999</LINK>; <LINK REF="STD-Silvestri-2000" TYPE="STUDY">Silvestri 2000</LINK>; <LINK REF="STD-Silvestri-2003" TYPE="STUDY">Silvestri 2003</LINK>) and not blinded in three cases (<LINK REF="STD-Francetti-2004" TYPE="STUDY">Francetti 2004</LINK>; <LINK REF="STD-Sanz-2004" TYPE="STUDY">Sanz 2004</LINK>; <LINK REF="STD-Tonetti-2002" TYPE="STUDY">Tonetti 2002</LINK>). After contacting the authors one trial was considered blinded (<LINK REF="STD-Pontoriero-1999" TYPE="STUDY">Pontoriero 1999</LINK>), and two were not (<LINK REF="STD-Silvestri-2000" TYPE="STUDY">Silvestri 2000</LINK>; <LINK REF="STD-Silvestri-2003" TYPE="STUDY">Silvestri 2003</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Withdrawals</HEADING>
<P>The reporting and explanation of withdrawals and drop outs were clear in 11 trials (<LINK REF="STD-Crea-2008" TYPE="STUDY">Crea 2008</LINK>; <LINK REF="STD-Francetti-2004" TYPE="STUDY">Francetti 2004</LINK>; <LINK REF="STD-Grusovin-2009" TYPE="STUDY">Grusovin 2009</LINK>; <LINK REF="STD-Heijl-1997" TYPE="STUDY">Heijl 1997</LINK>; <LINK REF="STD-Leknes-2009" TYPE="STUDY">Leknes 2009</LINK>; <LINK REF="STD-Okuda-2000" TYPE="STUDY">Okuda 2000</LINK>; <LINK REF="STD-R_x00f6_sing-2005" TYPE="STUDY">Rösing 2005</LINK>; <LINK REF="STD-Silvestri-2000" TYPE="STUDY">Silvestri 2000</LINK>; <LINK REF="STD-Silvestri-2003" TYPE="STUDY">Silvestri 2003</LINK>; <LINK REF="STD-Tonetti-2002" TYPE="STUDY">Tonetti 2002</LINK>; <LINK REF="STD-Zucchelli-2002" TYPE="STUDY">Zucchelli 2002</LINK>). After correspondence with authors all trials with only one exception (<LINK REF="STD-Sanz-2004" TYPE="STUDY">Sanz 2004</LINK>) were considered to have clear explanations for withdrawals and drop outs.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Sample size</HEADING>
<P>Sample size calculations were performed in six studies (<LINK REF="STD-Grusovin-2009" TYPE="STUDY">Grusovin 2009</LINK>; <LINK REF="STD-Heijl-1997" TYPE="STUDY">Heijl 1997</LINK>; <LINK REF="STD-Leknes-2009" TYPE="STUDY">Leknes 2009</LINK>; <LINK REF="STD-R_x00f6_sing-2005" TYPE="STUDY">Rösing 2005</LINK>; <LINK REF="STD-Sanz-2004" TYPE="STUDY">Sanz 2004</LINK>; <LINK REF="STD-Tonetti-2002" TYPE="STUDY">Tonetti 2002</LINK>). In one trial (<LINK REF="STD-Heijl-1997" TYPE="STUDY">Heijl 1997</LINK>), the sample size was calculated to detect 1 mm difference (assuming standard deviation (SD) of 1 mm) of PAL and radiographic bone gain between test and control with a power (one minus beta) of at least 90% 8 months after surgery. For <LINK REF="STD-Tonetti-2002" TYPE="STUDY">Tonetti 2002</LINK>, the size of the sample required to detect a true difference of 0.5 mm for PAL between test and control with 90% power and with an alpha error of 0.05 was 150 patients completing the trial. <LINK REF="STD-R_x00f6_sing-2005" TYPE="STUDY">Rösing 2005</LINK> was designed to have sufficient power to detect a 2 mm difference in PAL gain, adopting an alpha set at 0.05 and a power of 80%. It was calculated that a paired sample of nine individuals was sufficient. In those studies more patients than needed to detect the assumed differences completed the trials. <LINK REF="STD-Sanz-2004" TYPE="STUDY">Sanz 2004</LINK> was designed to have sufficient power to detect a true difference of 1 mm of PAL gain with alpha set at 0.05 and a power of 0.8. However, the authors concluded that the trial had insufficient power to detect potentially clinically relevant differences. <LINK REF="STD-Grusovin-2009" TYPE="STUDY">Grusovin 2009</LINK> was designed to have sufficient power to detect a true difference of 1 mm difference in mean values between the two groups (49 subjects in each group) with a 90% power, assuming that the common SD was 1.500 using a two-group t-test with a 0.050 two-sided significance level. It was planned to include 50 patients per group. However, the calculated sample size could not be obtained because the Emdogain manufacturer stopped supplying the placebos after the delivery of a first batch of 15 placebos. <LINK REF="STD-Leknes-2009" TYPE="STUDY">Leknes 2009</LINK>, which included 13 patients in a split-mouth study, was powered to detect a difference of 0.5 mm in PAL or PPD assuming a standard deviation of 0.7 mm with the level of significance set at 0.05 and 73% power. This calculation is obviously post hoc, i.e. it was made after the results were known and not a priori to correctly calculate the sample size needed to detect a 0.5 mm difference.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Agreement in methodological assessment</HEADING>
<P>The agreed quality of the included trials after having incorporated the information provided by the authors of the trials is summarized in Additional <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>. Six trials where considered to be at low risk of bias (<LINK REF="STD-Crea-2008" TYPE="STUDY">Crea 2008</LINK>; <LINK REF="STD-Grusovin-2009" TYPE="STUDY">Grusovin 2009</LINK>; <LINK REF="STD-Heijl-1997" TYPE="STUDY">Heijl 1997</LINK>; <LINK REF="STD-Leknes-2009" TYPE="STUDY">Leknes 2009</LINK>; <LINK REF="STD-Okuda-2000" TYPE="STUDY">Okuda 2000</LINK>; <LINK REF="STD-R_x00f6_sing-2005" TYPE="STUDY">Rösing 2005</LINK>), and the remaining trials at high risk of bias.</P>
</SUBSECTION>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2010-11-16 14:59:25 +0000" MODIFIED_BY="Helen Worthington">
<P>Data from parallel and split-mouth trials are analysed as separate subgroups, then combined using the generic inverse variance procedure in RevMan. No trial with a follow up of 5 years was included. It should be remembered that trials combining the use of Emdogain (EMD), guided tissue regeneration (GTR) and bone grafting (BG) as well as other regenerative procedures (e.g. BG plus GTR or EMD plus GTR) were not included in the present review.</P>
<SUBSECTION>
<HEADING LEVEL="3">Emdogain versus control/placebo at 1 year (Comparison 1, Outcomes 1.1 to 1.7)</HEADING>
<P>Nine trials provided data for this comparison between EMD and control or placebo interventions (<LINK REF="STD-Francetti-2004" TYPE="STUDY">Francetti 2004</LINK>; <LINK REF="STD-Grusovin-2009" TYPE="STUDY">Grusovin 2009</LINK>; <LINK REF="STD-Heijl-1997" TYPE="STUDY">Heijl 1997</LINK>; <LINK REF="STD-Okuda-2000" TYPE="STUDY">Okuda 2000</LINK>; <LINK REF="STD-Pontoriero-1999" TYPE="STUDY">Pontoriero 1999</LINK>; <LINK REF="STD-R_x00f6_sing-2005" TYPE="STUDY">Rösing 2005</LINK>; <LINK REF="STD-Silvestri-2000" TYPE="STUDY">Silvestri 2000</LINK>; <LINK REF="STD-Tonetti-2002" TYPE="STUDY">Tonetti 2002</LINK>; <LINK REF="STD-Zucchelli-2002" TYPE="STUDY">Zucchelli 2002</LINK>), four of which were split-mouth placebo-controlled trials (<LINK REF="STD-Heijl-1997" TYPE="STUDY">Heijl 1997</LINK>; <LINK REF="STD-Okuda-2000" TYPE="STUDY">Okuda 2000</LINK>; <LINK REF="STD-Pontoriero-1999" TYPE="STUDY">Pontoriero 1999</LINK>; <LINK REF="STD-R_x00f6_sing-2005" TYPE="STUDY">Rösing 2005</LINK>). The raw data for each trial for PAL, PPD and REC is given in Additional <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>; <LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK>; and <LINK REF="TBL-05" TYPE="TABLE">Table 5</LINK>.</P>
<UL>
<LI>Tooth loss: there were insufficient numbers of teeth lost to undertake an analysis of these. All teeth were extracted for prosthetic reasons. Four EMD treated teeth removed: two in <LINK REF="STD-Heijl-1997" TYPE="STUDY">Heijl 1997</LINK> and two in <LINK REF="STD-R_x00f6_sing-2005" TYPE="STUDY">Rösing 2005</LINK> versus two control teeth removed in <LINK REF="STD-Heijl-1997" TYPE="STUDY">Heijl 1997</LINK>. In another trial (<LINK REF="STD-Grusovin-2009" TYPE="STUDY">Grusovin 2009</LINK>) after 3 years two teeth were judged in need of a second surgical intervention. At the time of judgement the clinician was blinded. Both teeth belonged to the EMD group.</LI>
</UL>
<UL>
<LI>PAL: The meta-analysis of nine trials showed a significant gain in mean PAL for EMD compared with control sites with mean difference of 1.08 mm (95% confidence interval (CI) 0.61 to 1.55, Chi<SUP>2</SUP> = 38.10, 8 degrees of freedom (df), P<SUB>heterogeneity</SUB> &lt; 0.00001, I<SUP>2</SUP>
<SUB> </SUB>= 79%) (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>).</LI>
</UL>
<UL>
<LI>Aesthetics: there were two trials reporting this (<LINK REF="STD-Grusovin-2009" TYPE="STUDY">Grusovin 2009</LINK>; <LINK REF="STD-Tonetti-2002" TYPE="STUDY">Tonetti 2002</LINK>). The trials could not be combined in a meta-analysis but no statistically significant difference between EMD and control treatment was found (<LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>; <LINK REF="FIG-07" TYPE="FIGURE">Figure 7</LINK>).</LI>
</UL>
<UL>
<LI>Complications and other adverse events: no particular adverse events or infection attributable to EMD were recorded in any of the trials with the exception of few problems attributable to the use of postoperative antibiotics. There were no differences in postoperative frequency of subjects reporting pain, intensity of pain recorded on a visual analogue scale (VAS), duration of pain, use of analgesic tablets, edema, hematoma, wound dehiscence, and root sensitivity (<LINK REF="STD-Tonetti-2002" TYPE="STUDY">Tonetti 2002</LINK>).</LI>
</UL>
<UL>
<LI>PAL gain &lt; 2 mm: there were significantly more sites with less than 2 mm PAL gain in the control group risk ratio (RR) 0.53 (95% CI 0.34 to 0.82; Chi<SUP>2</SUP> = 5.3, 5 df, P = 0.39, I<SUP>2 </SUP>= 5%) (six trials) (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>). The number of patients needed to treat (NNT) in the control group to help one patient gain &gt; 2 mm is 9 (95% CI 6 to 22) based on a prevalence of 25% of patients having &lt; 2 mm gain in PAL. The NNT increases to 14 for a prevalence of 15%, and reduces to 4 with a prevalence of 50%.</LI>
</UL>
<UL>
<LI>PPD: The meta-analysis of nine trials showed a significant reduction in mean PPD for EMD compared with control sites with mean difference of 0.88 mm (95% CI 0.44 to 1.31; Chi<SUP>2</SUP> = 25.43, 8 df, P = 0.001, I<SUP>2 </SUP>= 69%) (<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>).</LI>
</UL>
<UL>
<LI>REC: there was no statistically significant difference between the EMD and the control in REC (six trials; P<SUB>effect </SUB>= 0.56, P<SUB>heterogeneity</SUB> = 0.13; I<SUP>2</SUP>
<SUB> </SUB>= 41%) (<LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>).</LI>
</UL>
<UL>
<LI>Radiographic bone level: there was no statistically significant difference between the EMD and the control for radiographic bone gain (three trials; P<SUB>effect </SUB>= 0.27, P<SUB>heterogeneity</SUB> = 0.01; I<SUP>2</SUP> = 78%) (<LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>).</LI>
</UL>
<SUBSECTION>
<HEADING LEVEL="4">Heterogeneity</HEADING>
<P>There was substantial heterogeneity for PAL (P &lt; 0.00001; I<SUP>2</SUP>
<SUB> </SUB>= 79%), PPD (P = 0.001; I<SUP>2 </SUP>= 69%), REC (P = 0.13; I<SUP>2</SUP>
<SUB> </SUB>= 41%) and radiographic bone levels (P = 0.01; I<SUP>2</SUP> = 78%). However, we decided to only investigate this for study design, comparing split-mouth with parallel group studies between EMD and the control group. The results are given in Additional <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK> and none of these were significant.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Sensitivity analysis</HEADING>
<P>Only four studies were judged as at low risk of bias (<LINK REF="STD-Grusovin-2009" TYPE="STUDY">Grusovin 2009</LINK>; <LINK REF="STD-Heijl-1997" TYPE="STUDY">Heijl 1997</LINK>; <LINK REF="STD-Okuda-2000" TYPE="STUDY">Okuda 2000</LINK>; <LINK REF="STD-R_x00f6_sing-2005" TYPE="STUDY">Rösing 2005</LINK>). From the sensitivity analysis including only these four trials, the effect size for PAL was 0.62 mm (95% CI RE 0.28 to 0.96), which was less than 1.08 mm for the overall result, and for PPD was 0.60 mm (95% CI (Random Effects) 0.26 to 0.95) compared with 0.88 mm of the overall result.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Emdogain versus GTR at 1 year (Comparison 2, Outcomes 2.1 to 2.5)</HEADING>
<P>Six trials provided data for this comparison between EMD and GTR (<LINK REF="STD-Crea-2008" TYPE="STUDY">Crea 2008</LINK>; <LINK REF="STD-Pontoriero-1999" TYPE="STUDY">Pontoriero 1999</LINK>; <LINK REF="STD-Sanz-2004" TYPE="STUDY">Sanz 2004</LINK>; <LINK REF="STD-Silvestri-2000" TYPE="STUDY">Silvestri 2000</LINK>; <LINK REF="STD-Silvestri-2003" TYPE="STUDY">Silvestri 2003</LINK>; <LINK REF="STD-Zucchelli-2002" TYPE="STUDY">Zucchelli 2002</LINK>), none of which was a split-mouth trial. The comparison for another split-mouth trial (<LINK REF="STD-Pontoriero-1999" TYPE="STUDY">Pontoriero 1999</LINK>) was between patients randomly allocated to the study groups, not using the split-mouth data. The raw data for each trial for PAL, PPD and REC is given in Additional <LINK REF="TBL-06" TYPE="TABLE">Table 6</LINK>; <LINK REF="TBL-07" TYPE="TABLE">Table 7</LINK>;and <LINK REF="TBL-08" TYPE="TABLE">Table 8</LINK>.</P>
<UL>
<LI>Tooth loss: there were no teeth lost in either group in any of these trials.</LI>
</UL>
<UL>
<LI>PAL: there were no statistically significant differences (six trials) (<LINK REF="FIG-08" TYPE="FIGURE">Figure 8</LINK>).</LI>
</UL>
<UL>
<LI>Aesthetics: no trial evaluated this.</LI>
</UL>
<UL>
<LI>Complications and other adverse events: there were statistically significant more postoperative complications in the GTR group<B> </B>(three trials; P = 0.03), RR 0.12 (95% CI 0.02 to 0.85) (<LINK REF="FIG-11" TYPE="FIGURE">Figure 11</LINK>).</LI>
</UL>
<UL>
<LI>PPD: there were no statistically significant differences (six trials) (<LINK REF="FIG-09" TYPE="FIGURE">Figure 9</LINK>).</LI>
</UL>
<UL>
<LI>REC: there were significant differences between EMD and GTR for change from baseline in REC (five trials), with a significant increase in recession for GTR with mean difference 0.41 mm (95% CI 0.15 to 0.66; Chi<SUP>2</SUP> = 3.10, 4 df, P = 0.54) (<LINK REF="FIG-10" TYPE="FIGURE">Figure 10</LINK>).</LI>
</UL>
<UL>
<LI>Radiographic bone level: there were no statistically significant differences (one trial) (<LINK REF="FIG-12" TYPE="FIGURE">Figure 12</LINK>).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Emdogain versus BG (Comparison 3, Outcomes 3.1 to 3.3)</HEADING>
<P>One trial comparing the use of EMD alone to BG alone was identified (<LINK REF="STD-Leknes-2009" TYPE="STUDY">Leknes 2009</LINK>). The standard deviations of the differences were not given for PAL, PPD and REC. These had to be estimated as described in the methods section. Only data at proximal sites were used.</P>
<UL>
<LI>Tooth loss: no teeth was lost in either group.</LI>
</UL>
<UL>
<LI>PAL: there were no statistically significant differences (<LINK REF="FIG-13" TYPE="FIGURE">Figure 13</LINK>).</LI>
</UL>
<UL>
<LI>Aesthetics: no trial evaluated this.</LI>
</UL>
<UL>
<LI>Complications and other adverse events: none occurred.</LI>
</UL>
<UL>
<LI>PPD: there were no statistically significant differences (<LINK REF="FIG-14" TYPE="FIGURE">Figure 14</LINK>).</LI>
</UL>
<UL>
<LI>REC: there was significantly more REC in the EMD group: -1.60 mm (95% CI -2.74 to -0.46; P = 0.006) (<LINK REF="FIG-15" TYPE="FIGURE">Figure 15</LINK>).<B> </B>A sensitivity analysis putting an intraclass correlation coefficient<B> </B>of zero in, to estimate the standard error also confirmed this statistically significant difference between the groups (P = 0.02).</LI>
</UL>
<UL>
<LI>Radiographic bone level: no trial evaluated this.</LI>
</UL>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2010-11-16 15:02:02 +0000" MODIFIED_BY="Helen Worthington">
<P>The meta-analysis of nine trials showed that the use of EMD led to a statistically significant improvement in average PAL (1.1 mm) and PPD (0.9 mm) over control flap surgery when used in the treatment of intrabony defects after 1 year. However, the high degree of heterogeneity found (I<SUP>2</SUP>
<SUB> </SUB>= 79% for PAL and I<SUP>2</SUP> = 69% for PPD) prevents us from assuming average values as a demonstration of the extent of the difference between the therapies (mean values in the included trials varied from -0.15 to 3.3 mm for PAL gain; from -0.22 to 3.5 mm for PPD reduction). From the sensitivity analysis (i.e. a meta-analysis including only those trials at low risk of bias), the effect size for PAL was reduced to 0.62 mm and for PPD to 0.60 mm. This may indicate that the overall treatment effects of EMD are actually overestimated in the present meta-analysis, and may go someway to explain the heterogeneity.</P>
<P>The number needed to treat (NNT) was calculated to help clinicians understand how many patients would need to be treated with Emdogain to have one more patient gaining 2 mm or more PAL than would have done so in the control group. NNT depends on the prevalence of gaining less than 2 mm PAL in the control group. The mean prevalence was calculated across six studies and NNTs for a range of prevalences considered. For example the mean prevalence in the control group was 25% and the NNT was 9, and this increased to 14 for a reduced prevalence of 15% and reduced to 4 for an increased prevalence of 50%.</P>
<P>Only two trials (<LINK REF="STD-Grusovin-2009" TYPE="STUDY">Grusovin 2009</LINK>; <LINK REF="STD-Tonetti-2002" TYPE="STUDY">Tonetti 2002</LINK>) investigated patient-centred outcomes and aesthetics as perceived by the patients themselves. After 1 year, there were no statistically differences among the EMD and the control groups. In <LINK REF="STD-Tonetti-2002" TYPE="STUDY">Tonetti 2002</LINK> a general statistically significant improvement in patient-centred outcomes was reported. The observation that both groups perceived an improvement in aesthetics despite that in reality some degree of gingival recession had occurred, emphasizes how the patient's judgement may be influenced simply by having received the therapy which they expected to improve their status (Hawthorne effect).</P>
<P>It is interesting to observe that in the multicentre trial in which a multivariate analysis was used to investigate whether the treating centre had an influence on PAL gain (<LINK REF="STD-Tonetti-2002" TYPE="STUDY">Tonetti 2002</LINK>), it was found that the centre effect (worse versus better) was statistically significant (-2.6 mm (SD 0.6)), while the overall treatment effect recalculated in the present review, was of 0.6 mm (SD 0.2). There could be several explanations for this: for instance, the technique is extremely sensitive to the operators, the characteristics of the patients were different, the measurements were differently biased in the various centres, since outcomes assessors were not blinded, or a combination of the various explanations.</P>
<P>While the improvements in PAL and PPD levels are without any doubt positive findings, the real clinical utility of EMD may be debated. In particular, there is no evidence that more compromised teeth could be saved using EMD, that the amount of tissue regeneration was clinically significant, or that patients preferred the EMD treatment for aesthetic reasons. It may be argued that only short-term follow-up studies on EMD are available, therefore it is unlikely that a difference in tooth loss could become apparent. Since the decision to remove a periodontally compromised tooth is generally driven by the dentist, it is imperative that the person who takes this decision is unaware of the precise nature of the treatment that the patient has received (i.e. EMD versus control flap surgery or EMD versus GTR). In fact, the knowledge of the type of therapy administered might influence the decision-making process of the dentist, who might systematically decide to remove more teeth from a certain patient group, according to personal belief, introducing bias in the results. In one trial with a 3-year follow up (<LINK REF="STD-Grusovin-2009" TYPE="STUDY">Grusovin 2009</LINK>), the clinician was still unaware whether patients received EMD or placebo and judged two teeth needing an additional surgical intervention, curiously both teeth were in the group treated with EMD.</P>
<P>When comparing EMD with GTR (five trials), we found that GTR produced a statistically significant increase in REC (0.41 mm) after 1 year. This statistical difference may not be of clinical significance. However, there were statistically significant more postoperative complications in the GTR treated group. Complications were reported in three trials (<LINK REF="STD-Crea-2008" TYPE="STUDY">Crea 2008</LINK>; <LINK REF="STD-Sanz-2004" TYPE="STUDY">Sanz 2004</LINK>; <LINK REF="STD-Silvestri-2003" TYPE="STUDY">Silvestri 2003</LINK>) and more specifically four patients in the EMD group experienced complications versus 59 patients treated with GTR. The great majority of these complications were small flap dehiscences over the barriers but we were also informed that two abscesses occurred at GTR treated sites in one study (<LINK REF="STD-Silvestri-2003" TYPE="STUDY">Silvestri 2003</LINK>). In one study<B> </B>(<LINK REF="STD-Sanz-2004" TYPE="STUDY">Sanz 2004</LINK>), 100% of the sites treated with GTR had at least one complication versus only 6% of the sites treated with EMD. It is known that postoperative complications are common when using the GTR technique, but a 100% complication rate looks rather high. It could be hypothesized that the antibiotic coverage used (500 mg of Amoxicillin for 4 days) was insufficient to prevent infection of the barriers.</P>
<P>Only few minor postoperative complications occurred at EMD treated sites (<LINK REF="STD-Crea-2008" TYPE="STUDY">Crea 2008</LINK>; <LINK REF="STD-Sanz-2004" TYPE="STUDY">Sanz 2004</LINK>). This suggests that EMD is a safe treatment procedure. In the literature there is only one report (<LINK REF="REF-St-George-2006" TYPE="REFERENCE">St George 2006</LINK>) of two cases describing inflammatory external root resorption in association with EMD treatment dictating tooth extraction. However, it is impossible to say whether the root resorption was triggered by EMD or it would have occurred independently of EMD application. No adverse reactions were reported for patients in the EMD or control groups with the exception of a few problems attributed to the use of antibiotics. While antibiotics may be useful when placing a barrier around teeth, they may not be necessary with EMD (<LINK REF="REF-Sculean-2001d" TYPE="REFERENCE">Sculean 2001d</LINK>), though this matter needs additional investigations in view of more recent findings (<LINK REF="STD-Mombelli-2005" TYPE="STUDY">Mombelli 2005</LINK>). It may also be useful to emphasize that the vehicle of EMD has shown antibacterial properties in vitro (<LINK REF="REF-Sculean-2001c" TYPE="REFERENCE">Sculean 2001c</LINK>; <LINK REF="REF-Spahr-2002" TYPE="REFERENCE">Spahr 2002</LINK>). In addition, if non-resorbable barriers are used a second operation is needed for their removal. Taken together, all these aspects suggest that EMD might be a preferable choice over GTR.</P>
<P>It is unclear whether patients treated with EMD may benefit from postoperative antibiotics since conflicting results were published (<LINK REF="STD-Mombelli-2005" TYPE="STUDY">Mombelli 2005</LINK>; <LINK REF="REF-Sculean-2001d" TYPE="REFERENCE">Sculean 2001d</LINK>). Postoperative antibiotics were prescribed in all but two trials (<LINK REF="STD-Grusovin-2009" TYPE="STUDY">Grusovin 2009</LINK>; <LINK REF="STD-Leknes-2009" TYPE="STUDY">Leknes 2009</LINK>). In one trial (<LINK REF="STD-Tonetti-2002" TYPE="STUDY">Tonetti 2002</LINK>) the operators were free to decide when to use systemic antibiotics. While the administration of antibiotics may be understandable for methodological reasons in trials comparing EMD with GTR, it should be considered whether it is appropriate to use antibiotics in those trials comparing EMD with flap surgery alone, since a generalized use of antibiotics is associated with some risk. The only trial evaluating the efficacy of antibiotics after surgical application of EMD, failed to disclose any advantages by using antibiotics (<LINK REF="REF-Sculean-2001d" TYPE="REFERENCE">Sculean 2001d</LINK>).</P>
<P>When comparing the efficacy of EMD with a bone grafting procedure, only one RCT (<LINK REF="STD-Leknes-2009" TYPE="STUDY">Leknes 2009</LINK>) could be found. Just 13 patients were included, therefore, only limited and provisional conclusions can be made. It appeared that less recessions (1.6 mm on average) occurred at proximal sites (papillae) when using a bone substitute. This might be tentatively explained by the presence of the filler which having physically occupied the space in the intrabony defect prevented the complete collapse of the papilla. If these findings are confirmed by other trials, a bone substitute could be a more interesting treatment alternative than EMD at least from an aesthetic point of view.</P>
<P>We intentionally did not include RCTs describing the use of EMD in conjunction with other treatments such as GTR, BG, etc. This was done because we wanted to know whether EMD was effective, and whether there were some differences when compared to other regenerative techniques. This can only be done by reducing the number of confounding factors.</P>
<P>The manufacturer suggests root-conditioning prior to the application of EMD and in all the included RCTs this was done. However, the clinical efficacy of such a procedure has not been validated (<LINK REF="REF-Sculean-2006" TYPE="REFERENCE">Sculean 2006</LINK>).</P>
<P>The quality of reporting of the trials (<LINK REF="STD-Crea-2008" TYPE="STUDY">Crea 2008</LINK>; <LINK REF="STD-Grusovin-2009" TYPE="STUDY">Grusovin 2009</LINK>; <LINK REF="STD-Leknes-2009" TYPE="STUDY">Leknes 2009</LINK>) included in the present update of this review has improved, and all trials were considered to be at low risk of bias. An improvement in trial design and reporting is a positive finding since it will increase the reliability of results and conclusions. With respect to the generalization of the findings of this review to a more general population, we have to be very cautious since treatments were administered, in many cases, by experienced clinicians, in some trials smokers were excluded and, moreover, very strict maintenance regimens were employed that are not generally used in routine clinical situations. In addition, the high degree of heterogeneity indicates that even within these 'optimal' conditions, the results of treatments were highly variable. Therefore, defining optimal patient selection, aspects of treatment delivery or maintenance is not possible from this review and this was not one the aims.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2009-07-15 18:48:16 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2009-06-28 17:24:39 +0100" MODIFIED_BY="[Empty name]">
<P>One year after treatment, the application of EMD during surgery showed statistically significant improvements in PAL (1.1 mm) and PPD reduction (0.9 mm) when compared to a placebo or a control. However, the high degree of heterogeneity observed among trials, and the fact that trials judged to be at a lower risk of bias showed less benefit of the use of EMD, suggests that results have to be interpreted with great caution and that the overall PAL gain may represent an overestimation of the actual treatment effect. Approximately nine patients needed to be treated with Emdogain to help one gain at least 2 mm of PAL. It is therefore the patient's and clinician's decision whether the clinical gain of periodontal attachment found in the present review is of clinical relevance.</P>
<P>No evidence of major differences between EMD and GTR could be found with the exception of slightly increased REC (0.4 mm) and significantly more postoperative complications in the GTR<B> </B>treated sites. EMD seems simpler to use, may not need antibiotic coverage and does not need a second surgical intervention (if compared with non-resorbable barriers). Therefore if patients and clinicians decide to attempt a regeneration of the lost periodontal tissues, they have to consider risk-benefits and, when comparing EMD with GTR, the EMD treatment might be preferable in light of the above issues.</P>
<P>The only trial comparing EMD with a ceramic filler suggested that more recession (1.6 mm) may occur at EMD treated sites.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2009-07-15 18:48:16 +0100" MODIFIED_BY="[Empty name]">
<P>The main implications for research are.<BR/>(1) More information is needed on whether EMD can actually save more teeth with a questionable prognosis. Teeth with questionable prognosis should be included in trials and followed for at least 5 years. Ideally those responsible to take the decision whether to extract or not a tooth should be unaware whether the tooth was treated with EMD or without.</P>
<P>(2) An independent and large multicentre placebo-controlled trial evaluating the efficacy of Emdogain would be useful. Ideally also the effect of the placebo per se (the EMD carrier) should be tested having as control the identical operations without the placebo.</P>
<P>(3) The advantages and disadvantages of bone substitutes should be compared with the use of EMD in intrabony defects. Aesthetic outcomes should also be considered.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2009-07-15 18:47:05 +0100" MODIFIED_BY="[Empty name]">
<P>We wish to thank Sylvia Bickley and Anne Littlewood (Cochrane Oral Health Group) for their assistance with literature searching; Emma Tavender and Luisa Fernandez Mauleffinch (Cochrane Oral Health Group) for their help with the preparation of this review; Regina Mitezki for translating a German article and Pierpaolo Cortellini, Orhun Dörtbudak, Luca Francetti, Stuart J Froum, Lars Heijl, Oliver Hoffmann, Jan Lindhe, Onur Ozcelik, Kazuhiro Okuda, Andreas Parashis, Cassiano Rösing, Mariano Sanz, Anton Sculean, Maurizio Silvestri, Maurizio Tonetti, K Vandana, Fridus Van der Weijden and Giovanni Zucchelli for providing us with information on their trials. We would also like to thank the following referees: Olaf F Alvarez, Jan Clarkson, Anne-Marie Glenny, Lars Heijl, Oliver Hoffmann, Lee Hooper, Anne Littlewood, David Moles, Ian Needleman, Michele Nieri, Anton Sculean and Leonardo Trombelli.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2009-07-15 18:47:47 +0100" MODIFIED_BY="[Empty name]">
<P>None known. Maria Gabriella Grusovin and Marco Esposito were authors of one of the included trials. However, they were not involved in the quality assessment of this trial.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2009-07-15 18:47:31 +0100" MODIFIED_BY="[Empty name]">
<P>Conceiving, designing and co-ordinating the review (Marco Esposito (ME)).<BR/>Developing search strategy and undertaking searches (ME, Paul Coulthard (PC)).<BR/>Screening search results and retrieved papers against inclusion criteria (ME, Gabriella Grusovin (GG), Nikolaos Papanikolaou (NP)).<BR/>Appraising quality (ME, PC, GG, NP, Helen Worthington (HW)).<BR/>Extracting data from papers (ME, HW).<BR/>Writing to authors for additional information (ME, HW, NP, GG).<BR/>Data management for the review and entering data into RevMan (HW, ME).<BR/>Analysis and interpretation of data (HW, ME).<BR/>Writing the review (ME, HW).<BR/>Providing general advice on the review (PC, GG).<BR/>Performing previous work that was the foundation of current study (ME, HW, PC).</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2009-07-15 18:48:08 +0100" MODIFIED_BY="[Empty name]">
<P>Changes from the protocol.<BR/>We investigated heterogeneity using post hoc factors found in the trial reports as follows: placebo or control group, antibiotics given, surgical technique used in control group, funded by manufacturer, depth of baseline intrabony defects, whether the trial was conducted in Italy or not.<BR/>We have added adverse effects to the list of outcomes, however none were found in the included trials.<BR/>
</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2010-11-16 15:06:22 +0000" MODIFIED_BY="Helen Worthington">
<STUDIES MODIFIED="2009-07-16 10:25:35 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2009-07-16 10:23:52 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="MIX" ID="STD-Crea-2008" MODIFIED="2009-07-16 10:23:35 +0100" MODIFIED_BY="[Empty name]" NAME="Crea 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-07-16 10:23:35 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Crea A, Dassatti L, Hoffmann O, Zafiropoulos GG, Deli G</AU>
<TI>Treatment of intrabony defects using guided tissue regeneration or enamel matrix derivative: a 3-year prospective randomized clinical study</TI>
<SO>Journal of Periodontology</SO>
<YR>2008</YR>
<VL>79</VL>
<NO>12</NO>
<PG>2281-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Francetti-2004" MODIFIED="2008-06-20 11:27:45 +0100" MODIFIED_BY="[Empty name]" NAME="Francetti 2004" YEAR="2004a">
<REFERENCE MODIFIED="2008-06-20 11:27:45 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Francetti L, Del Fabbro M, Basso M, Testori R, Weinstein R</AU>
<TI>Enamel matrix proteins in the treatment of intra-bony defects. A prospective 24-month clinical trial</TI>
<SO>Journal of Clinical Periodontology</SO>
<YR>2004</YR>
<VL>31</VL>
<NO>1</NO>
<PG>52-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Grusovin-2009" MODIFIED="2009-06-28 16:55:01 +0100" MODIFIED_BY="[Empty name]" NAME="Grusovin 2009" YEAR="2009">
<REFERENCE MODIFIED="2009-06-28 16:55:01 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Grusovin MG, Esposito M</AU>
<TI>The efficacy of enamel matrix derivates (Emdogain) for the treatment of infrabony defects. A placebo-controlled randomised clinical trial</TI>
<SO>European Journal of Oral Implantology</SO>
<YR>2009</YR>
<VL>2</VL>
<PG>43-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Heijl-1997" MODIFIED="2008-06-20 11:27:19 +0100" MODIFIED_BY="[Empty name]" NAME="Heijl 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Heijl L, Heden G, Svardstrom G, Ostgren A</AU>
<TI>EMDOGAIN in the treatment of intrabony periodontal defects</TI>
<SO>Journal of Dental Research</SO>
<YR>1997</YR>
<VL>76 (Special Abstract Issue 1)</VL>
<PG>292</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-06-20 11:27:19 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Heijl L, Heden G, Svardstrom G, Ostgren A</AU>
<TI>Enamel matrix derivative (EMDOGAIN) in the treatment of intrabony periodontal defects</TI>
<SO>Journal of Clinical Periodontology</SO>
<YR>1997</YR>
<VL>24</VL>
<NO>9 Pt 2</NO>
<PG>705-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Leknes-2009" MODIFIED="2009-07-16 10:23:52 +0100" MODIFIED_BY="[Empty name]" NAME="Leknes 2009" YEAR="2009">
<REFERENCE MODIFIED="2009-07-16 10:23:52 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Leknes KN, Andersen KM, Boe OE, Skavland RJ, Albandar JM</AU>
<TI>Enamel matrix derivative versus bioactive ceramic filler in the treatment of intrabony defects: 12-month results</TI>
<SO>Journal of Periodontology</SO>
<YR>2009</YR>
<VL>80</VL>
<NO>2</NO>
<PG>219-27</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Okuda-2000" MODIFIED="2008-06-20 11:25:19 +0100" MODIFIED_BY="[Empty name]" NAME="Okuda 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Okuda K, Miyazaki A, Momose M, Murata M, Yokoyama S, Yonezawa Y</AU>
<TI>Enamel matrix derivative (EMD) in the treatment of human intrabony periodontal osseous defects</TI>
<SO>Journal of Periodontology</SO>
<YR>2000</YR>
<VL>71</VL>
<PG>1913</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-06-20 11:25:19 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Okuda K, Momose M, Miyazaki A, Murata M, Yokoyama S, Yonezawa Y et al</AU>
<TI>Enamel matrix derivative in the treatment of human intrabony osseous defects</TI>
<SO>Journal of Periodontology</SO>
<YR>2000</YR>
<VL>71</VL>
<NO>12</NO>
<PG>1821-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Pontoriero-1999" MODIFIED="2008-06-20 11:26:55 +0100" MODIFIED_BY="[Empty name]" NAME="Pontoriero 1999" YEAR="1999">
<REFERENCE MODIFIED="2008-06-20 11:26:55 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pontoriero R, Wennstrom J, Lindhe J</AU>
<TI>The use of barrier membranes and enamel matrix proteins in the treatment of angular bone defects. A prospective controlled clinical study</TI>
<SO>Journal of Clinical Periodontology</SO>
<YR>1999</YR>
<VL>26</VL>
<NO>12</NO>
<PG>833-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-R_x00f6_sing-2005" MODIFIED="2008-06-20 11:13:31 +0100" MODIFIED_BY="[Empty name]" NAME="Rösing 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-06-20 11:13:31 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rösing CK, Aass AM, Mavropoulos A, Gjermo P</AU>
<TI>Clinical and radiographic effects of enamel matrix derivative in the treatment of intrabony periodontal defects: a 12-month longitudinal placebo-controlled clinical trial in adult periodontitis patients</TI>
<SO>Journal of Periodontology</SO>
<YR>2005</YR>
<VL>76</VL>
<NO>1</NO>
<PG>129-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sanz-2004" MODIFIED="2008-06-20 11:26:38 +0100" MODIFIED_BY="[Empty name]" NAME="Sanz 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-06-20 11:26:38 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Sanz M, Tonetti M, Zabalegui I, Blanco J, Rebelo H, Sicilia A et al</AU>
<TI>Treatment of infrabony defects with enamel matrix proteins. A multicentre practice-based study</TI>
<SO>Conference Proceedings of the Pan European Federation of the International Association for Dental Research</SO>
<YR>2002</YR>
<PG>Abstract No 164</PG>
<PB>Pattinson and Sons</PB>
<CY>Newcastle</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sanz M, Tonetti MS, Zabalegui I, Sicilia A, Blanco J, Rebelo H et al</AU>
<TI>Treatment of intrabony defects with enamel matrix proteins or barrier membranes. Results from a multicentre practice-based clinical trial</TI>
<SO>Journal of Periodontology</SO>
<YR>2004</YR>
<VL>75</VL>
<PG>726-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Silvestri-2000" MODIFIED="2008-06-20 11:13:36 +0100" MODIFIED_BY="[Empty name]" NAME="Silvestri 2000" YEAR="2000">
<REFERENCE MODIFIED="2008-06-20 11:13:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Silvestri M, Ricci G, Rasperini G, Sartori S, Cattaneo V</AU>
<TI>Comparison of treatments of infrabony defects with enamel matrix derivative, guided tissue regeneration with a nonresorbable membrane and Widman modified flap. A pilot study</TI>
<SO>Journal of Clinical Periodontology</SO>
<YR>2000</YR>
<VL>27</VL>
<NO>8</NO>
<PG>603-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Silvestri-2003" MODIFIED="2009-05-18 02:46:48 +0100" MODIFIED_BY="[Empty name]" NAME="Silvestri 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-06-20 11:24:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Silvestri M, Sartori S, Rasperini G, Ricci G, Rota C, Cattaneo V</AU>
<TI>Comparison of infrabony defects treated with enamel matrix derivative versus guided tissue regeneration with a non-resorbable membrane</TI>
<SO>Journal of Clinical Periodontology</SO>
<YR>2003</YR>
<VL>30</VL>
<NO>5</NO>
<PG>386-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-05-18 02:46:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Silvestri M, Sartori S, Rasperini G, Ricci G, Rota C, Cattaneo V</AU>
<TI>The treatment of infrabony defects. Clinical/statistical comparison in cases treated with enamel matrix derivative (Emdogain) versus GTR procedure and Widman modified flap</TI>
<SO>Journal of Clinical Periodontoloy</SO>
<YR>2001</YR>
<VL>27 (Supplement 1 July)</VL>
<PG>60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Silvestri M, Sartori S, Rasperini G, Ricci G, Rota C, Cattaneo V</AU>
<TI>Treatment of infrabony defects with enamel matrix derivative (EMD) or non-resorbable membrane: a randomized controlled multicenter clinical trial</TI>
<SO>Journal of Periodontology</SO>
<YR>2002</YR>
<VL>73</VL>
<PG>1402</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Tonetti-2002" NAME="Tonetti 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tonetti MS, Fourmousis I, Suvan J, Cortellini P, Brägger U, Lang NP</AU>
<TI>Healing, post-operative morbidity and patient perception of outcomes following regenerative therapy of intrabony defects</TI>
<SO>Journal of Clinical Periodontology</SO>
<YR>2004</YR>
<VL>31</VL>
<NO>12</NO>
<PG>1092-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Tonetti MS, Lang NP, Cortellini P, Suvan, JE, Adriaens P, Dubravec D et al</AU>
<TI>Enamel matrix proteins in the regenerative therapy of deep intrabony defects</TI>
<SO>Journal of Clinical Periodontology</SO>
<YR>2002</YR>
<VL>29</VL>
<NO>4</NO>
<PG>317-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Zucchelli-2002" MODIFIED="2008-06-20 11:13:48 +0100" MODIFIED_BY="[Empty name]" NAME="Zucchelli 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-06-20 11:13:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zucchelli G, Bernardi F, Montebugnoli L, De M</AU>
<TI>Enamel matrix proteins and guided tissue regeneration with titanium-reinforced expanded polytetrafluoroethylene membranes in the treatment of infrabony defects: a comparative controlled clinical trial</TI>
<SO>Journal of Periodontology</SO>
<YR>2002</YR>
<VL>73</VL>
<NO>1</NO>
<PG>3-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2009-07-16 10:25:35 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Bokan-2006" MODIFIED="2009-06-28 16:18:46 +0100" MODIFIED_BY="[Empty name]" NAME="Bokan 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-06-28 16:18:46 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bokan I, Bill JS, Schlagenhauf U</AU>
<TI>Primary flap closure combined with Emdogain alone or Emdogain and Cerasorb in the treatment of intra-bony defects</TI>
<SO>Journal of Clinical Periodontology</SO>
<YR>2006</YR>
<VL>33</VL>
<PG>885-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chambrone-2007" MODIFIED="2009-07-16 10:24:09 +0100" MODIFIED_BY="[Empty name]" NAME="Chambrone 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-07-16 10:24:09 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chambrone D, Pasin IM, Conde MC, Panutti C, Carneiro S, Lima LA</AU>
<TI>Effect of enamel matrix proteins on the treatment of intrabony defects: a split-mouth randomized controlled trial study</TI>
<SO>Brazilian Oral Research</SO>
<YR>2007</YR>
<VL>21</VL>
<NO>3</NO>
<PG>241-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Doertbudak-2000" MODIFIED="2008-06-20 11:14:03 +0100" MODIFIED_BY="[Empty name]" NAME="Doertbudak 2000" YEAR="2000">
<REFERENCE MODIFIED="2008-06-20 11:14:03 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Doertbudak O, Durstberger G, Bernhart T, Haas R</AU>
<TI>Treatment of periodontal defects with an enamel matrix derivative (Emdogain)</TI>
<SO>Journal of Clinical Periodontology</SO>
<YR>2000</YR>
<VL>27 (Supplement 1 July)</VL>
<PG>61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Eger-1998" MODIFIED="2008-06-20 11:14:06 +0100" MODIFIED_BY="[Empty name]" NAME="Eger 1998" YEAR="1998">
<REFERENCE MODIFIED="2008-06-20 11:14:06 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Eger T, Muller H-P</AU>
<TI>Periodontal regeneration in vertical bone defects with resorbable barriers and enamel-matrix proteins</TI>
<TO>Parodontale regeneration in vertikalen knochendefecten mit resorbierbaren membranen und schmelz-matrix-proteinen</TO>
<SO>Deutsche Zahnrztliche Zeitschrift</SO>
<YR>1998</YR>
<VL>53</VL>
<PG>590-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Francetti-2005" MODIFIED="2009-07-16 10:24:28 +0100" MODIFIED_BY="[Empty name]" NAME="Francetti 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-07-16 10:24:28 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Francetti L, Trombelli L, Lombardo G, Guida L, Cafiero C, Roccuzzo M et al</AU>
<TI>Evaluation of efficacy of enamel matrix derivative in the treatment of intrabony defects: a 24-month multicenter study</TI>
<SO>International Journal of Periodontics and Restorative Dentistry</SO>
<YR>2005</YR>
<VL>25</VL>
<PG>461-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Francetti L</AU>
<TI>A multicenter study to evaluate the clinical eligibility to periodontal treatment with enamel matrix derivative. Preliminary data</TI>
<SO>Journal of Clinical Periodontology</SO>
<YR>2000</YR>
<VL>27 (Supplement 1 July)</VL>
<PG>60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Froum-2001" MODIFIED="2008-06-20 11:14:12 +0100" MODIFIED_BY="[Empty name]" NAME="Froum 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-06-20 11:14:12 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Froum SJ, Weinberg MA, Rosenberg E, Tarnow D</AU>
<TI>A comparative study utilizing open flap debridement with and without enamel matrix derivative in the treatment of periodontal intrabony defects: a 12-month re-entry study</TI>
<SO>Journal of Periodontology</SO>
<YR>2001</YR>
<VL>72</VL>
<NO>1</NO>
<PG>25-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ghaffar-2001" MODIFIED="2009-05-18 02:50:56 +0100" MODIFIED_BY="[Empty name]" NAME="Ghaffar 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-05-18 02:50:56 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ghaffar KA, Hosny MM, Garrett S</AU>
<TI>Enamel matrix proteins and bioresorbable membranes in the treatment of early onset periodontitis</TI>
<SO>Journal of Dental Education</SO>
<YR>2001</YR>
<VL>80 (January 2001 Special Issue AADR Abstracts)</VL>
<PG>82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Hagenaars-2004" MODIFIED="2008-06-20 11:14:21 +0100" MODIFIED_BY="[Empty name]" NAME="Hagenaars 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-06-20 11:14:21 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hagenaars S, Louwerse PH, Timmerman MF, Van der Velden U, Van der Weijden GA</AU>
<TI>Soft-tissue wound healing following periodontal surgery and Emdogain application</TI>
<SO>Journal of Clinical Periodontology</SO>
<YR>2004</YR>
<VL>31</VL>
<NO>10</NO>
<PG>850-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lombardo--2000" MODIFIED="2008-06-20 11:14:27 +0100" MODIFIED_BY="[Empty name]" NAME="Lombardo  2000" YEAR="2000">
<REFERENCE MODIFIED="2008-06-20 11:14:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lombardo G, Bernini R, Urbani G</AU>
<TI>Treatment of intrabony periodontal defects using enamel matrix derivative (EMDOGAIN)</TI>
<SO>Journal of Clinical Periodontology</SO>
<YR>2000</YR>
<VL>27 (Supplement 1 July)</VL>
<PG>61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Martinez-2001" MODIFIED="2008-06-20 11:14:31 +0100" MODIFIED_BY="[Empty name]" NAME="Martinez 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-06-20 11:14:31 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Martinez GA, Rodriguez F, Sanz M</AU>
<TI>Efficacy of enamel matrix proteins derivate (EMDOGAIN) in intra-osseous defects</TI>
<SO>Journal of Dental Research</SO>
<YR>2001</YR>
<VL>80</VL>
<PG>1213</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Martu-2000a" MODIFIED="2008-06-20 11:14:35 +0100" MODIFIED_BY="[Empty name]" NAME="Martu 2000a" YEAR="2000">
<REFERENCE MODIFIED="2008-06-20 11:14:35 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Martu S, Burlui V, Mocanu C, Forna N</AU>
<TI>Periodontal regeneration with enamel derivate proteins (Emdogain) - clinical evaluation</TI>
<SO>Revista Medico-Chirurgicala a Societatii de Medici si Naturalisti din Iasi</SO>
<YR>2000</YR>
<VL>104</VL>
<NO>4</NO>
<PG>147-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Martu-2000b" MODIFIED="2009-07-16 10:24:44 +0100" MODIFIED_BY="[Empty name]" NAME="Martu 2000b" YEAR="2000">
<REFERENCE MODIFIED="2009-07-16 10:24:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Martu S, Burlui V, Forna N, Mocanu C</AU>
<TI>Preliminary account on the use of enamel matrix derivate (Emdogain) in intra-osseous defects</TI>
<SO>Journal of Clinical Periodontology</SO>
<YR>2000</YR>
<VL>27 (Supplement 1 July)</VL>
<PG>61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Minabe-2002" MODIFIED="2008-06-20 11:14:47 +0100" MODIFIED_BY="[Empty name]" NAME="Minabe 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-06-20 11:14:47 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Minabe M, Kodama T, Kogou T, Takeuchi K, Fushimi H, Sugiyama T et al</AU>
<TI>A comparative study of combined treatment with a collagen membrane and enamel matrix proteins for the regeneration of intraosseous defects</TI>
<SO>The International Journal of Periodontics and Restorative Dentistry</SO>
<YR>2002</YR>
<VL>22</VL>
<NO>6</NO>
<PG>595-605</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mombelli-2005" MODIFIED="2008-06-20 11:14:52 +0100" MODIFIED_BY="[Empty name]" NAME="Mombelli 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-06-20 11:14:52 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mombelli A, Brochut P, Plagnat D, Casagni F, Giannopoulou C</AU>
<TI>Enamel matrix proteins and systemic antibiotics as adjuncts to non-surgical periodontal treatment: clinical effects</TI>
<SO>Journal of Clinical Periodontology</SO>
<YR>2005</YR>
<VL>32</VL>
<NO>3</NO>
<PG>225-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Ozcelik-2007" MODIFIED="2009-03-28 10:46:54 +0000" MODIFIED_BY="[Empty name]" NAME="Ozcelik 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-03-28 10:46:54 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ozcelik O, Haytac MC, Seydaoglu G</AU>
<TI>Immediate post-operative effects of different periodontal treatment modalities on oral health-related quality of life: a randomized clinical trial</TI>
<SO>Journal of Clinical Periodontology</SO>
<YR>2007</YR>
<VL>34</VL>
<PG>788-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Parashis-2004" NAME="Parashis 2004" YEAR="2004">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Parashis A, Andronikaki-Faldami A, Tsiklakis K</AU>
<TI>Clinical and radiographic comparison of three regenerative procedures in the treatment of intrabony defects</TI>
<SO>International Journal of Periodontics and Restorative Dentistry</SO>
<YR>2004</YR>
<VL>24</VL>
<NO>1</NO>
<PG>81-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Parashis A, Andronikaki-Faldami A, Tsiklakis K</AU>
<TI>Comparison of three regenerative procedures in the treatment of intrabony defects: a clinical &amp; radiographic study</TI>
<SO>Journal of Clinical Periodontology</SO>
<YR>2000</YR>
<VL>27 (Supplement 1 July)</VL>
<PG>29</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sculean-1999" MODIFIED="2009-07-16 10:24:58 +0100" MODIFIED_BY="[Empty name]" NAME="Sculean 1999" YEAR="1999">
<REFERENCE MODIFIED="2009-07-16 10:24:58 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Sculean A, Donos N, Windisch P, Brecx M, Gera I, Reich E, et al. Healing of human intrabony defects following treatment with enamel matrix proteins or guided tissue regeneration. Journal of Periodontal Research 1999;34(6):310-322.&lt;/p&gt;" NOTES_MODIFIED="2009-07-16 10:24:58 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sculean A, Donos N, Windisch P, Brecx M, Gera I, Reich E et al</AU>
<TI>Healing of human intrabony defects following treatment with enamel matrix proteins or guided tissue regeneration</TI>
<SO>Journal of Periodontal Research</SO>
<YR>1999</YR>
<VL>34</VL>
<NO>6</NO>
<PG>310-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Sculean-2001a" MODIFIED="2009-07-16 10:25:17 +0100" MODIFIED_BY="[Empty name]" NAME="Sculean 2001a" YEAR="2001a">
<REFERENCE MODIFIED="2008-06-20 11:28:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sculean A, Donos N, Blaes A, Lauermann M, Reich E, Brecx M</AU>
<TI>Comparison of enamel matrix proteins and bioabsorbable membranes in the treatment of intrabony periodontal defects. A split-mouth study</TI>
<SO>Journal of Periodontology</SO>
<YR>1999</YR>
<VL>70</VL>
<NO>3</NO>
<PG>255-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sculean A, Donos N, Blaes A, Reich E, Brecx M</AU>
<TI>Enamel matrix proteins (Emdogain) and guided tissue regeneration in the treatment of intrabony periodontal defects. A split-mouth clinical study</TI>
<SO>Journal of Dental Research</SO>
<YR>1998</YR>
<VL>77 (June Special Abstract Issue B)</VL>
<PG>924</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sculean A, Donos N, Blaes A, Reich E, Brecx M</AU>
<TI>Enamel matrix proteins and GTR in the treatment of intrabony defects. Three year results of a split-mouth study</TI>
<SO>Journal of Clinical Periodontology</SO>
<YR>2000</YR>
<VL>27 (Supplement 1 July)</VL>
<PG>62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-06-20 11:29:01 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sculean A, Donos N, Miliauskaite A, Arweiler N, Brecx M</AU>
<TI>Treatment of intrabony defects with enamel matrix proteins or bioabsorbable membranes. A 4-year follow-up split-mouth study</TI>
<SO>Journal of Periodontology</SO>
<YR>2001</YR>
<VL>72</VL>
<NO>12</NO>
<PG>1695-701</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-07-16 10:25:17 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sculean A, Schwarz, F, Miliauskaite A, Kiss A, Arweiler N, Becker J et al</AU>
<TI>Treatment of intrabony defects with an enamel matrix protein derivative or bioabsorbable membrane: an 8-year follow-up split-mouth study</TI>
<SO>Journal of Periodontology</SO>
<YR>2006</YR>
<VL>77</VL>
<PG>1879-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Sculean-2001b" MODIFIED="2009-03-21 09:57:04 +0000" MODIFIED_BY="[Empty name]" NAME="Sculean 2001b" YEAR="2001b">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sculean A, Donos N, Schwarz F, Becker J, Brecx M, Arweiler NB</AU>
<TI>Five-year results following treatment of intrabony defects with enamel matrix proteins and guided tissue regeneration</TI>
<SO>Journal of Clinical Periodontology</SO>
<YR>2004</YR>
<VL>31</VL>
<NO>7</NO>
<PG>545-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-03-21 09:57:04 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sculean A, Kiss A, Miliauskaite A, Schwarz F, Arweiler NB, Hannig M</AU>
<TI>Ten-year results following treatment of intra-bony defects with enamel matrix proteins and guided tissue regeneration</TI>
<SO>Journal of Clinical Periodontology</SO>
<YR>2008</YR>
<VL>35</VL>
<PG>817-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sculean A, Windisch P, Blaes A, Gera I, Brecx M, Donos N</AU>
<TI>Treatment of intrabony defects with enamel matrix proteins and GTR</TI>
<SO>Journal of dental Research</SO>
<YR>2000</YR>
<VL>79 (Special Abstract Issue 1)</VL>
<PG>171</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sculean A, Windisch P, Chiantella GC, Donos N, Brecx M, Reich E</AU>
<TI>Treatment of intrabony defects with enamel matrix proteins and guided tissue regeneration. A prospective controlled clinical study</TI>
<SO>Journal of Clinical Periodontology</SO>
<YR>2001</YR>
<VL>28</VL>
<NO>5</NO>
<PG>397-403</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vandana-2004" MODIFIED="2008-06-20 11:15:02 +0100" MODIFIED_BY="[Empty name]" NAME="Vandana 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-06-20 11:15:02 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vandana KL, Shah K, Prakash S</AU>
<TI>Clinical and radiographic evaluation of Emdogain as a regenerative material in the treatment of interproximal vertical defects in chronic and aggressive periodontitis patients</TI>
<SO>The International Journal of Periodontics and Restorative Dentistry</SO>
<YR>2004</YR>
<VL>24</VL>
<NO>2</NO>
<PG>185-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wachtel-2003" MODIFIED="2008-06-20 11:15:05 +0100" MODIFIED_BY="[Empty name]" NAME="Wachtel 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-06-20 11:15:05 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wachtel H, Schenk G, Böhm S, Weng D, Zuhr O, Hürzeler MB</AU>
<TI>Microsurgical access flap and enamel matrix derivative for the treatment of periodontal intrabony defects: a controlled clinical study</TI>
<SO>Journal of Clinical Periodontology</SO>
<YR>2003</YR>
<VL>30</VL>
<NO>6</NO>
<PG>496-504</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Windisch-2002" MODIFIED="2009-07-16 10:25:35 +0100" MODIFIED_BY="[Empty name]" NAME="Windisch 2002" YEAR="">
<REFERENCE MODIFIED="2009-07-16 10:25:35 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Windisch P, Sculean A, Klein F, Toth V, Gera I, Reich E et al</AU>
<TI>Comparison of clinical, radiographic, and histometric measurements following treatment with guided tissue regeneration or enamel matrix proteins in human periodontal defects</TI>
<SO>Journal of Periodontology</SO>
<YR>2002</YR>
<VL>73</VL>
<NO>4</NO>
<PG>409-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES MODIFIED="2009-03-18 10:33:22 +0000" MODIFIED_BY="[Empty name]"/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2010-11-16 15:06:22 +0000" MODIFIED_BY="Helen Worthington">
<ADDITIONAL_REFERENCES MODIFIED="2010-11-16 15:06:22 +0000" MODIFIED_BY="Helen Worthington">
<REFERENCE ID="REF-Arweiler-2002" NAME="Arweiler 2002" TYPE="JOURNAL_ARTICLE">
<AU>Arweiler NB, Auschill TM, Donos N, Sculean A</AU>
<TI>Antibacterial effect of an enamel matrix protein derivative on in vivo dental biofilm vitality</TI>
<SO>Clinical Oral Investigations</SO>
<YR>2002</YR>
<VL>6</VL>
<NO>4</NO>
<PG>205-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bosshardt-2005" NAME="Bosshardt 2005" TYPE="JOURNAL_ARTICLE">
<AU>Bosshardt DD, Sculean A, Windisch P, Pjetursson BE, Lang NP</AU>
<TI>Effects of enamel matrix proteins on tissue formation along the roots of human teeth</TI>
<SO>Journal of Periodontal Research</SO>
<YR>2005</YR>
<VL>40</VL>
<NO>2</NO>
<PG>158-67</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bowers-1989a" MODIFIED="2009-07-16 10:25:48 +0100" MODIFIED_BY="[Empty name]" NAME="Bowers 1989a" TYPE="JOURNAL_ARTICLE">
<AU>Bowers GM, Chadroff B, Carnevale R, Mellonig J, Corio R, Emerson J et al</AU>
<TI>Histologic evaluation of new attachment apparatus formation in humans. Part I</TI>
<SO>Journal of Periodontology</SO>
<YR>1989</YR>
<VL>60</VL>
<NO>12</NO>
<PG>664-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bowers-1989b" MODIFIED="2009-07-16 10:25:59 +0100" MODIFIED_BY="[Empty name]" NAME="Bowers 1989b" TYPE="JOURNAL_ARTICLE">
<AU>Bowers GM, Chadroff B, Carnevale R, Mellonig J, Corio R, Emerson J et al</AU>
<TI>Histologic evaluation of new attachment apparatus formation in humans. Part II</TI>
<SO>Journal of Periodontology</SO>
<YR>1989</YR>
<VL>60</VL>
<NO>12</NO>
<PG>675-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bratthall-2001" NAME="Bratthall 2001" TYPE="JOURNAL_ARTICLE">
<AU>Bratthall G, Lindberg P, Havemose-Poulsen A, Holmstrup P, Bay L, Soderholm G et al</AU>
<TI>Comparison of ready-to-use Emdogain-gel and Emdogain in patients with chronic adult periodontitis. A multicenter clinical trial</TI>
<SO>Journal of Clinical Periodontology</SO>
<YR>2001</YR>
<VL>28</VL>
<NO>10</NO>
<PG>923-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brookes-1995" NAME="Brookes 1995" TYPE="JOURNAL_ARTICLE">
<AU>Brookes SJ, Robinson C, Kirkham J, Bonass WA</AU>
<TI>Biochemistry and molecular biology of amelogenin proteins of developing dental enamel</TI>
<SO>Archives of Oral Biology</SO>
<YR>1995</YR>
<VL>40</VL>
<NO>1</NO>
<PG>1-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Elbourne-2002" MODIFIED="2008-06-20 11:15:49 +0100" MODIFIED_BY="[Empty name]" NAME="Elbourne 2002" TYPE="JOURNAL_ARTICLE">
<AU>Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A</AU>
<TI>Meta-analyses involving cross-over trials: methodological issues</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2002</YR>
<VL>31</VL>
<NO>1</NO>
<PG>140-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Filippi-2001" NAME="Filippi 2001" TYPE="JOURNAL_ARTICLE">
<AU>Filippi A, Pohl Y, von Arx T</AU>
<TI>Treatment of replacement resorption with Emdogain. Preliminary results after 10 months</TI>
<SO>Dental Traumatology</SO>
<YR>2001</YR>
<VL>17</VL>
<NO>3</NO>
<PG>134-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Filippi-2002" NAME="Filippi 2002" TYPE="JOURNAL_ARTICLE">
<AU>Filippi A, Pohl Y, von Arx T</AU>
<TI>Treatment of resorption with Emdogain. A prospective clinical study</TI>
<SO>Dental Traumatology</SO>
<YR>2002</YR>
<VL>18</VL>
<NO>3</NO>
<PG>138-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Follmann-1992" MODIFIED="2008-06-20 11:15:54 +0100" MODIFIED_BY="[Empty name]" NAME="Follmann 1992" TYPE="JOURNAL_ARTICLE">
<AU>Follmann D, Elliott P, Suh I, Cutler J</AU>
<TI>Variance imputation for overviews of clinical trials with continuous response</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>1992</YR>
<VL>45</VL>
<PG>769-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Froum-2004" NAME="Froum 2004" TYPE="JOURNAL_ARTICLE">
<AU>Froum S, Weinberg M, Novak J, Mailhot J, Mellonig J, Van Dyke T et al</AU>
<TI>A multicenter study evaluating the sensitization potential of enamel matrix derivative after treatment of two infrabony defects</TI>
<SO>Journal of Periodontology</SO>
<YR>2004</YR>
<VL>75</VL>
<NO>7</NO>
<PG>1001-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Giannobile-2003" NAME="Giannobile 2003" TYPE="JOURNAL_ARTICLE">
<AU>Giannobile WV, Somerman MJ</AU>
<TI>Growth and amelogenin-like factors in periodontal wound healing. A systematic review</TI>
<SO>Annals of Periodontology</SO>
<YR>2003</YR>
<VL>8</VL>
<NO>1</NO>
<PG>193-204</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hammarstr_x00f6_m-1997a" MODIFIED="2008-06-20 11:16:02 +0100" MODIFIED_BY="[Empty name]" NAME="Hammarström 1997a" TYPE="JOURNAL_ARTICLE">
<AU>Hammarström L</AU>
<TI>Enamel matrix, cementum development and regeneration</TI>
<SO>Journal of Clinical Periodontology</SO>
<YR>1997</YR>
<VL>24</VL>
<NO>9 Pt 2</NO>
<PG>658-68</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hammarstr_x00f6_m-1997b" MODIFIED="2008-06-20 11:16:06 +0100" MODIFIED_BY="[Empty name]" NAME="Hammarström 1997b" TYPE="JOURNAL_ARTICLE">
<AU>Hammarström L, Heijl L, Gestrelius S</AU>
<TI>Periodontal regeneration in a buccal dehiscence model in monkeys after application of enamel matrix proteins</TI>
<SO>Journal of Clinical Periodontology</SO>
<YR>1997</YR>
<VL>24</VL>
<NO>9 Pt 2</NO>
<PG>669-77</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Heard-2000" NAME="Heard 2000" TYPE="JOURNAL_ARTICLE">
<AU>Heard RH, Mellonig JT, Brunsvold MA, Lasho DJ, Meffert RM, Cochran DL</AU>
<TI>Clinical evaluation of wound healing following multiple exposures to enamel matrix protein derivative in the treatment of intrabony periodontal defects</TI>
<SO>Journal of Periodontology</SO>
<YR>2000</YR>
<VL>71</VL>
<NO>11</NO>
<PG>1715-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2008" MODIFIED="2009-07-15 17:08:01 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2008" TYPE="OTHER">
<AU>Higgins JPT, Green S, editors</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions 5.0.1 [updated September 2008]. The Cochrane Collaboration, 2008</TI>
<SO>Available from: www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kalpidis-2002" NAME="Kalpidis 2002" TYPE="JOURNAL_ARTICLE">
<AU>Kalpidis CD, Ruben MP</AU>
<TI>Treatment of intrabony periodontal defects with enamel matrix derivative: a literature review</TI>
<SO>Journal of Periodontology</SO>
<YR>2002</YR>
<VL>73</VL>
<NO>1</NO>
<PG>1360-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mariotti-2003" NAME="Mariotti 2003" TYPE="JOURNAL_ARTICLE">
<AU>Mariotti A</AU>
<TI>Efficacy of chemical root surface modifiers in the treatment of periodontal disease</TI>
<SO>Annals of Periodontology</SO>
<YR>2003</YR>
<VL>8</VL>
<NO>1</NO>
<PG>205-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Needleman-2006" MODIFIED="2009-06-29 13:11:01 +0100" MODIFIED_BY="[Empty name]" NAME="Needleman 2006" TYPE="COCHRANE_REVIEW">
<AU>Needleman IG, Worthington HV, Giedrys-Leeper E, Tucker R</AU>
<TI>Guided tissue regeneration for periodontal infra-bony defects</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2008-06-20 11:20:23 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-06-20 11:20:23 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="DOI: 10.1002/14651858.CD001724"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Reynolds-2003" NAME="Reynolds 2003" TYPE="JOURNAL_ARTICLE">
<AU>Reynolds MA, Aichelmann-Reidy ME, Branch-Mays GL, Gunsolley JC</AU>
<TI>The efficacy of bone replacement grafts in the treatment of periodontal osseous defects. A systematic review</TI>
<SO>Annals of Periodontology</SO>
<YR>2003</YR>
<VL>8</VL>
<NO>1</NO>
<PG>227-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schj_x00f8_tt-2005" NAME="Schjøtt 2005" TYPE="JOURNAL_ARTICLE">
<AU>Schjøtt M, Andreasen JO</AU>
<TI>Emdogain does not prevent progressive root resorption after replantation of avulsed teeth: a clinical study</TI>
<SO>Dental Traumatology</SO>
<YR>2005</YR>
<VL>21</VL>
<NO>1</NO>
<PG>46-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sculean-2001c" MODIFIED="2008-06-20 11:20:43 +0100" MODIFIED_BY="[Empty name]" NAME="Sculean 2001c" TYPE="JOURNAL_ARTICLE">
<AU>Sculean A, Auschill TM, Donos N, Brecx M, Arweiler NB</AU>
<TI>Effect of an enamel matrix protein derivative (Emdogain) on ex vivo dental plaque vitality</TI>
<SO>Journal of Clinical Periodontology</SO>
<YR>2001</YR>
<VL>28</VL>
<NO>11</NO>
<PG>1074-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sculean-2001d" NAME="Sculean 2001d" TYPE="JOURNAL_ARTICLE">
<AU>Sculean A, Blaes A, Arweiler N, Reich E, Donos N, Brecx M</AU>
<TI>The effect of postsurgical antibiotics on the healing of intrabony defects following treatment with enamel matrix proteins</TI>
<SO>Journal of Periodontology</SO>
<YR>2001</YR>
<VL>72</VL>
<NO>2</NO>
<PG>190-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sculean-2006" MODIFIED="2009-03-21 10:21:58 +0000" MODIFIED_BY="[Empty name]" NAME="Sculean 2006" TYPE="JOURNAL_ARTICLE">
<AU>Sculean A, Berakdar M, Willershausen B, Arweiler NB, Becker J, Schwarz F</AU>
<TI>Effect of EDTA root conditioning on the healing of intrabony defects treated with an enamel matrix protein derivative</TI>
<SO>Journal of Periodontology</SO>
<YR>2006</YR>
<VL>77</VL>
<PG>1167-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Spahr-2002" NAME="Spahr 2002" TYPE="JOURNAL_ARTICLE">
<AU>Spahr A, Lyngstadaas SP, Boeckh C, Andersson C, Podbielski A, Haller B</AU>
<TI>Effect of the enamel matrix derivative Emdogain on the growth of periodontal pathogens in vitro</TI>
<SO>Journal of Clinical Periodontology</SO>
<YR>2002</YR>
<VL>29</VL>
<NO>1</NO>
<PG>62-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-St-George-2006" MODIFIED="2009-03-29 17:00:15 +0100" MODIFIED_BY="[Empty name]" NAME="St George 2006" TYPE="JOURNAL_ARTICLE">
<AU>St George G, Darbar U, Thomas G</AU>
<TI>Inflammatory external root resorption following surgical treatment for intra-bony defects: a report of two cases involving Emdogain and a review of the literature</TI>
<SO>Journal of Clinical Periodontology</SO>
<YR>2006</YR>
<VL>33</VL>
<PG>449-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Trombelli-2002" NAME="Trombelli 2002" TYPE="JOURNAL_ARTICLE">
<AU>Trombelli L, Heitz-Mayfield LJ, Needleman I, Moles D, Scabbia A</AU>
<TI>A systematic review of graft materials and biological agents for periodontal intraosseous defects</TI>
<SO>Journal of Clinical Periodontology</SO>
<YR>2002</YR>
<VL>29 Suppl 3</VL>
<PG>117-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Venezia-2004" NAME="Venezia 2004" TYPE="JOURNAL_ARTICLE">
<AU>Venezia E, Goldstein M, Boyan BD, Schwartz Z</AU>
<TI>The use of enamel matrix derivative in the treatment of periodontal defects: a literature review and meta-analysis</TI>
<SO>Critical Reviews in Oral Biology and Medicine</SO>
<YR>2004</YR>
<VL>15</VL>
<NO>6</NO>
<PG>382-402</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wennstr_x00f6_m-2002" NAME="Wennström 2002" TYPE="JOURNAL_ARTICLE">
<AU>Wennström JL, Lindhe J</AU>
<TI>Some effects of enamel matrix proteins on wound healing in the dento-gingival region</TI>
<SO>Journal of Clinical Periodontology</SO>
<YR>2002</YR>
<VL>29</VL>
<NO>1</NO>
<PG>9-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zetterstr_x00f6_m-1997" MODIFIED="2009-07-16 10:26:31 +0100" MODIFIED_BY="[Empty name]" NAME="Zetterström 1997" TYPE="JOURNAL_ARTICLE">
<AU>Zetterström O, Andersson C, Eriksson L, Fredriksson A, Friskopp J, Heden G et al</AU>
<TI>Clinical safety of enamel matrix derivative (EMDOGAIN) in the treatment of periodontal defects</TI>
<SO>Journal of Clinical Periodontology</SO>
<YR>1997</YR>
<VL>24</VL>
<NO>9 Pt 2</NO>
<PG>697-704</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2009-07-16 10:27:06 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Esposito-2003" MODIFIED="2008-06-20 11:22:39 +0100" MODIFIED_BY="[Empty name]" NAME="Esposito 2003" TYPE="COCHRANE_REVIEW">
<AU>Esposito M, Coulthard P, Worthington HV</AU>
<TI>Enamel matrix derivative (Emdogain®) for periodontal tissue regeneration in intrabony defects</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2008-06-20 11:22:34 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-06-20 11:22:34 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="DOI: 10.1002/14651858.CD003875"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Esposito-2004" NAME="Esposito 2004" TYPE="JOURNAL_ARTICLE">
<AU>Esposito M, Coulthard P, Thomsen P, Worthington HV</AU>
<TI>Enamel matrix derivative for periodontal tissue regeneration in treatment of intrabony defects: a Cochrane systematic review</TI>
<SO>Journal of Dental Education</SO>
<YR>2004</YR>
<VL>68</VL>
<NO>8</NO>
<PG>834-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Esposito-2005" MODIFIED="2009-07-16 10:27:06 +0100" MODIFIED_BY="[Empty name]" NAME="Esposito 2005" TYPE="COCHRANE_REVIEW">
<AU>Esposito M, Grusovin MG, Coulthard P, Worthington HV</AU>
<TI>Enamel matrix derivative (Emdogain®) for periodontal tissue regeneration in intrabony defects</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2009-07-16 10:27:06 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-16 10:27:01 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003875.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2009-11-05 16:38:38 +0000" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2009-11-05 16:38:38 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2009-07-15 18:49:46 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Crea-2008">
<CHAR_METHODS MODIFIED="2009-07-15 18:49:20 +0100" MODIFIED_BY="[Empty name]">
<P>3-year follow-up parallel-group study including 2 groups with 40 patients in total. 1 drop out from the Emdogain group since the patient failed to attend the scheduled appointments following surgery.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-06-28 16:50:52 +0100" MODIFIED_BY="[Empty name]">
<P>Patients in good general health and with good oral hygiene. Teeth with IBD deeper than or equal to 4 mm with 3-wall defects were included. Endodontically treated teeth, teeth with crowns or fixed partial dentures were excluded. Smokers were excluded. All patients had received non-surgical periodontal treatment without antibiotic therapy. Age ranging between 35<B> </B>and 66; 18 males and 21 females recruited at Department of Periodontology, Catholic University of Sacred Heart, Rome, Italy, and treated by the same clinician.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-15 18:49:34 +0100" MODIFIED_BY="[Empty name]">
<P>Emdogain versus GTR with Gore-Tex non-resorbable barriers. In case of postoperative wound dehiscence in both groups the intervention was repeated.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-15 18:49:46 +0100" MODIFIED_BY="[Empty name]">
<P>PAL, PPD, REC, IBD on standardised intraoral radiographs at baseline, 1 and 3 years. Tooth loss, postoperative complications and adverse events. Additional intrasurgical measurements were taken. 1-year data used.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-07-15 18:51:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Francetti-2004">
<CHAR_METHODS MODIFIED="2009-03-28 18:57:16 +0000" MODIFIED_BY="[Empty name]">
<P>2-year follow-up parallel group study including 2 groups with 24 patients in total. No drop outs at 1 year.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-15 18:51:01 +0100" MODIFIED_BY="[Empty name]">
<P>Patients in good general health and motivated for good oral hygiene. Teeth with PPD greater or equal to 6 mm and IBD greater or equal to 4 mm. 1-, 2- and 3-wall defects were included. Teeth with degree III mobility, necrotic, with incongruous reconstructions or under occlusal trauma were excluded. Patients should not have been treated for periodontitis in the last 3 years. Age ranging between 30 and 66; 11 males and 13 females recruited at 1 university dental clinic.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Emdogain versus flap surgery.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-15 18:51:29 +0100" MODIFIED_BY="[Empty name]">
<P>FMPS, FMBS. For experimental teeth only: PAL, PPD, IBD on standardised intraoral radiographs at baseline, 1 and 2 years. Tooth loss, postoperative infections and adverse events. Additional intrasurgical measurements were taken. 1-year data used.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-07-15 18:53:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Grusovin-2009">
<CHAR_METHODS MODIFIED="2009-07-15 18:52:54 +0100" MODIFIED_BY="[Empty name]">
<P>3-year follow-up parallel-group study including 2 groups with 30 patients in total, however most of the data were presented at 1 year. 1 drop out from the placebo group at 1 year though the 6-month data were evaluated instead.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-15 18:53:12 +0100" MODIFIED_BY="[Empty name]">
<P>Patients in good general health and with good oral hygiene (full mouth plaque, bleeding and bleeding on probing score less than 20%). Teeth with IBD deeper than or equal to 4 mm and larger than or equal to 2 mm. 1-, 2- and 3-wall defects were included. Teeth with vertical tooth mobility, endo-perio lesions and overhangs were excluded. All patients had received systematic periodontal treatments (repeated debridement in some cases supplemented with surgical treatment). Age ranging between 25<B> </B>and 68; 16 males and 14 females recruited at 2 private practices but treated by the same clinician.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-03-22 11:52:01 +0000" MODIFIED_BY="[Empty name]">
<P>Emdogain versus flap surgery and placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-15 18:53:29 +0100" MODIFIED_BY="[Empty name]">
<P>PAL, PPD, REC, IBD on standardised intraoral radiographs at baseline, 6 months, 1 and 3 years but only 1-year data presented. Patient evaluation of treatment and aesthetics at 1 year. Tooth loss, any complications and adverse events. Additional intrasurgical measurements were taken. 1-year data used.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-07-15 18:54:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Heijl-1997">
<CHAR_METHODS MODIFIED="2009-07-15 18:54:17 +0100" MODIFIED_BY="[Empty name]">
<P>3-year follow-up split-mouth study including 33 patients. 3 drop outs at 16 months (tooth extractions in 2 cases and accident for 1 patient).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Patients in good general health and motivated for good oral hygiene. Teeth with PPD greater or equal to 6 mm and IBD greater or equal to 4 mm. 1-, 2- and 3-wall defects were included. All patients had received systematic periodontal treatments (repeated debridement in some cases supplemented with antimicrobial and surgical treatment over long periods of time). Age ranging between 33 and 68; 7 males and 26 females recruited at 3 specialist clinics.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Emdogain versus flap surgery and placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-15 18:54:41 +0100" MODIFIED_BY="[Empty name]">
<P>FMPS and for experimental teeth only: BOP, PAL, PPD, IBD on standardised intraoral radiographs at baseline, 8, 16 months and 3 years. Tooth loss, postoperative infections and adverse events. Additional intrasurgical measurements were taken. 1-year data used.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-07-15 18:55:18 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Leknes-2009">
<CHAR_METHODS MODIFIED="2009-03-28 18:49:13 +0000" MODIFIED_BY="[Empty name]">
<P>1-year follow-up split-mouth study including 13 patients. No drop outs at 1 year. </P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-03-29 11:22:25 +0100" MODIFIED_BY="[Empty name]">
<P>Patients in good general health and motivated for good oral hygiene. Teeth with PPD greater or equal to 6 mm and IBD greater or equal to 3 mm. 2- and 3-wall defects were included. All patients had received 2-4 weeks of subgingival debridement. Age ranging between 41 and 74; 5 males and 8 females recruited at a university clinic.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-03-29 11:24:31 +0100" MODIFIED_BY="[Empty name]">
<P>Emdogain versus a granular ceramic filler (PerioGlas, US Biomaterials, Alachua, FL, USA).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-15 18:55:18 +0100" MODIFIED_BY="[Empty name]">
<P>PAL, PPD, REC, tooth mobility at baseline and 1 year. Tooth loss and postoperative complications. 1-year data used.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-07-15 18:55:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Okuda-2000">
<CHAR_METHODS MODIFIED="2009-03-28 18:59:12 +0000" MODIFIED_BY="[Empty name]">
<P>1-year follow-up split-mouth study including 16 patients. No drop outs at 1 year.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-15 18:55:46 +0100" MODIFIED_BY="[Empty name]">
<P>Patients in good general health and motivated for good oral hygiene. Teeth with PPD greater or equal to 6 mm and IBD greater or equal to 4 mm in presence of 2 mm of keratinized gingiva on the buccal aspect. Patients should not have been treated for periodontitis in the last 2 years. No antibiotics in the previous 6 months. Smokers were excluded. Age ranging between 45 and 67; 8 males and 8 females recruited at 1 university dental clinic.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Emdogain versus flap surgery and placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-15 18:55:54 +0100" MODIFIED_BY="[Empty name]">
<P>FMPS and FMBS. For experimental teeth only: vertical relative attachment gain, tooth mobility, PAL, PPD, REC, IBD on standardised intraoral radiographs measured as radiographic bone density at baseline and 1 year. Tooth loss, postoperative infections and adverse events. 1-year data used.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-03-29 11:26:06 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-07-15 18:57:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pontoriero-1999">
<CHAR_METHODS MODIFIED="2009-03-28 18:59:41 +0000" MODIFIED_BY="[Empty name]">
<P>1-year follow-up split-mouth study including 4 parallel arms with 40 patients in total. Only 2 parallel arms evaluated. No drop outs at 1 year. </P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-15 18:56:55 +0100" MODIFIED_BY="[Empty name]">
<P>Patients in good general health and motivated for good oral hygiene. Teeth with PPD greater or equal to 6 mm and IBD greater or equal to 3 mm. In 2 groups, however, defects shallower than 3 mm were included and therefore were excluded from the present review. Age ranging between 32-61; 15 males and 25 females recruited in 1 private practice.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-15 18:57:24 +0100" MODIFIED_BY="[Empty name]">
<P>4 split-mouth groups were included: (1) GTR with Guidor resorbable barriers versus flap surgery; (2) GTR with Resolut resorbable barriers versus flap surgery; (3) GTR with Gore-Tex non-resorbable barriers versus flap surgery; (4) Emdogain versus flap surgery and placebo. We analysed only groups (3) and (4) since in the other 2 groups defects shallower than 3 mm were included.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-15 18:57:31 +0100" MODIFIED_BY="[Empty name]">
<P>FMPS, BOP and for experimental teeth only: PAL, PPD, REC at baseline and 1 year. Tooth loss and postoperative infections. Additional intrasurgical measurements were taken. 1-year data used.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-07-15 18:59:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-R_x00f6_sing-2005">
<CHAR_METHODS MODIFIED="2009-07-15 18:58:19 +0100" MODIFIED_BY="[Empty name]">
<P>1-year follow-up split-mouth study including 16 patients. </P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-15 18:58:50 +0100" MODIFIED_BY="[Empty name]">
<P>Patients in good general health and motivated for good oral hygiene. Teeth with IBD greater or equal to 3 mm and wider than 2 mm on intraoral radiographs. Age ranging between 29-54; patients recruited in 1 university dental clinic.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Emdogain versus flap surgery and placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-15 18:59:14 +0100" MODIFIED_BY="[Empty name]">
<P>FMPS and FMBS. For experimental teeth only: BOP, PAL, PPD, IBD on standardised intraoral radiographs at baseline, 6 months, and 1 year. Tooth loss, postoperative infections and adverse events. Additional intrasurgical measurements were taken. 1-year data used.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-07-15 19:00:15 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sanz-2004">
<CHAR_METHODS MODIFIED="2009-03-28 19:07:14 +0000" MODIFIED_BY="[Empty name]">
<P>1-year follow-up parallel group study including 2 groups with 72 patients in total. 5 drop outs for unknown reasons and from unspecified groups. </P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-15 19:00:08 +0100" MODIFIED_BY="[Empty name]">
<P>Patients in good general health and motivated for good oral hygiene. Teeth with IBD greater or equal to 3 mm in presence of 2 to 3 mm of keratinized gingiva on the buccal aspect. Heavy smokers (&gt; 20 cigarettes per day) were excluded. 1-, 2- and 3-wall defects were included. Age ranging between 43 to 61; females were 54.3% in the test and 53.1% in the control groups. Patients were recruited both from university dental clinics and private practices.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Emdogain versus GTR with Resolut resorbable barriers.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-15 19:00:15 +0100" MODIFIED_BY="[Empty name]">
<P>FMPS and FMBS. For experimental teeth only: PAL, PPD, REC at baseline and 1 year. Postoperative infections. Additional intrasurgical measurements were taken. 1-year data used.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>100% of postoperative complications (flap dehiscence, suppuration) in the GTR group versus 6% in the Emdogain group.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-07-15 19:00:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Silvestri-2000">
<CHAR_METHODS MODIFIED="2009-07-15 19:00:40 +0100" MODIFIED_BY="[Empty name]">
<P>1-year follow-up parallel-group study including 3 groups with 30 patients in total. No drop outs at 1 year.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-15 19:00:48 +0100" MODIFIED_BY="[Empty name]">
<P>Patients in good general health and motivated for good oral hygiene. Teeth with PPD greater or equal to 6 mm and IBD greater or equal to 4 mm. Smokers were excluded. Age ranging between 37 and 59; 11 males and 19 females recruited in 1 university dental clinic and several private practices.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Emdogain versus GTR with Gore-Tex non-resorbable barriers versus flap surgery.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-15 19:00:53 +0100" MODIFIED_BY="[Empty name]">
<P>FMPS and FMBS. For experimental teeth only: PAL, PPD, REC at baseline and 1 year. Tooth loss and postoperative infections. 1-year data used.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-07-15 19:01:43 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Silvestri-2003">
<CHAR_METHODS MODIFIED="2009-07-15 19:01:21 +0100" MODIFIED_BY="[Empty name]">
<P>1-year follow-up parallel-group study including 2 groups with 100 patients in total. 2 drop outs at 1 year. 2 patients (1 from each group) did not show up at the 1-year examination for personal reasons.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-15 19:01:36 +0100" MODIFIED_BY="[Empty name]">
<P>Patients in good general health and motivated for good oral hygiene. Teeth with PPD greater or equal to 6 mm and IBD greater or equal to 4 mm. Smokers (&gt; 10 cigarettes per day) were excluded. 1-, 2- and 3-wall defects were included. Age ranging between 39 and 58; 45 males and 53 females recruited in 1 university dental clinic and several private practices.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Emdogain versus GTR with Gore-Tex non-resorbable barriers.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-15 19:01:43 +0100" MODIFIED_BY="[Empty name]">
<P>FMPS and FMBS. For experimental teeth only: PAL, PPD, REC at baseline and 1 year. Tooth loss and postoperative infections. Additional intrasurgical measurements were taken. 1-year data used.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-07-15 19:02:52 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tonetti-2002">
<CHAR_METHODS MODIFIED="2009-07-15 19:02:38 +0100" MODIFIED_BY="[Empty name]">
<P>1-year follow-up parallel-group study including 2 groups with 172 patients in total. 6 drop outs at 1 year. 3 patients withdrew consent before surgery. 3 patients (2 from the test and 1 from the control group) were unable to comply with the follow up for reasons independent from the treatments.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-15 19:02:46 +0100" MODIFIED_BY="[Empty name]">
<P>Patients in good general health and motivated for good oral hygiene. Teeth with IBD greater or equal to 3 mm in presence of 2 to 3 mm of keratinized gingiva on the buccal aspect. Heavy smokers (&gt; 20 cigarettes per day) were excluded. 1-, 2- and 3-wall defects were included. Age ranging between 39 and 57; females were 54.2% in the test and 60.2% in the control groups. Patients were recruited both from university dental clinics and private practices.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Emdogain versus flap surgery.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-15 19:02:52 +0100" MODIFIED_BY="[Empty name]">
<P>FMPS and FMBS. For experimental teeth only: PAL, PPD, REC at baseline and 1 year. Tooth loss and postoperative infections. Additional intrasurgical measurements were taken. 1-year data used. Postoperative morbidity, patient satisfaction, aesthetics and several other patient-centred outcomes were evaluated.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-07-15 19:03:49 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zucchelli-2002">
<CHAR_METHODS MODIFIED="2009-07-15 19:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>1-year follow-up parallel-group study including 3 groups with 90 patients in total. No drop outs at 1 year.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-15 19:03:44 +0100" MODIFIED_BY="[Empty name]">
<P>Patients in good general health and motivated for good oral hygiene. Teeth with PPD greater or equal to 7 mm and IBD greater or equal to 3 mm. Heavy smokers (more than 20 cigarettes per day) were excluded. No antibiotics in the previous 6 months. Age ranging between 39 and 57; 30 males and 61 females. Patients were recruited from 1 university dental clinic and several private practices.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Emdogain versus GTR with Gore-Tex titanium-reinforced non-resorbable barriers versus flap surgery.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-15 19:03:49 +0100" MODIFIED_BY="[Empty name]">
<P>FMPS and FMBS. For experimental teeth only: PAL, PPD, REC at baseline and 1 year. Tooth loss and postoperative infections. Additional intrasurgical measurements were taken. 1-year data used.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>BOP = bleeding on probing<BR/>FMBS = full mouth bleeding score<BR/>FMPS = full mouth plaque score<BR/>GTR = guided tissue regeneration<BR/>IBD = intrabony depth<BR/>PAL = probing attachment level<BR/>PPD = probing pocket depth<BR/>REC = gingival recession<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2009-07-16 11:09:12 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2009-07-15 19:04:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bokan-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-15 19:04:40 +0100" MODIFIED_BY="[Empty name]">
<P>Different flap designs used in test and control sites that made the comparison inappropriate to answer the question of this review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-16 11:09:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chambrone-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-16 11:09:12 +0100" MODIFIED_BY="[Empty name]">
<P>Included patients with less than 3 mm intrabony defect component and follow up to 6 months.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Doertbudak-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Authors informed us that trial was a CCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Eger-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Francetti-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Multicentre study comparing Emdogain versus control, with data presented on site not patient basis. The authors have replied to a request for further information however have not supplied this.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Froum-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Trial comparing Emdogain versus control. This study was designed as a split-mouth study, and the data are presented for 53 defects in Emdogain group and 31 defects in control, in 23 subjects. The presentation of the data does not include an estimate of the standard error for the paired data and cannot therefore be included in the meta-analyses for this review. The authors have replied to a request for further information however they have not supplied the required standard errors, or variance estimates, despite repeated requests as suggested by one of the referees.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ghaffar-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Insufficient data presented. Written to author and sponsor but no reply to letters.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hagenaars-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Trial designed to evaluate the early postoperative phase (up to 8 weeks). Written to authors asking whether longer follow up was planned, but they replied that this was not their intention.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lombardo--2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Judged to be a CCT. No reply to letter.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Martinez-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Insufficient data presented. No reply to letter.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Martu-2000a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Judged to be a CCT. No reply to letter. Possibly same trial as Marthu 2000b.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Martu-2000b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Judged to be a CCT. No reply to letter. Possibly same trial as Marthu 2000a.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-15 19:05:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Minabe-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-15 19:05:25 +0100" MODIFIED_BY="[Empty name]">
<P>Parallel-group study with more than 1 site per patient treated in the Emdogain group. We are unable to extract data at a patient level. Authors did not respond to our request for further data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-03-18 10:34:57 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mombelli-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-03-18 10:34:57 +0000" MODIFIED_BY="[Empty name]">
<P>Included patients with less than 3 mm intrabony defect component.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-15 19:05:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ozcelik-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-15 19:05:31 +0100" MODIFIED_BY="[Empty name]">
<P>No outcomes of interest and follow up of only 1 week.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Parashis-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Authors informed us that trial was a CCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-15 19:05:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sculean-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-15 19:05:42 +0100" MODIFIED_BY="[Empty name]">
<P>Study designed so that teeth are extracted after 6 months. Unclear if this is the same study as Windisch 2002.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-03-21 15:48:29 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sculean-2001a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-03-21 15:48:29 +0000" MODIFIED_BY="[Empty name]">
<P>Included patients with less than 3 mm intrabony defect component.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-03-21 15:48:33 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sculean-2001b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-03-21 15:48:33 +0000" MODIFIED_BY="[Empty name]">
<P>Included patients with less than 3 mm intrabony defect component.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-15 19:05:57 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vandana-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-15 19:05:57 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear whether RCT or CCT. Authors replied it was a RCT. Trial excluded since the follow up was 9 months instead of 1 year and the intrabony components of some defects were less than 3 mm.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-15 19:06:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wachtel-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-15 19:06:09 +0100" MODIFIED_BY="[Empty name]">
<P>Split-mouth study with more than 1 site per quadrant treated with 1 intervention. We were unable to extract simple 'paired data' for each patient and the authors did not respond to our request for further data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-15 19:06:18 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Windisch-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-15 19:06:18 +0100" MODIFIED_BY="[Empty name]">
<P>6-month study designed so that teeth are extracted after 6 months. Unclear if this is the same study as Sculean 1999.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>CCT = controlled clinical trial<BR/>RCT = randomised controlled trial</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2009-03-18 10:33:22 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2009-11-05 16:38:38 +0000" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2009-07-15 18:51:38 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-12 15:48:06 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Crea-2008">
<DESCRIPTION>
<P>Quote: "At the beginning of the study, the 40 recruited patients were randomly assigned to one of the two treatment groups (n = 20 per group). Study statisticians prepared a randomized, numbered (1 to 40) list with the technique as variable, and forms with the chosen treatment modality were put into envelopes with the corresponding number on the outside".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-15 18:51:38 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Francetti-2004">
<DESCRIPTION>
<P>Quote: "They were subsequently allocated to either test or control group in accordance with a 1:1 computer-generated randomization list".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-04-30 23:09:45 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Grusovin-2009">
<DESCRIPTION>
<P>Quote: "A manual restricted randomisation list was generated by a person not involved in the study and stored in a password-protected computer. The randomisation codes were associated to the sequential numbers given to the patients and applied to identical packages by the same person".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-26 13:51:46 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Heijl-1997">
<DESCRIPTION>
<P>Quote: "The sites were distinguished by their tooth number (18 through 48) and the randomization code specified the treatment assignment for the site with the lowest as well as highest tooth number. The randomization process targeted one of the sites for test treatment and the other site for control treatment. Patient numbers were assigned in chronological order as patients were enrolled in the trial".</P>
<P>Author's reply: "Randomization codes were computer generated in blocks".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-26 13:58:06 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Leknes-2009">
<DESCRIPTION>
<P>Quote: "...assigned randomly (by flipping a coin) to EMD or BCF treatment using a split-mouth design".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-18 02:32:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Okuda-2000">
<DESCRIPTION>
<P>Quote: "The paired intrabony defects selected for treatment were randomly assigned to receive either the EMD treatment or the placebo treatment by a flip of a coin".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-15 20:52:48 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pontoriero-1999">
<DESCRIPTION>
<P>Quote: "The 40 subjects were randomly divided into 4 treatment groups including 10 subjects each: 3 membrane groups and one Emdogain® group".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-02 15:04:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-R_x00f6_sing-2005">
<DESCRIPTION>
<P>Quote: "Then, by means of the flip of a coin, the experimental (EMD) and the placebo (both provided by the manufacturer) solutions were applied in accordance to the instructions".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-02 15:35:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sanz-2004">
<DESCRIPTION>
<P>Quote: "All subjects were assigned a patient number and were assigned to one of the two treatment regimens using a random number table".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-16 15:54:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Silvestri-2000">
<DESCRIPTION>
<P>Quote: "Once the patients met on all entry criteria, they were randomly (Fleiss 1992) assigned to 1 of 3 surgical procedures".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-03 17:44:23 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Silvestri-2003">
<DESCRIPTION>
<P>Quote: "Group assignment was determined by central randomization using balanced random permuted blocks".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-03 18:31:49 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tonetti-2002">
<DESCRIPTION>
<P>Quote: "All subjects were assigned a patient number, and were randomly assigned to one of the two treatment regiments. Assignment was performed by a central randomization facility using a custom-made program based on balanced random permuted blocks".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-03 18:51:45 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zucchelli-2002">
<DESCRIPTION>
<P>Quote: "Before surgery, assignment to the 3 treatment regimens (30 patients/group) was performed using a custom-made program based on balanced permuted blocks".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2009-11-05 16:38:38 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-04-30 14:24:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Crea-2008">
<DESCRIPTION>
<P>Quote: "The sealed envelopes were placed into the custody of a surgeon (LD) who was not involved in diagnosis or treatment delivery. After the defect was degranulated, surgeon LD entered the surgical room, opened an envelope bearing the number by which the patient would subsequently be identified, and informed the surgeon which randomly assigned treatment was to be performed".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-15 18:51:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Francetti-2004">
<DESCRIPTION>
<P>Quote: "The allocation to treatment group was concealed from clinicians until the patients received the treatment".</P>
<P>Comment: Author informed us that the allocation to the intervention groups was concealed. During surgery, after debridement a sequentially numbered sealed opaque envelope containing the randomisation code was opened.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-04-30 23:09:56 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Grusovin-2009">
<DESCRIPTION>
<P>Quote: "At the time of EDTA conditioning the package was opened according to the sequential number. Division in two groups according to the code was done at the time of statistical analysis. The code assigned to the treatment was known only by the person not involved in the study that generated the codes and was disclosed after data processing (3 years after the last patient was treated)".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-01 18:23:43 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Heijl-1997">
<DESCRIPTION>
<P>Quote: "At the time of periodontal surgery, and only after the first surgical site was fully prepared, the envelope containing the randomisation code was opened to expose treatment assignments".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-01 18:24:16 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Leknes-2009">
<DESCRIPTION>
<P>Quote: "A mucoperiosteal flap was elevated using a sulcular incision under local anaesthesia. Vertical release incisions were used as necessary. The defects were evaluated and, if meeting the inclusion criteria with regard to defect configuration, they were assigned randomly (by flipping a coin) to EMD or BCF treatment using a split-mouth design".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-15 18:56:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Okuda-2000">
<DESCRIPTION>
<P>Author's reply: "At first a surgeon operated open flap and debridement at both sites. After these procedures<BR/>were finished, the surgeon was put a blindfold condition. At next stage, another person who was not involved in the surgery, applied EMD or placebo to the site determined by a flip of a coin. The surgeon again open eyes, sutured the flap".<BR/>
<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-28 18:59:48 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pontoriero-1999">
<DESCRIPTION>
<P>Author informed us that allocation to intervention group was concealed, but did not explain how.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-15 18:59:30 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-R_x00f6_sing-2005">
<DESCRIPTION>
<P>Quote: "The present study was carried out according to a typical double-masked, split-mouth design, with the codes kept by the manufacturer until the data had been collected and organised in the computer program for statistical analysis".</P>
<P>Author's reply: "Randomization of the site was decided with the flip of a coin after debridement of both sites and application of the EDTA solution".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-05 16:38:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sanz-2004">
<DESCRIPTION>
<P>Quote: "Clinicians were not aware of treatment allocation until after root debridement".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-28 19:06:50 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Silvestri-2000">
<DESCRIPTION>
<P>Author informed us that group allocation was not concealed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-26 14:53:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Silvestri-2003">
<DESCRIPTION>
<P>Author's reply: "The clinicians learned the treatment during the surgery after defect debridement by a code inside an envelope".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-28 19:08:52 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tonetti-2002">
<DESCRIPTION>
<P>Author informed us that the allocation to the intervention groups was concealed. During surgery, after debridement, a sealed opaque envelope containing the randomisation code was opened.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-28 19:09:12 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zucchelli-2002">
<DESCRIPTION>
<P>Author informed us that allocation to intervention group was concealed, but did not explain how.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2009-07-15 18:56:14 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-05-14 12:15:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Crea-2008">
<DESCRIPTION>
<P>Quote: "The researchers who performed the measurements (GD) and the randomization (GGZ) did not include the periodontist who performed the initial treatment or the surgeon who provided the surgical treatment. Hence, the examiner was masked to the treatment designations and was not involved in the delivery of treatment or maintenance care".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-07-15 18:51:55 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Francetti-2004">
<DESCRIPTION>
<P>Quotes: "It was conducted according to an open-label, randomized parallel study protocol". "Patients were blinded as to treatment assignment throughout the study". "All radiographs were evaluated by a single examiner blind to treatment".</P>
<P>Comment: Assessor was not blinded for the clinical outcomes due to open-label procedure. He was blinded only for the radiographic evaluation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-04-30 23:10:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Grusovin-2009">
<DESCRIPTION>
<P>Quote: "Since the same packing was used for Emdogain and placebo the treatment was blind to the operator who also acted as outcome assessor".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-05-14 23:55:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Heijl-1997">
<DESCRIPTION>
<P>Quotes: "Readings of all radiographs were performed by a separate, blinded examiner and in a randomised fashion". "All re-examination measurements were made by the same blinded investigator who made the initial measurements".</P>
<P>Comment: Assessors were blinded both for the clinical and radiographic outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-07-15 18:55:30 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Leknes-2009">
<DESCRIPTION>
<P>Quote: "The clinical examinations were performed by one examiner who was not involved in the surgical procedure and was masked with regard to the treatment".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-07-15 18:56:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Okuda-2000">
<DESCRIPTION>
<P>Quote: "The clinical examinations were performed by a single examiner (author KO), who was not involved in the surgical procedures".</P>
<P>Also the author made it clear that the trial was triple blinded, i.e. patient, clinicians and evaluators had no information regarding the treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-05-02 14:20:17 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pontoriero-1999">
<DESCRIPTION>
<P>Author informed us that both the outcome assessor and the patients were blinded to which site received which treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-05-16 11:11:33 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-R_x00f6_sing-2005">
<DESCRIPTION>
<P>Quote: "Analysis of the radiographic outcomes were performed using computerized linear measurements from the cemento-enamel junction (CEJ) to the bone crest (BC), CEJ to the bottom of the defect (BD), and BC to BD by an examiner masked to time and treatment. All clinical and radiographic measurements were performed according to a double-masked protocol".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-05-02 15:37:11 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sanz-2004">
<DESCRIPTION>
<P>Quote: "In each center a single clinician served as examiner and surgeon".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-05-03 17:20:22 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Silvestri-2000">
<DESCRIPTION>
<P>Author informed us that no blinding method was used.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-05-03 17:33:00 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Silvestri-2003">
<DESCRIPTION>
<P>Author informed us that no blinding method was used.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-05-03 18:26:08 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Tonetti-2002">
<DESCRIPTION>
<P>Quote: "In each center, the examiner and the therapist were identical".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-05-03 19:01:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zucchelli-2002">
<DESCRIPTION>
<P>Quote: "A single investigator blinded with respect to the treatments, performed the clinical measurements at baseline and at 1 year".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2009-07-15 19:04:01 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-07-15 18:50:09 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Crea-2008">
<DESCRIPTION>
<P>Outcome data are presented in Table 2: Changes in clinical parameters over time.</P>
<P>Comment: No missing outcome data. Drop out is explained adequately.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-07-15 18:52:00 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Francetti-2004">
<DESCRIPTION>
<P>Outcome data are presented in Table 1: Mean values of the parameters at baseline and after 12 months and 24 months.</P>
<P>Comment: No missing outcome data. No drop outs.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-07-15 18:53:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Grusovin-2009">
<DESCRIPTION>
<P>Outcome data for 30 patients are presented in Tables 3, 4 and 5.</P>
<P>Comment: No missing outcome data. Drop outs are explained adequately.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-07-15 18:55:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Heijl-1997">
<DESCRIPTION>
<P>Outcome data are presented in Table 3: Mean values for pocket depth, clinical attachment level and radiographic bone level.</P>
<P>Comment: No missing outcome data. Drop outs are explained adequately.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-07-15 18:55:32 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Leknes-2009">
<DESCRIPTION>
<P>Clinical outcome data for PPD, PAL and REC are presented in Tables 2, 3 and 4.</P>
<P>Comment: No missing outcome data. No drop outs.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-07-15 18:56:22 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Okuda-2000">
<DESCRIPTION>
<P>Outcome data are presented in Table 3: Mean clinical and radiographical (RBD) changes at 12 months (mean ± SD).</P>
<P>Comment: No missing data. No drop outs.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-07-15 18:57:43 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pontoriero-1999">
<DESCRIPTION>
<P>Outcome data on PAL, PPD and REC are presented in Table 2: Result of GTR and Emdogain® therapy.</P>
<P>Comment: No missing data. No drop outs.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-07-15 18:59:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-R_x00f6_sing-2005">
<DESCRIPTION>
<P>Outcome data are presented in Tables 1 and 3.</P>
<P>Comment: No missing data. Drop outs are explained adequately.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-07-15 19:00:26 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sanz-2004">
<DESCRIPTION>
<P>All outcome data for PAL, PPD and REC are presented in Clinical Outcomes part of the Results section of the paper.</P>
<P>Comment: No missing data regarding PAL, PPD and REC. Unclear explanation for the 5 drop outs and withdrawals.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-07-15 19:01:03 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Silvestri-2000">
<DESCRIPTION>
<P>Outcome data for PAL, PPD and REC are presented in Table 1.</P>
<P>Comment: No missing data. No drop outs.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-07-15 19:02:03 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Silvestri-2003">
<DESCRIPTION>
<P>Outcome data for PAL and PPD are reported in Table 3: PAL gain and PD reduction for the two groups 1 year postop.</P>
<P>Comment: The reason for 2 drop outs (1 for each group) was explained.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-07-15 19:03:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tonetti-2002">
<DESCRIPTION>
<P>All outcome data are presented in Table 2: Clinical outcomes at 1 year.</P>
<P>Comment: No missing data. Drop outs are explained adequately.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-07-15 19:04:01 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zucchelli-2002">
<DESCRIPTION>
<P>Outcome data are presented in Table 2: Clinical parameters at 1 year.</P>
<P>Comment: No missing data. No drop outs.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2009-07-15 19:04:10 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-15 18:50:17 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Crea-2008">
<DESCRIPTION>
<P>All the pre-specified clinical outcomes are properly presented in Table 2: Changes in clinical parameters over time.</P>
<P>Adverse events are reported in the Results section. No teeth were extracted. This trial has not evaluated aesthetics.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-15 18:52:15 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Francetti-2004">
<DESCRIPTION>
<P>All the pre-specified outcomes are properly presented in Table 1: Mean values of the parameters at baseline and after 12 months and 24 months.</P>
<P>No adverse events for 1-year data. No teeth were extracted. REC and aesthetics were not evaluated as treatment outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-26 13:42:48 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Grusovin-2009">
<DESCRIPTION>
<P>All the pre-specified clinical outcomes are properly presented in Tables 3, 4 and 5.</P>
<P>The aesthetic evaluation is reported in Table 6. No adverse events are reported and no teeth were extracted.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-15 18:55:06 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Heijl-1997">
<DESCRIPTION>
<P>All the primary pre-specified clinical outcomes are properly presented in Table 3: Mean values for pocket depth, clinical attachment level and radiographic bone level.</P>
<P>Adversed events are reported in Safety (AEs) section. 4 teeth were extracted, 2 for each group. REC and aesthetics were not evaluated as treatment outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-26 15:27:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Leknes-2009">
<DESCRIPTION>
<P>All primary pre-specified outcomes are reported in Tables 2, 3 and 4.</P>
<P>Comment: Infrabony defects were recorded at baseline on periapical radiographs but were not reported. No adverse complications were seen or reported. No teeth were extracted. Aesthetics were not evaluated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-15 18:56:27 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Okuda-2000">
<DESCRIPTION>
<P>All pre-specified outcomes for PPD, PAL, REC and IBD are reported in Table 3: Mean clinical and radiographical (RBD) changes at 12 months (mean ± SD).</P>
<P>No teeth were extracted and no adverse complications were reported. Aesthetics were not evaluated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-15 18:58:09 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pontoriero-1999">
<DESCRIPTION>
<P>All pre-specified outcomes are reported in Tables 2 and 4.</P>
<P>Comment: Only data from the Gore-Tex® and Emdogain® groups (3 and 4) are included in this review. Data from the other 2 groups had to be excluded on the basis of not meeting the 3 mm intrabony defect criterion.</P>
<P>The author informed us that no teeth were extracted and no postoperative complication was reported. Changes in bone level and aesthetics were not evaluated as treatment outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-16 11:51:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-R_x00f6_sing-2005">
<DESCRIPTION>
<P>All pre-specified outcomes for PPD, PAL and IBD are reported in Tables 1 and 3.</P>
<P>2 teeth were extracted. No adverse events were noted. REC and aesthetics were not evaluated as treatment outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-15 19:00:34 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sanz-2004">
<DESCRIPTION>
<P>All the pre-specified outcomes are reported in the Results section of the paper.</P>
<P>Tooth loss was not described. Postoperative complications are discussed in the Results and Discussion parts of the paper but not clearly described, not even after requesting the data. Changes in bone level and aesthetics were not evaluated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-17 17:45:57 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Silvestri-2000">
<DESCRIPTION>
<P>All the pre-specified outcomes are reported in Table 1.</P>
<P>No teeth were extracted. Aesthetics and changes in bone level were not evaluated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-15 19:02:17 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Silvestri-2003">
<DESCRIPTION>
<P>Only PAL and PPD outcomes are reported in Table 3: PAL gain and PD reduction for the two groups 1 year postop.</P>
<P>Comment: No teeth were extracted. No report of REC in 1-year data. Aesthetics and changes in bone level were not evaluated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-15 19:03:30 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tonetti-2002">
<DESCRIPTION>
<P>All the pre-specified outcomes are reported in Table 2: Clinical outcomes at 1 year.</P>
<P>No teeth were extracted. No infectious complications were observed. The aesthetics evaluation was reported in Tonetti et al 2004 JCP 31:1092-8. Changes in bone level were not assessed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-15 19:04:10 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zucchelli-2002">
<DESCRIPTION>
<P>All pre-specified outcomes are reported in Table 2: Clinical parameters at 1 year.</P>
<P>Postoperative infections are reported in Early Healing Event part of the Results section of the paper. No teeth were extracted. Aesthetics and changes in bone level were not evaluated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2009-07-15 18:50:27 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-15 18:50:27 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Crea-2008">
<DESCRIPTION>
<P>Quote: "The authors report no conflicts of interest related to this study. No financial or material support was provided by any company to the authors or the patients involved in this study".</P>
<P>Comment: The GTR group had slightly more advanced periodontal disease than the EMD group for all outcomes on baseline. Nevertheless there is no indication of extreme baseline imbalance.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-26 13:40:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Francetti-2004">
<DESCRIPTION>
<P>No other source of bias can be identified. No fixed reference points were used in the radiographic assessment and therefore we decided not to use those data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-26 13:47:32 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Grusovin-2009">
<DESCRIPTION>
<P>Quote: "It was planned to include 50 patients per group; however, the trial had to be stopped after the first 30 patients were included owing to lack of placebo".</P>
<P>Comment: Early termination of trial precluded the achievement of the planned sample size.</P>
<P>Comment: Although the manufacturer provided the placebos, this trial has been conducted independently.</P>
<P>Comment: The average baseline intrabony component was 1 mm deeper and 1.1 mm wider in EMD group than placebo group. Nonetheless this slight imbalance is not considered significant enough to increase selection bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-26 13:52:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Heijl-1997">
<DESCRIPTION>
<P>The trial was supported by the manufacturer.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-01 18:53:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Leknes-2009">
<DESCRIPTION>
<P>No other source of bias can be identified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-01 22:27:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Okuda-2000">
<DESCRIPTION>
<P>No other source of bias can be identified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-02 14:42:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pontoriero-1999">
<DESCRIPTION>
<P>No other source of bias can be identified. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-02 15:12:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-R_x00f6_sing-2005">
<DESCRIPTION>
<P>Although EMD and placebo materials were provided by the manufacturer, this was an independently conducted study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-16 13:23:21 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sanz-2004">
<DESCRIPTION>
<P>The study received a research grant from the manufacturer Biora AB. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-26 15:06:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Silvestri-2000">
<DESCRIPTION>
<P>Manufacturers partially supported the trial by offering free materials. We do not think that this has affected the outcome of the trial.</P>
<P>Connective tissue grafts were placed in 6 patients after membrane removal. We are unsure whether this affected the outcome of the trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-26 15:11:32 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Silvestri-2003">
<DESCRIPTION>
<P>The manufacturer partially supported the trial. We do not think that this has affected the outcome of the trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-26 15:12:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tonetti-2002">
<DESCRIPTION>
<P>The trial was partially supported with a research grant from the manufacturer. We do not think that this has affected the outcome of the trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-03 19:03:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zucchelli-2002">
<DESCRIPTION>
<P>No other source of bias can be identified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2010-11-29 16:29:29 +0000" MODIFIED_BY="Helen Worthington">
<SOF_TABLE ID="SOF-01" MODIFIED="2010-11-29 16:25:28 +0000" MODIFIED_BY="Helen Worthington" NO="1">
<TITLE MODIFIED="2009-04-01 12:07:10 +0100" MODIFIED_BY="[Empty name]">Summary of findings</TITLE>
<TABLE COLS="7" ROWS="11">
<TR>
<TD COLSPAN="7">
<P>
<B>Emdogain compared with Control for periodontal tissue regeneration in intrabony defects</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:patients</B> <B>with intrabony defects</B>
</P>
<P>
<B>Settings: practice</B>
</P>
<P>
<B>Intervention: Emdogain</B>
</P>
<P>
<B>Comparison: Control flap surgery</B>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>Outcomes</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="2" VALIGN="MIDDLE">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>Assumed risk</P>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>Control flap surgery</P>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>Emdogain</P>
</TH>
</TR>
<TR>
<TD>
<P>Tooth loss</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P/>
</TD>
<TD ALIGN="CENTER">
<P>371<BR/>[9]</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>too few teeth lost to undertake analysis</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>PAL<SUP>1</SUP>
</P>
<P>mm gain from baseline</P>
<P>1 year</P>
</TD>
<TD ALIGN="CENTER">
<P>The mean PAL gain ranged across control groups from<BR/>0.8 to 2.2</P>
</TD>
<TD ALIGN="CENTER">
<P>The mean PAL gain in the intervention groups was<BR/>1.1 higher<BR/>(0.6 to 1.6 higher)</P>
</TD>
<TD>
<P/>
</TD>
<TD ALIGN="CENTER">
<P>
<BR/>371<BR/>[9]</P>
</TD>
<TD ALIGN="CENTER">
<P/>
<P/>
<P>++OO<BR/>low</P>
<P/>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Aesthetics</P>
</TD>
<TD>
<P>The mean VAS score for the control group was 62</P>
<P/>
</TD>
<TD ALIGN="CENTER">
<P>The mean VAS gain in the intervention groups was<BR/>1.0 higher<BR/>(-5.4 to 7.4)</P>
</TD>
<TD>
<P/>
</TD>
<TD ALIGN="CENTER">
<P>
<BR/>166<BR/>[1]</P>
</TD>
<TD ALIGN="CENTER">
<P>++OO<BR/>low</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>PPD<SUP>2</SUP>
</P>
<P>mm reduction from baseline</P>
<P>1 year</P>
</TD>
<TD ALIGN="CENTER">
<P>The mean PPD reduction ranged across control groups from<BR/>1.4 to 4.5</P>
</TD>
<TD ALIGN="CENTER">
<P>The mean PPD reduction in the intervention groups was<BR/>0.7 higher<BR/>(0.5 to 1.0 higher)</P>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD ALIGN="CENTER">
<P>
<BR/>371<BR/>[9]</P>
</TD>
<TD ALIGN="CENTER">
<P/>
<P>++OO<BR/>low</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>REC<SUP>3</SUP>
</P>
<P>mm change from baseline</P>
<P>1 year</P>
</TD>
<TD ALIGN="CENTER">
<P>The mean REC ranged across control groups from<BR/>-1.7 to -0.2</P>
</TD>
<TD ALIGN="CENTER">
<P>The mean REC in the intervention groups was<BR/>0.02 higher (-0.3 to 0.3 higher)(less recession)<BR/>
</P>
</TD>
<TD>
<P/>
</TD>
<TD ALIGN="CENTER">
<P>
<BR/>302<BR/>[6]</P>
</TD>
<TD ALIGN="CENTER">
<P>++OO<BR/>low</P>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<BR/>CI: Confidence interval; GRADE: GRADE Working Group grades of evidence (see explanations)</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality (++++):</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality (+++O):</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality (++OO):</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality (+OOO):</B> We are very uncertain about the estimate.</P>
<P>1 probing attachment level</P>
<P>2 probing pocket depth</P>
<P>3 gingival recession</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2010-11-29 16:29:29 +0000" MODIFIED_BY="Helen Worthington" NO="2">
<TITLE MODIFIED="2009-04-01 12:20:56 +0100" MODIFIED_BY="[Empty name]">Summary of findings</TITLE>
<TABLE COLS="7" ROWS="11">
<TR>
<TD COLSPAN="7">
<P>
<B>Emdogain compared with GTR for periodontal tissue regeneration in intrabony defects</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:patients</B> <B>with intrabony defects</B>
</P>
<P>
<B>Settings: practice</B>
</P>
<P>
<B>Intervention: Emdogain</B>
</P>
<P>
<B>Comparison: GTR</B>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>Outcomes</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="2" VALIGN="MIDDLE">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>Assumed risk</P>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>GTR<SUP>4</SUP>
</P>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>Emdogain</P>
</TH>
</TR>
<TR>
<TD>
<P>Tooth loss</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P/>
</TD>
<TD ALIGN="CENTER">
<P>237<BR/>[5]</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>too few teeth lost to undertake analysis</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>PAL<SUP>1</SUP>
</P>
<P>mm gain from baseline</P>
<P>1 year</P>
</TD>
<TD ALIGN="CENTER">
<P>The mean PAL gain ranged across GTR groups from<BR/>2.5 to 4.9</P>
</TD>
<TD ALIGN="CENTER">
<P>The mean PAL gain in the intervention groups was<BR/>0.2 lower<BR/>(-0.20 to 0.55 lower)</P>
</TD>
<TD>
<P/>
</TD>
<TD ALIGN="CENTER">
<P>
<BR/>304<BR/>[6]</P>
</TD>
<TD ALIGN="CENTER">
<P>++OO<BR/>low</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>PPD<SUP>2</SUP>
</P>
<P>mm reduction from baseline</P>
<P>1 year</P>
</TD>
<TD ALIGN="CENTER">
<P>The mean PPD reduction ranged across GTR groups from<BR/>3.3 to 6.5</P>
</TD>
<TD ALIGN="CENTER">
<P>The mean PPD reduction in the intervention groups was<BR/>0.4 lower<BR/>(-0.2 to 1.1 lower)</P>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD ALIGN="CENTER">
<P>
<BR/>304<BR/>[6]</P>
</TD>
<TD ALIGN="CENTER">
<P>++OO<BR/>low</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Aesthetics</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P/>
</TD>
<TD ALIGN="CENTER">
<P>0</P>
<P>[0]</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>No studies reported this</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>REC<SUP>3</SUP>
</P>
<P>mm change from baseline</P>
<P>1 year</P>
</TD>
<TD ALIGN="CENTER">
<P>The mean REC change ranged across GTR groups from<BR/>-1.8 to 1.0</P>
</TD>
<TD ALIGN="CENTER">
<P>The mean REC change in the intervention groups was<BR/>0.4 higher (0.2 to 0.7 higher)(less recession)<BR/>
</P>
</TD>
<TD>
<P/>
</TD>
<TD ALIGN="CENTER">
<P>
<BR/>206<BR/>[5]</P>
</TD>
<TD ALIGN="CENTER">
<P>++OO<BR/>low</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<BR/>CI: Confidence interval; GRADE: GRADE Working Group grades of evidence (see explanations)</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality (++++):</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality (+++O):</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality (++OO):</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality (+OOO):</B> We are very uncertain about the estimate.</P>
<P>1 probing attachment level</P>
<P>2 probing pocket depth</P>
<P>3 gingival recession</P>
<P>4 Guided Tissue Regeneration</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2009-07-16 10:23:19 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2009-07-16 09:17:02 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE>Results of quality assessment after correspondence with authors</TITLE>
<TABLE COLS="5" ROWS="14">
<TR>
<TH VALIGN="TOP">
<P>Study</P>
</TH>
<TH VALIGN="TOP">
<P>Concealment of allocation</P>
</TH>
<TH VALIGN="TOP">
<P>Blinding of assessor</P>
</TH>
<TH VALIGN="TOP">
<P>Reasons for drop outs</P>
</TH>
<TH VALIGN="TOP">
<P>Risk of bias</P>
</TH>
</TR>
<TR>
<TD>
<P>Heijl 1997</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Reasons given</P>
</TD>
<TD>
<P>Low</P>
</TD>
</TR>
<TR>
<TD>
<P>Pontoriero 1999</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>No drop outs</P>
</TD>
<TD>
<P>High</P>
</TD>
</TR>
<TR>
<TD>
<P>Okuda 2000</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>No drop outs</P>
</TD>
<TD>
<P>Low</P>
</TD>
</TR>
<TR>
<TD>
<P>Silvestri 2000</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No drop outs</P>
</TD>
<TD>
<P>High</P>
</TD>
</TR>
<TR>
<TD>
<P>Tonetti 2002</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Reasons given</P>
</TD>
<TD>
<P>High</P>
</TD>
</TR>
<TR>
<TD>
<P>Zucchelli 2002</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>No drop outs</P>
</TD>
<TD>
<P>High</P>
</TD>
</TR>
<TR>
<TD>
<P>Silvestri 2003</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Reasons given</P>
</TD>
<TD>
<P>High</P>
</TD>
</TR>
<TR>
<TD>
<P>Francetti 2004</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No drop outs</P>
</TD>
<TD>
<P>High</P>
</TD>
</TR>
<TR>
<TD>
<P>Sanz 2004</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No reasons given</P>
</TD>
<TD>
<P>High</P>
</TD>
</TR>
<TR>
<TD>
<P>Rösing 2005</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Reasons given</P>
</TD>
<TD>
<P>Low</P>
</TD>
</TR>
<TR>
<TD>
<P>Crea 2008</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Reasons given</P>
</TD>
<TD>
<P>Low</P>
</TD>
</TR>
<TR>
<TD>
<P>Grusovin 2009</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Reasons given</P>
</TD>
<TD>
<P>Low</P>
</TD>
</TR>
<TR>
<TD>
<P>Leknes 2009</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>No drop outs</P>
</TD>
<TD>
<P>Low</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2009-07-16 09:19:07 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE>Random-effects metaregression analysis of outcomes PAL, PPD, REC</TITLE>
<TABLE COLS="7" ROWS="4">
<TR>
<TH>
<P>Characteristic</P>
</TH>
<TH>
<P>Outcome</P>
</TH>
<TH>
<P>Studies</P>
</TH>
<TH>
<P>Slope estimate (SE)</P>
</TH>
<TH>
<P>95% CI</P>
</TH>
<TH>
<P>Slope</P>
</TH>
<TH>
<P>P value</P>
</TH>
</TR>
<TR>
<TD>
<P>Parallel versus split mouth</P>
</TD>
<TD>
<P>PAL</P>
</TD>
<TD>
<P>9</P>
</TD>
<TD>
<P>0.68 (0.63)</P>
</TD>
<TD>
<P>(-0.81, 2.19)</P>
</TD>
<TD>
<P>Emdogain in parallel group trials has higher effect</P>
</TD>
<TD>
<P>0.31</P>
</TD>
</TR>
<TR>
<TD>
<P>Parallel versus split mouth</P>
</TD>
<TD>
<P>PPD</P>
</TD>
<TD>
<P>9</P>
</TD>
<TD>
<P>0.71 (0.66)</P>
</TD>
<TD>
<P>(-0.87, 2.28)</P>
</TD>
<TD>
<P>Emdogain in parallel group trials has higher effect</P>
</TD>
<TD>
<P>0.32</P>
</TD>
</TR>
<TR>
<TD>
<P>Parallel versus split mouth</P>
</TD>
<TD>
<P>REC</P>
</TD>
<TD>
<P>6</P>
</TD>
<TD>
<P>0.28 (0.36)</P>
</TD>
<TD>
<P>(-0.72, 1.28)</P>
</TD>
<TD>
<P>Emdogain in parallel group trials has higher effect</P>
</TD>
<TD>
<P>0.48</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>CI = confidence interval<BR/>PAL = probing attachment level<BR/>PPD = probing pocket depth<BR/>REC = gingival recession</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" MODIFIED="2009-07-16 09:31:00 +0100" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2009-07-16 09:19:23 +0100" MODIFIED_BY="[Empty name]">Control versus Emdogain: PAL at 1 year</TITLE>
<TABLE COLS="5" ROWS="10">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Parallel group/Split mouth</P>
</TH>
<TH>
<P/>
<P>
<B>EMD</B>
</P>
<P/>
<P>
<B>n mean (SD)</B>
</P>
<P/>
</TH>
<TH>
<P/>
<P>
<B>Control</B>
</P>
<P/>
<P>
<B>n  mean (SD)</B>
</P>
<P/>
</TH>
<TH>
<P/>
<P>
<B>Difference </B>
</P>
<P/>
<P>
<B>n mean (SE)</B>
</P>
<P/>
</TH>
</TR>
<TR>
<TD>
<P/>
<P>Silvestri 2000</P>
<P/>
</TD>
<TD>
<P/>
<P>P</P>
<P/>
</TD>
<TD>
<P/>
<P>10 4.5 (1.58)</P>
<P/>
</TD>
<TD>
<P/>
<P>10  1.20 (1.03)</P>
<P/>
</TD>
<TD>
<P/>
<P>20  <B>3.30</B> (0.60)</P>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
<P>Tonetti 2002</P>
<P/>
</TD>
<TD>
<P/>
<P>P</P>
<P/>
</TD>
<TD>
<P/>
<P>83  3.1 (1.5)</P>
<P/>
</TD>
<TD>
<P/>
<P>83  2.5 (1.5)</P>
<P/>
</TD>
<TD>
<P/>
<P>166  <B>0.60</B> (0.23)</P>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
<P>Zucchelli 2002</P>
<P/>
</TD>
<TD>
<P/>
<P>P</P>
<P/>
</TD>
<TD>
<P/>
<P>30  4.2 (0.9)</P>
<P/>
</TD>
<TD>
<P/>
<P>30  2.6 (0.8)</P>
<P/>
</TD>
<TD>
<P/>
<P>60  <B>1.6</B> (0.22)</P>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
<P>Francetti 2004</P>
<P/>
</TD>
<TD>
<P/>
<P>P</P>
<P/>
</TD>
<TD>
<P/>
<P>12  4.14 (1.35)</P>
<P/>
</TD>
<TD>
<P/>
<P>12  2.29 (0.95)</P>
<P/>
</TD>
<TD>
<P/>
<P>24  <B>1.85</B> (0.48)</P>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
<P>Grusovin 2009</P>
<P/>
</TD>
<TD>
<P/>
<P>P</P>
<P/>
</TD>
<TD>
<P/>
<P>15  3.4 (1.1)</P>
<P/>
</TD>
<TD>
<P/>
<P>15  3.3 (1.2)</P>
<P/>
</TD>
<TD>
<P/>
<P>30  <B>0.1</B> (0.42)</P>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
<P>Heijl 1997</P>
<P/>
</TD>
<TD>
<P/>
<P>S</P>
<P/>
</TD>
<TD>
<P/>
<P>31  2.3 (1.6)</P>
<P/>
</TD>
<TD>
<P/>
<P>31  1.7 (1.2)</P>
<P/>
</TD>
<TD>
<P/>
<P>31  <B>0.6</B> (0.22)</P>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
<P>Pontoriero 1999</P>
<P/>
</TD>
<TD>
<P/>
<P>S</P>
<P/>
</TD>
<TD>
<P/>
<P> 10 3.0</P>
<P/>
</TD>
<TD>
<P/>
<P> 10 1.8</P>
<P/>
</TD>
<TD>
<P/>
<P>10 <B>1.1</B> (0.43)</P>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
<P>Okuda 2000</P>
<P/>
</TD>
<TD>
<P/>
<P>S</P>
<P/>
</TD>
<TD>
<P/>
<P>16  1.72 (1.07)</P>
<P/>
</TD>
<TD>
<P/>
<P>16  0.83 (0.86)</P>
<P/>
</TD>
<TD>
<P/>
<P>16  <B>0.89</B> (0.22)</P>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
<P>Rosing 2005</P>
<P/>
</TD>
<TD>
<P/>
<P>S</P>
<P/>
</TD>
<TD>
<P/>
<P>14  2.01 (1.76)</P>
<P/>
</TD>
<TD>
<P/>
<P>14  2.16 (1.87)</P>
<P/>
</TD>
<TD>
<P/>
<P>14  <B>-0.15</B> (0.69) (0.90)*</P>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>*authors' value from e-mail<BR/>PAL = probing attachment level<BR/>SD = standard deviation<BR/>SE = standard error<BR/>
</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-04" MODIFIED="2009-07-16 09:42:32 +0100" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2009-07-16 09:31:33 +0100" MODIFIED_BY="[Empty name]">Control versus Emdogain: PPD at 1 year</TITLE>
<TABLE COLS="5" ROWS="10">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Parallel group/Split mouth</P>
</TH>
<TH>
<P/>
<P>
<B>EMD</B>
</P>
<P/>
<P>
<B>n mean (SD)</B>
</P>
<P/>
</TH>
<TH>
<P/>
<P>
<B>Control</B>
</P>
<P/>
<P>
<B>n  mean (SD)</B>
</P>
<P/>
</TH>
<TH>
<P/>
<P>
<B>Difference </B>
</P>
<P/>
<P>
<B>n mean (SE)</B>
</P>
<P/>
</TH>
</TR>
<TR>
<TD>
<P/>
<P>Silvestri 2000</P>
<P/>
</TD>
<TD>
<P/>
<P>P</P>
<P/>
</TD>
<TD>
<P/>
<P>10  4.9 (1.79)</P>
<P/>
</TD>
<TD>
<P/>
<P>10  1.40 (1.26)</P>
<P/>
</TD>
<TD>
<P/>
<P>20  <B>3.5</B> (0.69)</P>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
<P>Tonetti 2002</P>
<P/>
</TD>
<TD>
<P/>
<P>P</P>
<P/>
</TD>
<TD>
<P/>
<P>83  3.9 (1.7)</P>
<P/>
</TD>
<TD>
<P/>
<P>83  3.3 (1.7)</P>
<P/>
</TD>
<TD>
<P/>
<P>166 <B>0.60</B> (0.26)</P>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
<P>Zucchelli 2002</P>
<P/>
</TD>
<TD>
<P/>
<P>P</P>
<P/>
</TD>
<TD>
<P/>
<P>30  5.1 (0.7)</P>
<P/>
</TD>
<TD>
<P/>
<P>30  4.5 (1.0)</P>
<P/>
</TD>
<TD>
<P/>
<P>60  <B>0.60</B> (0.22)</P>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
<P>Francetti 2004</P>
<P/>
</TD>
<TD>
<P/>
<P>P</P>
<P/>
</TD>
<TD>
<P/>
<P>12  4.71 (1.60)</P>
<P/>
</TD>
<TD>
<P/>
<P>12  2.57 (1.27)</P>
<P/>
</TD>
<TD>
<P/>
<P>24  <B>2.14</B> (0.59)</P>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
<P>Grusovin 2009</P>
<P/>
</TD>
<TD>
<P/>
<P>P</P>
<P/>
</TD>
<TD>
<P/>
<P>15  3.9 (1.0)</P>
<P/>
</TD>
<TD>
<P/>
<P>15  4.2 (1.6)</P>
<P/>
</TD>
<TD>
<P/>
<P>30  <B>0.3</B> (0.49)</P>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
<P>Heijl 1997</P>
<P/>
</TD>
<TD>
<P/>
<P>S</P>
<P/>
</TD>
<TD>
<P/>
<P>31  3.3 (1.4)</P>
<P/>
</TD>
<TD>
<P/>
<P>31  2.6 (1.2)</P>
<P/>
</TD>
<TD>
<P/>
<P>31  <B>0.70</B> (0.25)</P>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
<P>Pontoriero 1999</P>
<P/>
</TD>
<TD>
<P/>
<P>S</P>
<P/>
</TD>
<TD>
<P/>
<P>10  4.4</P>
<P/>
</TD>
<TD>
<P/>
<P>10  3.5 </P>
<P/>
</TD>
<TD>
<P/>
<P>10  <B>0.7</B> (0.47)</P>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
<P>Okuda 2000</P>
<P/>
</TD>
<TD>
<P/>
<P>S</P>
<P/>
</TD>
<TD>
<P/>
<P>16  3.0 (0.97)</P>
<P/>
</TD>
<TD>
<P/>
<P>16  2.22 (0.81)</P>
<P/>
</TD>
<TD>
<P/>
<P>16  <B>0.78</B> (0.32)</P>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
<P>Rosing 2005</P>
<P/>
</TD>
<TD>
<P/>
<P>S</P>
<P/>
</TD>
<TD>
<P/>
<P>14  4.17 (1.80)</P>
<P/>
</TD>
<TD>
<P/>
<P>14  4.39 (1.14)</P>
<P/>
</TD>
<TD>
<P/>
<P>14  <B>-0.22</B> (0.57) (0.64)*</P>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>*authors' value from e-mail<BR/>PPD = probing pocket depth<BR/>SD = standard deviation<BR/>SE = standard error<BR/>
</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-05" MODIFIED="2009-07-16 09:59:44 +0100" MODIFIED_BY="[Empty name]" NO="5">
<TITLE MODIFIED="2009-07-16 09:42:43 +0100" MODIFIED_BY="[Empty name]">Control versus Emdogain: REC at 1 year</TITLE>
<TABLE COLS="5" ROWS="7">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Parallel group/Split mouth</P>
</TH>
<TH>
<P/>
<P>
<B>EMD</B>
</P>
<P/>
<P>
<B>n  mean (SD)</B>
</P>
<P/>
</TH>
<TH>
<P/>
<P>
<B>Control</B>
</P>
<P/>
<P>
<B>n  mean (SD)</B>
</P>
<P/>
</TH>
<TH>
<P/>
<P>
<B>Difference </B>
</P>
<P/>
<P>
<B>n mean (SE)</B>
</P>
<P/>
</TH>
</TR>
<TR>
<TD>
<P/>
<P>Silvestri 2000</P>
<P/>
</TD>
<TD>
<P/>
<P>P</P>
<P/>
</TD>
<TD>
<P/>
<P>10  -0.5 (0.97)</P>
<P/>
</TD>
<TD>
<P/>
<P>10  -0.20 (0.63)</P>
<P/>
</TD>
<TD>
<P/>
<P>20  <B>-0.30</B> (0.37)</P>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
<P>Tonetti 2002</P>
<P/>
</TD>
<TD>
<P/>
<P>P</P>
<P/>
</TD>
<TD>
<P/>
<P>83  -0.8 (1.2)</P>
<P/>
</TD>
<TD>
<P/>
<P>83  -0.8 (1.2)</P>
<P/>
</TD>
<TD>
<P/>
<P>166  <B>0</B> (0.19)</P>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
<P>Zucchelli 2002</P>
<P/>
</TD>
<TD>
<P/>
<P>P</P>
<P/>
</TD>
<TD>
<P/>
<P>30  -1.0 (0.5)</P>
<P/>
</TD>
<TD>
<P/>
<P>30  -1.6 (1.0)</P>
<P/>
</TD>
<TD>
<P/>
<P>60  <B>0.60</B> (0.20)</P>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
<P>Grusovin 2009</P>
<P/>
</TD>
<TD>
<P/>
<P>P</P>
<P/>
</TD>
<TD>
<P/>
<P>15  -0.8 (1.0)</P>
<P/>
</TD>
<TD>
<P/>
<P>15  -0.6 (1.1)</P>
<P/>
</TD>
<TD>
<P/>
<P>30  <B>-0.2</B> (0.38)</P>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
<P>Pontoriero 1999</P>
<P/>
</TD>
<TD>
<P/>
<P>S</P>
<P/>
</TD>
<TD>
<P/>
<P>10  -1.7</P>
<P/>
</TD>
<TD>
<P/>
<P>10  -1.7</P>
<P/>
</TD>
<TD>
<P/>
<P>10  <B>0</B> (0.34)</P>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
<P>Okuda 2000</P>
<P/>
</TD>
<TD>
<P/>
<P>S</P>
<P/>
</TD>
<TD>
<P/>
<P>16  -1.22 (0.16)</P>
<P/>
</TD>
<TD>
<P/>
<P>16  -1.22 (0.88)</P>
<P/>
</TD>
<TD>
<P/>
<P>16  <B>0</B> (0.27)</P>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>REC = gingival recession<BR/>SD = standard deviation<BR/>SE = standard error</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-06" MODIFIED="2009-07-16 10:16:58 +0100" MODIFIED_BY="[Empty name]" NO="6">
<TITLE MODIFIED="2009-07-16 09:59:53 +0100" MODIFIED_BY="[Empty name]">GTR versus Emdogain: PAL at 1 year</TITLE>
<TABLE COLS="5" ROWS="7">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Parallel group/Split mouth</P>
</TH>
<TH>
<P/>
<P>
<B>EMD</B>
</P>
<P/>
<P>
<B>n  mean (SD)</B>
</P>
<P/>
</TH>
<TH>
<P/>
<P>
<B>Control</B>
</P>
<P/>
<P>
<B>n  mean (SD)</B>
</P>
<P/>
</TH>
<TH>
<P/>
<P>
<B>Difference </B>
</P>
<P/>
<P>
<B>n mean (SE)</B>
</P>
<P/>
</TH>
</TR>
<TR>
<TD>
<P/>
<P>Pontoriero 1999</P>
<P/>
</TD>
<TD>
<P/>
<P>P</P>
<P/>
</TD>
<TD>
<P/>
<P>10  2.9 (1.5)</P>
<P/>
</TD>
<TD>
<P/>
<P>10  2.9 (1.1)</P>
<P/>
</TD>
<TD>
<P/>
<P>20  <B>0 </B>(0.59)</P>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
<P>Silvestri 2000</P>
<P/>
</TD>
<TD>
<P/>
<P>P</P>
<P/>
</TD>
<TD>
<P/>
<P>10  4.5 (1.58)</P>
<P/>
</TD>
<TD>
<P/>
<P>10  4.80 (2.10)</P>
<P/>
</TD>
<TD>
<P/>
<P>20  <B>-0.30</B> (0.83)</P>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
<P>Zucchelli 2002</P>
<P/>
</TD>
<TD>
<P/>
<P>P</P>
<P/>
</TD>
<TD>
<P/>
<P>30  4.2 (0.9)</P>
<P/>
</TD>
<TD>
<P/>
<P>30  4.9 (1.6)</P>
<P/>
</TD>
<TD>
<P/>
<P>60  <B>-0.70</B> (0.34)</P>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
<P>Silvestri 2003</P>
<P/>
</TD>
<TD>
<P/>
<P>P</P>
<P/>
</TD>
<TD>
<P/>
<P>49  4.1 (1.8)</P>
<P/>
</TD>
<TD>
<P/>
<P>49  4.3 (1.9)</P>
<P/>
</TD>
<TD>
<P/>
<P>98 <B>-0.20</B> (0.38)</P>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
<P>Sanz 2004</P>
<P/>
</TD>
<TD>
<P/>
<P>P</P>
<P/>
</TD>
<TD>
<P/>
<P>35  3.1 (1.8)</P>
<P/>
</TD>
<TD>
<P/>
<P>32  2.5 (1.9)</P>
<P/>
</TD>
<TD>
<P/>
<P>67  <B>0.60</B> (0.45)</P>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
<P>Crea 2008</P>
<P/>
</TD>
<TD>
<P/>
<P>P</P>
<P/>
</TD>
<TD>
<P/>
<P>19  2.7 </P>
<P/>
</TD>
<TD>
<P/>
<P>20  2.8 </P>
<P/>
</TD>
<TD>
<P/>
<P>39  <B>0.1</B> (0.66)</P>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>GTR = guided tissue regeneration<BR/>PAL = probing attachment level<BR/>SD = standard deviation<BR/>SE = standard error</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-07" MODIFIED="2009-07-16 10:20:44 +0100" MODIFIED_BY="[Empty name]" NO="7">
<TITLE MODIFIED="2009-07-16 10:17:09 +0100" MODIFIED_BY="[Empty name]">GTR versus Emdogain: PPD at 1 year</TITLE>
<TABLE COLS="5" ROWS="7">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Parallel group/Split mouth</P>
</TH>
<TH>
<P/>
<P>
<B>EMD</B>
</P>
<P/>
<P>
<B>n  mean (SD)</B>
</P>
<P/>
</TH>
<TH>
<P/>
<P>
<B>Control</B>
</P>
<P/>
<P>
<B>n  mean (SD)</B>
</P>
<P/>
</TH>
<TH>
<P/>
<P>
<B>Difference </B>
</P>
<P/>
<P>
<B>n mean (SE)</B>
</P>
<P/>
</TH>
</TR>
<TR>
<TD>
<P/>
<P>Pontoriero 1999</P>
<P/>
</TD>
<TD>
<P/>
<P>P</P>
<P/>
</TD>
<TD>
<P/>
<P>10  4.2 (1.3)</P>
<P/>
</TD>
<TD>
<P/>
<P>10  4.7 (1.4)</P>
<P/>
</TD>
<TD>
<P/>
<P>20  <B>-0.50</B> (0.60)</P>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
<P>Silvestri 2000</P>
<P/>
</TD>
<TD>
<P/>
<P>P</P>
<P/>
</TD>
<TD>
<P/>
<P>10  4.9 (1.79)</P>
<P/>
</TD>
<TD>
<P/>
<P>10  5.7 (1.06)</P>
<P/>
</TD>
<TD>
<P/>
<P>20  <B>-0.80</B> (0.66)</P>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
<P>Zucchelli 2002</P>
<P/>
</TD>
<TD>
<P/>
<P>P</P>
<P/>
</TD>
<TD>
<P/>
<P>30  5.1 (0.7)</P>
<P/>
</TD>
<TD>
<P/>
<P>30  6.5 (1.6)</P>
<P/>
</TD>
<TD>
<P/>
<P>60  <B>-1.40</B> (0.32)</P>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
<P>Silvestri 2003</P>
<P/>
</TD>
<TD>
<P/>
<P>P</P>
<P/>
</TD>
<TD>
<P/>
<P>49  5.3 (1.9)</P>
<P/>
</TD>
<TD>
<P/>
<P>49 5.6 (1.5)</P>
<P/>
</TD>
<TD>
<P/>
<P>98  <B>-0.30</B> (0.35)</P>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
<P>Sanz 2004</P>
<P/>
</TD>
<TD>
<P/>
<P>P</P>
<P/>
</TD>
<TD>
<P/>
<P>35  3.8 (1.5)</P>
<P/>
</TD>
<TD>
<P/>
<P>32 3.3 (1.5)</P>
<P/>
</TD>
<TD>
<P/>
<P>67  <B>0.50</B> (0.37)</P>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
<P>Crea 2008</P>
<P/>
</TD>
<TD>
<P/>
<P>P</P>
<P/>
</TD>
<TD>
<P/>
<P>19  3.4 </P>
<P/>
</TD>
<TD>
<P/>
<P>20  3.6 </P>
<P/>
</TD>
<TD>
<P/>
<P>39  <B>-0.2</B> (0.45)</P>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>GTR = guided tissue regeneration<BR/>PPD = probing pocket depth<BR/>SD = standard deviation<BR/>SE = standard error</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-08" MODIFIED="2009-07-16 10:23:19 +0100" MODIFIED_BY="[Empty name]" NO="8">
<TITLE MODIFIED="2009-07-16 10:20:51 +0100" MODIFIED_BY="[Empty name]">GTR versus Emdogain: REC at 1 year</TITLE>
<TABLE COLS="5" ROWS="6">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Parallel group/Split mouth</P>
</TH>
<TH>
<P/>
<P>
<B>EMD</B>
</P>
<P/>
<P>
<B>n  mean (SD)</B>
</P>
<P/>
</TH>
<TH>
<P/>
<P>
<B>Control</B>
</P>
<P/>
<P>
<B>n  mean (SD)</B>
</P>
<P/>
</TH>
<TH>
<P/>
<P>
<B>Difference </B>
</P>
<P/>
<P>
<B>n mean (SE)</B>
</P>
<P/>
</TH>
</TR>
<TR>
<TD>
<P/>
<P>Pontoriero 1999</P>
<P/>
</TD>
<TD>
<P/>
<P>P</P>
<P/>
</TD>
<TD>
<P/>
<P>10  -1.3  (0.9)</P>
<P/>
</TD>
<TD>
<P/>
<P>10  -1.8  (0.9)</P>
<P/>
</TD>
<TD>
<P/>
<P>20  <B>0.50</B> (0.40)</P>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
<P>Silvestri 2000</P>
<P/>
</TD>
<TD>
<P/>
<P>P</P>
<P/>
</TD>
<TD>
<P/>
<P>10  -0.5 (0.97)</P>
<P/>
</TD>
<TD>
<P/>
<P>10  -0.95 (1.40)</P>
<P/>
</TD>
<TD>
<P/>
<P>20  <B>0.45</B> (0.54)</P>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
<P>Zucchelli 2002</P>
<P/>
</TD>
<TD>
<P/>
<P>P</P>
<P/>
</TD>
<TD>
<P/>
<P>30  -1.0 (0.5)</P>
<P/>
</TD>
<TD>
<P/>
<P>30  -1.6 (1.0)</P>
<P/>
</TD>
<TD>
<P/>
<P>60  <B>0.60</B> (0.20) </P>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
<P>Sanz 2004</P>
<P/>
</TD>
<TD>
<P/>
<P>P</P>
<P/>
</TD>
<TD>
<P/>
<P>35  -0.6 (0.9)</P>
<P/>
</TD>
<TD>
<P/>
<P>32  -0.7 (0.9)</P>
<P/>
</TD>
<TD>
<P/>
<P>67  <B>0.1</B> (0.22)</P>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
<P>Crea 2008</P>
<P/>
</TD>
<TD>
<P/>
<P>P</P>
<P/>
</TD>
<TD>
<P/>
<P>19  -0.6 </P>
<P/>
</TD>
<TD>
<P/>
<P>20  1.0  </P>
<P/>
</TD>
<TD>
<P/>
<P>39  <B>0.6</B> (0.478)</P>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>GTR = guided tissue regeneration<BR/>REC = gingival recession<BR/>SD = standard deviation<BR/>SE = standard error</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2009-07-16 11:12:59 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2009-07-16 10:27:23 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Emdogain versus control: 1 year</NAME>
<IV_OUTCOME CHI2="38.10163607746496" CI_END="1.552023034881227" CI_START="0.610218510756171" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_SIZE="1.081120772818699" ESTIMABLE="YES" I2="79.00352629547169" I2_Q="77.92600899586365" ID="CMP-001.01" LOG_CI_END="0.19089816270024276" LOG_CI_START="-0.21451462232893168" LOG_DATA="NO" LOG_EFFECT_SIZE="0.033874212028191984" MODIFIED="2009-06-28 17:48:53 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="7.209687829412559E-6" P_Q="0.03330141878887083" P_Z="6.802301246866498E-6" Q="4.53021839056025" RANDOM="YES" SCALE="4.0" SHOW_PARTICIPANTS="YES" SORT_BY="USER" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.3622473252800521" TOTALS="YES" TOTAL_1="221" TOTAL_2="221" WEIGHT="100.0" Z="4.49978254167188">
<NAME>PAL</NAME>
<GROUP_LABEL_1>Emdogain</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Emdogain</GRAPH_LABEL_2>
<EFFECT_MEASURE>mean difference</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="31.045960325537994" CI_END="2.2376200121370715" CI_START="0.5695628708528255" DF="4" EFFECT_SIZE="1.4035914414949484" ESTIMABLE="YES" I2="87.11587608159876" ID="CMP-001.01.01" LOG_CI_END="0.34978633749014065" LOG_CI_START="-0.2444583296052393" LOG_EFFECT_SIZE="0.1472407114079672" MODIFIED="2009-06-28 17:48:53 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="2.9960446795707085E-6" P_Z="9.722553400525381E-4" STUDIES="5" TAU2="0.7460821142843489" TOTAL_1="150" TOTAL_2="150" WEIGHT="56.411230654713286" Z="3.2984345754735442">
<NAME>Parallel group</NAME>
<IV_DATA CI_END="4.475978390724032" CI_START="2.1240216092759674" EFFECT_SIZE="3.3" ESTIMABLE="YES" ESTIMATE="3.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-06-28 17:48:53 +0100" MODIFIED_BY="[Empty name]" ORDER="1" SE="0.6" STUDY_ID="STD-Silvestri-2000" TOTAL_1="10" TOTAL_2="10" WEIGHT="7.992440817590723"/>
<IV_DATA CI_END="1.0507917164442124" CI_START="0.14920828355578747" EFFECT_SIZE="0.6" ESTIMABLE="YES" ESTIMATE="0.6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-06-28 17:48:52 +0100" MODIFIED_BY="[Empty name]" ORDER="3" SE="0.23" STUDY_ID="STD-Tonetti-2002" TOTAL_1="83" TOTAL_2="83" WEIGHT="13.904748149515257"/>
<IV_DATA CI_END="2.031192076598812" CI_START="1.168807923401188" EFFECT_SIZE="1.6" ESTIMABLE="YES" ESTIMATE="1.6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-06-28 17:48:51 +0100" MODIFIED_BY="[Empty name]" ORDER="4" SE="0.22" STUDY_ID="STD-Zucchelli-2002" TOTAL_1="30" TOTAL_2="30" WEIGHT="14.05712066680889"/>
<IV_DATA CI_END="2.790782712579226" CI_START="0.9092172874207741" EFFECT_SIZE="1.85" ESTIMABLE="YES" ESTIMATE="1.85" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-06-28 17:48:50 +0100" MODIFIED_BY="[Empty name]" ORDER="5" SE="0.48" STUDY_ID="STD-Francetti-2004" TOTAL_1="12" TOTAL_2="12" WEIGHT="9.740226196475689"/>
<IV_DATA CI_END="0.9231848735068228" CI_START="-0.7231848735068228" EFFECT_SIZE="0.1" ESTIMABLE="YES" ESTIMATE="0.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-06-28 17:47:00 +0100" MODIFIED_BY="[Empty name]" ORDER="68" SE="0.42" STUDY_ID="STD-Grusovin-2009" TOTAL_1="15" TOTAL_2="15" WEIGHT="10.716694824322724"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="2.5254573613667155" CI_END="1.0449908740531002" CI_START="0.47899285909674466" DF="3" EFFECT_SIZE="0.7619918665749225" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="0.019112497752635762" LOG_CI_START="-0.31967096106977183" LOG_EFFECT_SIZE="-0.11804966425158295" MODIFIED="2009-06-28 17:48:48 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.4707082399994015" P_Z="1.3108612130555957E-7" STUDIES="4" TAU2="0.0" TOTAL_1="71" TOTAL_2="71" WEIGHT="43.58876934528671" Z="5.2773210348254">
<NAME>Split mouth</NAME>
<IV_DATA CI_END="1.0311920765988118" CI_START="0.16880792340118805" EFFECT_SIZE="0.6" ESTIMABLE="YES" ESTIMATE="0.6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1" SE="0.22" STUDY_ID="STD-Heijl-1997" TOTAL_1="31" TOTAL_2="31" WEIGHT="14.05712066680889"/>
<IV_DATA CI_END="1.3211920765988119" CI_START="0.4588079234011881" EFFECT_SIZE="0.89" ESTIMABLE="YES" ESTIMATE="0.89" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-28 18:40:12 +0000" MODIFIED_BY="[Empty name]" ORDER="2" SE="0.22" STUDY_ID="STD-Okuda-2000" TOTAL_1="16" TOTAL_2="16" WEIGHT="14.05712066680889"/>
<IV_DATA CI_END="1.9427845133522235" CI_START="0.2572154866477767" EFFECT_SIZE="1.1" ESTIMABLE="YES" ESTIMATE="1.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-06-28 17:48:48 +0100" MODIFIED_BY="[Empty name]" ORDER="3" SE="0.43" STUDY_ID="STD-Pontoriero-1999" TOTAL_1="10" TOTAL_2="10" WEIGHT="10.550209671607925"/>
<IV_DATA CI_END="1.613967586086049" CI_START="-1.9139675860860488" EFFECT_SIZE="-0.15" ESTIMABLE="YES" ESTIMATE="-0.15" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="4" SE="0.9" STUDY_ID="STD-R_x00f6_sing-2005" TOTAL_1="14" TOTAL_2="14" WEIGHT="4.924318340060999"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="5.246213767892033" CI_END="0.821880581451129" CI_START="0.3371066878151903" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_SIZE="0.5263662608798296" ESTIMABLE="YES" I2="4.693170709110528" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-0.08519128049454895" LOG_CI_START="-0.47223263148252215" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.27871195598853554" MODIFIED="2009-03-31 15:46:48 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.38657689859408806" P_Q="1.0" P_Z="0.004760991681713974" Q="0.0" RANDOM="YES" SCALE="1000.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.018648881353817516" TOTALS="YES" TOTAL_1="181" TOTAL_2="181" WEIGHT="100.0" Z="2.822775367044525">
<NAME>PAL &lt; 2 mm</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Emdogain</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>risk ratio</EFFECT_MEASURE>
<IV_DATA CI_END="3.7808391290611616" CI_START="0.010567775273362483" EFFECT_SIZE="0.1998876140751445" ESTIMABLE="YES" ESTIMATE="-1.61" LOG_CI_END="0.5775881989580485" LOG_CI_START="-1.9760164306865196" LOG_EFFECT_SIZE="-0.6992141158642354" ORDER="20385" SE="1.5" STUDY_ID="STD-Francetti-2004" TOTAL_1="12" TOTAL_2="12" WEIGHT="2.2783616012876715"/>
<IV_DATA CI_END="4.181933538962121" CI_START="0.23912383845492238" EFFECT_SIZE="1.0" ESTIMABLE="YES" ESTIMATE="0.0" LOG_CI_END="0.6213771265468448" LOG_CI_START="-0.6213771265468448" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-31 14:37:43 +0100" MODIFIED_BY="[Empty name]" ORDER="78" SE="0.73" STUDY_ID="STD-Grusovin-2009" TOTAL_1="15" TOTAL_2="15" WEIGHT="9.37143138681301"/>
<IV_DATA CI_END="1.012993717850392" CI_START="0.34201180542881227" EFFECT_SIZE="0.5886049696783552" ESTIMABLE="YES" ESTIMATE="-0.53" LOG_CI_END="0.005606752061791698" LOG_CI_START="-0.46595890287923863" LOG_EFFECT_SIZE="-0.23017607540872348" ORDER="20386" SE="0.277" STUDY_ID="STD-Heijl-1997" TOTAL_1="31" TOTAL_2="31" WEIGHT="54.19288439534924"/>
<IV_DATA CI_END="1.2385602029774707" CI_START="0.005123335545300528" EFFECT_SIZE="0.07965902028589804" ESTIMABLE="YES" ESTIMATE="-2.53" LOG_CI_END="0.09291712128557113" LOG_CI_START="-2.2904471997160254" LOG_EFFECT_SIZE="-1.098765039215227" ORDER="20387" SE="1.4" STUDY_ID="STD-Silvestri-2000" TOTAL_1="10" TOTAL_2="10" WEIGHT="2.6122888940983846"/>
<IV_DATA CI_END="1.1664740822171606" CI_START="0.243172163723191" EFFECT_SIZE="0.5325918010068972" ESTIMABLE="YES" ESTIMATE="-0.63" LOG_CI_END="0.06687509368689372" LOG_CI_START="-0.614086140884991" LOG_EFFECT_SIZE="-0.27360552359904866" ORDER="20388" SE="0.4" STUDY_ID="STD-Tonetti-2002" TOTAL_1="83" TOTAL_2="83" WEIGHT="28.93274482835331"/>
<IV_DATA CI_END="1.0875740551545596" CI_START="0.004498777533401297" EFFECT_SIZE="0.06994822174465536" ESTIMABLE="YES" ESTIMATE="-2.66" LOG_CI_END="0.03645883863814822" LOG_CI_START="-2.346905482363448" LOG_EFFECT_SIZE="-1.15522332186265" ORDER="20389" SE="1.4" STUDY_ID="STD-Zucchelli-2002" TOTAL_1="30" TOTAL_2="30" WEIGHT="2.6122888940983846"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="25.42946502666928" CI_END="1.3141019993061458" CI_START="0.4385788256929807" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_SIZE="0.8763404124995632" ESTIMABLE="YES" I2="68.54043137907165" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.11862907604309167" LOG_CI_START="-0.35795233961398787" LOG_DATA="NO" LOG_EFFECT_SIZE="-0.05732716032450674" MODIFIED="2009-06-28 17:49:39 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0013142465449256235" P_Q="0.5074978818218286" P_Z="8.724026077432937E-5" Q="0.43922271063779306" RANDOM="YES" SCALE="4.0" SHOW_PARTICIPANTS="YES" SORT_BY="USER" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.27361202707959503" TOTALS="YES" TOTAL_1="221" TOTAL_2="221" WEIGHT="100.0" Z="3.923586944267472">
<NAME>PPD</NAME>
<GROUP_LABEL_1>Emdogain</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Emdogain</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean difference</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="22.92688776783769" CI_END="2.0538925206566763" CI_START="0.4385859928321909" DF="4" EFFECT_SIZE="1.2462392567444336" ESTIMABLE="YES" I2="82.55323600610423" ID="CMP-001.03.01" LOG_CI_END="0.3125777134058481" LOG_CI_START="-0.35794524254638016" LOG_EFFECT_SIZE="0.09560142748282491" MODIFIED="2009-06-28 17:49:39 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.3095718365896403E-4" P_Z="0.0024921092455678206" STUDIES="5" TAU2="0.642925804942008" TOTAL_1="150" TOTAL_2="150" WEIGHT="54.50113934377729" Z="3.0242978868274095">
<NAME>Parallel group</NAME>
<IV_DATA CI_END="4.852375149332637" CI_START="2.1476248506673628" EFFECT_SIZE="3.5" ESTIMABLE="YES" ESTIMATE="3.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-06-28 17:49:39 +0100" MODIFIED_BY="[Empty name]" ORDER="1" SE="0.69" STUDY_ID="STD-Silvestri-2000" TOTAL_1="10" TOTAL_2="10" WEIGHT="6.65402824275021"/>
<IV_DATA CI_END="1.109590635980414" CI_START="0.09040936401958588" EFFECT_SIZE="0.6" ESTIMABLE="YES" ESTIMATE="0.6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-06-28 17:49:38 +0100" MODIFIED_BY="[Empty name]" ORDER="3" SE="0.26" STUDY_ID="STD-Tonetti-2002" TOTAL_1="83" TOTAL_2="83" WEIGHT="14.620249599095862"/>
<IV_DATA CI_END="1.0311920765988118" CI_START="0.16880792340118805" EFFECT_SIZE="0.6" ESTIMABLE="YES" ESTIMATE="0.6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-06-28 17:49:37 +0100" MODIFIED_BY="[Empty name]" ORDER="4" SE="0.22" STUDY_ID="STD-Zucchelli-2002" TOTAL_1="30" TOTAL_2="30" WEIGHT="15.491983474530443"/>
<IV_DATA CI_END="3.296378750878632" CI_START="0.9836212491213681" EFFECT_SIZE="2.14" ESTIMABLE="YES" ESTIMATE="2.14" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-06-28 17:49:36 +0100" MODIFIED_BY="[Empty name]" ORDER="5" SE="0.59" STUDY_ID="STD-Francetti-2004" TOTAL_1="12" TOTAL_2="12" WEIGHT="8.023980210822698"/>
<IV_DATA CI_END="1.2603823524246265" CI_START="-0.6603823524246266" EFFECT_SIZE="0.3" ESTIMABLE="YES" ESTIMATE="0.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-21 07:18:29 +0000" MODIFIED_BY="[Empty name]" ORDER="69" SE="0.49" STUDY_ID="STD-Grusovin-2009" TOTAL_1="15" TOTAL_2="15" WEIGHT="9.710897816578074"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="2.063354548193798" CI_END="0.997819601584506" CI_START="0.31268047488275924" DF="3" EFFECT_SIZE="0.6552500382336326" ESTIMABLE="YES" I2="0.0" ID="CMP-001.03.02" LOG_CI_END="-9.479688510645462E-4" LOG_CI_START="-0.5048992371306633" LOG_EFFECT_SIZE="-0.18359294504041546" MODIFIED="2009-06-28 17:49:35 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5593619330053102" P_Z="1.775965051814795E-4" STUDIES="4" TAU2="0.0" TOTAL_1="71" TOTAL_2="71" WEIGHT="45.49886065622272" Z="3.748921717517025">
<NAME>Split mouth</NAME>
<IV_DATA CI_END="1.1899909961350135" CI_START="0.2100090038649864" EFFECT_SIZE="0.7" ESTIMABLE="YES" ESTIMATE="0.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-05-26 15:48:55 +0100" MODIFIED_BY="[Empty name]" ORDER="1" SE="0.25" STUDY_ID="STD-Heijl-1997" TOTAL_1="31" TOTAL_2="31" WEIGHT="14.842090137214218"/>
<IV_DATA CI_END="1.6211830727338254" CI_START="-0.22118307273382554" EFFECT_SIZE="0.7" ESTIMABLE="YES" ESTIMATE="0.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-06-28 17:49:35 +0100" MODIFIED_BY="[Empty name]" ORDER="2" SE="0.47" STUDY_ID="STD-Pontoriero-1999" TOTAL_1="10" TOTAL_2="10" WEIGHT="10.08793462836079"/>
<IV_DATA CI_END="1.4071884750528174" CI_START="0.15281152494718264" EFFECT_SIZE="0.78" ESTIMABLE="YES" ESTIMATE="0.78" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-29 12:50:49 +0100" MODIFIED_BY="[Empty name]" ORDER="3" SE="0.32" STUDY_ID="STD-Okuda-2000" TOTAL_1="16" TOTAL_2="16" WEIGHT="13.267142120060795"/>
<IV_DATA CI_END="1.0343769501056348" CI_START="-1.4743769501056347" EFFECT_SIZE="-0.22" ESTIMABLE="YES" ESTIMATE="-0.22" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-21 07:18:33 +0000" MODIFIED_BY="[Empty name]" ORDER="4" SE="0.64" STUDY_ID="STD-R_x00f6_sing-2005" TOTAL_1="14" TOTAL_2="14" WEIGHT="7.301693770586912"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="8.473053998774851" CI_END="0.3696956352208587" CI_START="-0.19939711372791732" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_SIZE="0.0851492607464707" ESTIMABLE="YES" I2="40.98940003541854" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="-0.43215567685639245" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="-1.0698191181667023" MODIFIED="2009-04-14 10:42:19 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.13202003981427302" P_Q="0.48464943969925167" P_Z="0.5575323971827515" Q="0.4883832341647416" RANDOM="YES" SCALE="4.0" SHOW_PARTICIPANTS="YES" SORT_BY="USER" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.049880903920450644" TOTALS="YES" TOTAL_1="164" TOTAL_2="164" WEIGHT="100.00000000000003" Z="0.5865106687146155">
<NAME>REC</NAME>
<GROUP_LABEL_1>Emdogain</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Emdogain</GRAPH_LABEL_2>
<EFFECT_MEASURE>mean difference</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="7.98467076461011" CI_END="0.517284009626892" CI_START="-0.33243425321469344" DF="3" EFFECT_SIZE="0.09242487820609932" ESTIMABLE="YES" I2="62.428006257982645" ID="CMP-001.04.01" LOG_CI_END="-0.2862709463698437" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-1.0342111130508127" MODIFIED="2009-03-13 10:34:23 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0463296900997896" P_Z="0.6698344099393305" STUDIES="4" TAU2="0.11172827388724677" TOTAL_1="138" TOTAL_2="138" WEIGHT="70.09675452376342" Z="0.4263752833878484">
<NAME>Parallel group</NAME>
<IV_DATA CI_END="0.4251866742798201" CI_START="-1.0251866742798201" EFFECT_SIZE="-0.3" ESTIMABLE="YES" ESTIMATE="-0.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1" SE="0.37" STUDY_ID="STD-Silvestri-2000" TOTAL_1="10" TOTAL_2="10" WEIGHT="11.284373646971801"/>
<IV_DATA CI_END="0.37239315706261034" CI_START="-0.37239315706261034" EFFECT_SIZE="0.0" ESTIMABLE="YES" ESTIMATE="0.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="3" SE="0.19" STUDY_ID="STD-Tonetti-2002" TOTAL_1="83" TOTAL_2="83" WEIGHT="24.51364679659044"/>
<IV_DATA CI_END="0.9919927969080109" CI_START="0.2080072030919891" EFFECT_SIZE="0.6" ESTIMABLE="YES" ESTIMATE="0.6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="4" SE="0.2" STUDY_ID="STD-Zucchelli-2002" TOTAL_1="30" TOTAL_2="30" WEIGHT="23.44998123097356"/>
<IV_DATA CI_END="0.5447863141252207" CI_START="-0.9447863141252206" EFFECT_SIZE="-0.2" ESTIMABLE="YES" ESTIMATE="-0.2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-13 10:34:23 +0000" MODIFIED_BY="[Empty name]" ORDER="70" SE="0.38" STUDY_ID="STD-Grusovin-2009" TOTAL_1="15" TOTAL_2="15" WEIGHT="10.848752849227614"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.4144146453898096" CI_START="-0.4144146453898096" DF="1" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-001.04.02" LOG_CI_END="-0.382564905049527" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2009-04-14 10:42:19 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="1.0" STUDIES="2" TAU2="0.0" TOTAL_1="26" TOTAL_2="26" WEIGHT="29.903245476236606" Z="0.0">
<NAME>Split mouth</NAME>
<IV_DATA CI_END="0.6663877547436186" CI_START="-0.6663877547436186" EFFECT_SIZE="0.0" ESTIMABLE="YES" ESTIMATE="0.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-04-14 10:42:19 +0100" MODIFIED_BY="[Empty name]" ORDER="1" SE="0.34" STUDY_ID="STD-Pontoriero-1999" TOTAL_1="10" TOTAL_2="10" WEIGHT="12.736850355680394"/>
<IV_DATA CI_END="0.5291902758258147" CI_START="-0.5291902758258147" EFFECT_SIZE="0.0" ESTIMABLE="YES" ESTIMATE="0.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2" SE="0.27" STUDY_ID="STD-Okuda-2000" TOTAL_1="16" TOTAL_2="16" WEIGHT="17.166395120556214"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="9.134946127629185" CI_END="1.9225441520152948" CI_START="-0.532787983370882" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_SIZE="0.6948780843222064" ESTIMABLE="YES" I2="78.10605588629711" I2_Q="72.52546712331839" ID="CMP-001.05" LOG_CI_END="0.28387632233896937" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="-0.15809138526690492" MODIFIED="2009-03-31 14:47:16 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.010384184959675413" P_Q="0.05641613118910127" P_Z="0.2672705765936372" Q="3.639734311365592" RANDOM="YES" SCALE="4.0" SHOW_PARTICIPANTS="YES" SORT_BY="USER" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.9162623091482649" TOTALS="YES" TOTAL_1="60" TOTAL_2="60" WEIGHT="100.0" Z="1.1093700923712344">
<NAME>Marginal bone level</NAME>
<GROUP_LABEL_1>Emdogain</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Emdogain</GRAPH_LABEL_2>
<EFFECT_MEASURE>mean difference</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="0.8231848735068228" CI_START="-0.8231848735068228" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-001.05.01" LOG_CI_END="-0.08450261858196319" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2009-03-13 10:35:59 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="35.90693701449649" Z="0.0">
<NAME>Parallel group</NAME>
<IV_DATA CI_END="0.8231848735068228" CI_START="-0.8231848735068228" EFFECT_SIZE="0.0" ESTIMABLE="YES" ESTIMATE="0.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-13 10:35:59 +0000" MODIFIED_BY="[Empty name]" ORDER="71" SE="0.42" STUDY_ID="STD-Grusovin-2009" TOTAL_1="15" TOTAL_2="15" WEIGHT="35.90693701449649"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="5.495211816263593" CI_END="2.8861734788309756" CI_START="-0.7201408701353236" DF="1" EFFECT_SIZE="1.083016304347826" ESTIMABLE="YES" I2="81.80233931947069" ID="CMP-001.05.02" LOG_CI_END="0.4603224316205114" LOG_CI_START="NaN" LOG_EFFECT_SIZE="0.03463499479244108" NO="2" P_CHI2="0.019068711747337375" P_Z="0.2391165226209977" STUDIES="2" TAU2="1.38475" TOTAL_1="45" TOTAL_2="45" WEIGHT="64.09306298550351" Z="1.1771979621243192">
<NAME>Split mouth</NAME>
<IV_DATA CI_END="3.07798019149703" CI_START="0.92201980850297" EFFECT_SIZE="2.0" ESTIMABLE="YES" ESTIMATE="2.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1" SE="0.55" STUDY_ID="STD-Heijl-1997" TOTAL_1="31" TOTAL_2="31" WEIGHT="32.19180345355439"/>
<IV_DATA CI_END="1.2575798313424305" CI_START="-0.9375798313424305" EFFECT_SIZE="0.16" ESTIMABLE="YES" ESTIMATE="0.16" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2" SE="0.56" STUDY_ID="STD-R_x00f6_sing-2005" TOTAL_1="14" TOTAL_2="14" WEIGHT="31.901259531949115"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="7.41806406874967" CI_START="-5.41806406874967" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="1.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.06" MODIFIED="2009-06-28 17:08:17 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.7600749043163039" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="83" TOTAL_2="83" UNITS="" WEIGHT="99.99999999999999" Z="0.30538242740258015">
<NAME>Aesthetics (continuous data)</NAME>
<GROUP_LABEL_1>Emdogain</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Emdogain</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="7.41806406874967" CI_START="-5.41806406874967" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" I2="0.0" ID="CMP-001.06.01" MODIFIED="2009-03-22 16:38:54 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.7600749043163039" STUDIES="1" TAU2="0.0" TOTAL_1="83" TOTAL_2="83" WEIGHT="99.99999999999999" Z="0.30538242740258015">
<NAME>Parallel group</NAME>
<CONT_DATA CI_END="7.41806406874967" CI_START="-5.41806406874967" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="63.0" MEAN_2="62.0" ORDER="20412" SD_1="23.0" SD_2="19.0" SE="3.2745826552806787" STUDY_ID="STD-Tonetti-2002" TOTAL_1="83" TOTAL_2="83" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="1.9430071557167782E-32" CI_END="8.069223012379137" CI_START="0.015666905338032795" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3555555555555555" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="100.0" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="0.9068317184046121" LOG_CI_START="-1.8050167806434498" LOG_EFFECT_SIZE="-0.44909253111941894" METHOD="MH" MODIFIED="2009-03-31 14:47:16 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.5162381126854431" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="14" TOTAL_2="15" WEIGHT="100.0" Z="0.6491551331344451">
<NAME>Aesthetics (dichotomous data)</NAME>
<GROUP_LABEL_1>Emdogain</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Emdogain</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.069223012379133" CI_START="0.015666905338032795" EFFECT_SIZE="0.35555555555555557" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9068317184046119" LOG_CI_START="-1.8050167806434498" LOG_EFFECT_SIZE="-0.4490925311194189" MODIFIED="2009-03-22 17:18:24 +0000" MODIFIED_BY="[Empty name]" ORDER="78" O_E="0.0" SE="1.592953232207399" STUDY_ID="STD-Grusovin-2009" TOTAL_1="14" TOTAL_2="15" VAR="2.5374999999999996" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2009-07-16 11:12:59 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Emdogain versus GTR: 1 year</NAME>
<IV_OUTCOME CHI2="5.638790540447682" CI_END="0.25333588791690376" CI_START="-0.5629358436365632" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_SIZE="-0.15479997785982977" ESTIMABLE="YES" I2="11.328502732377903" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="-0.5963032830864191" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2009-06-28 17:36:51 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3429669848385537" P_Q="1.0" P_Z="0.4572481828406406" Q="0.0" RANDOM="YES" SCALE="4.0" SHOW_PARTICIPANTS="YES" SORT_BY="USER" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.030225838187393782" TOTALS="YES" TOTAL_1="153" TOTAL_2="151" WEIGHT="100.00000000000001" Z="0.7433857370889264">
<NAME>PAL</NAME>
<GROUP_LABEL_1>Emdogain</GROUP_LABEL_1>
<GROUP_LABEL_2>GTR</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours GTR</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Emdogain</GRAPH_LABEL_2>
<EFFECT_MEASURE>mean difference</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="5.638790540447682" CI_END="0.25333588791690376" CI_START="-0.5629358436365632" DF="5" EFFECT_SIZE="-0.15479997785982977" ESTIMABLE="YES" I2="11.328502732377903" ID="CMP-002.01.01" LOG_CI_END="-0.5963032830864191" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2009-03-31 21:33:58 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3429669848385537" P_Z="0.4572481828406406" STUDIES="6" TAU2="0.030225838187393782" TOTAL_1="153" TOTAL_2="151" WEIGHT="100.00000000000001" Z="0.7433857370889264">
<NAME>Parallel group</NAME>
<IV_DATA CI_END="1.156378750878632" CI_START="-1.156378750878632" EFFECT_SIZE="0.0" ESTIMABLE="YES" ESTIMATE="0.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1" SE="0.59" STUDY_ID="STD-Pontoriero-1999" TOTAL_1="10" TOTAL_2="10" WEIGHT="11.461655133739322"/>
<IV_DATA CI_END="1.326770107168245" CI_START="-1.926770107168245" EFFECT_SIZE="-0.3" ESTIMABLE="YES" ESTIMATE="-0.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2" SE="0.83" STUDY_ID="STD-Silvestri-2000" TOTAL_1="10" TOTAL_2="10" WEIGHT="6.029876907797621"/>
<IV_DATA CI_END="-0.0336122452563814" CI_START="-1.3663877547436185" EFFECT_SIZE="-0.7" ESTIMABLE="YES" ESTIMATE="-0.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="4" SE="0.34" STUDY_ID="STD-Zucchelli-2002" TOTAL_1="30" TOTAL_2="30" WEIGHT="29.735747377734796"/>
<IV_DATA CI_END="0.5447863141252207" CI_START="-0.9447863141252206" EFFECT_SIZE="-0.2" ESTIMABLE="YES" ESTIMATE="-0.2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-31 21:33:58 +0100" MODIFIED_BY="[Empty name]" ORDER="5" SE="0.38" STUDY_ID="STD-Silvestri-2003" TOTAL_1="49" TOTAL_2="49" WEIGHT="24.83160757020095"/>
<IV_DATA CI_END="1.4819837930430244" CI_START="-0.28198379304302446" EFFECT_SIZE="0.6" ESTIMABLE="YES" ESTIMATE="0.6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="6" SE="0.45" STUDY_ID="STD-Sanz-2004" TOTAL_1="35" TOTAL_2="32" WEIGHT="18.632397327516244"/>
<IV_DATA CI_END="1.393576229796436" CI_START="-1.1935762297964359" EFFECT_SIZE="0.1" ESTIMABLE="YES" ESTIMATE="0.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-13 10:54:30 +0000" MODIFIED_BY="[Empty name]" ORDER="73" SE="0.66" STUDY_ID="STD-Crea-2008" TOTAL_1="19" TOTAL_2="20" WEIGHT="9.308715683011078"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Split mouth</NAME>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="16.16722301591468" CI_END="0.18015159483792542" CI_START="-1.060853841432455" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_SIZE="-0.4403511232972648" ESTIMABLE="YES" I2="69.07322924241161" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="-0.7443618888217641" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2009-04-01 12:25:58 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.006382531934938096" P_Q="1.0" P_Z="0.1642483669099427" Q="0.0" RANDOM="YES" SCALE="4.0" SHOW_PARTICIPANTS="YES" SORT_BY="USER" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.3977720178339899" TOTALS="YES" TOTAL_1="153" TOTAL_2="151" WEIGHT="100.0" Z="1.390924353737249">
<NAME>PPD</NAME>
<GROUP_LABEL_1>Emdogain</GROUP_LABEL_1>
<GROUP_LABEL_2>GTR</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours GTR</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Emdogain</GRAPH_LABEL_2>
<EFFECT_MEASURE>mean difference</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="16.16722301591468" CI_END="0.18015159483792542" CI_START="-1.060853841432455" DF="5" EFFECT_SIZE="-0.4403511232972648" ESTIMABLE="YES" I2="69.07322924241161" ID="CMP-002.02.01" LOG_CI_END="-0.7443618888217641" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2009-04-01 12:25:58 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.006382531934938096" P_Z="0.1642483669099427" STUDIES="6" TAU2="0.3977720178339899" TOTAL_1="153" TOTAL_2="151" WEIGHT="100.0" Z="1.390924353737249">
<NAME>Parallel group</NAME>
<IV_DATA CI_END="0.6759783907240324" CI_START="-1.6759783907240324" EFFECT_SIZE="-0.5" ESTIMABLE="YES" ESTIMATE="-0.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1" SE="0.6" STUDY_ID="STD-Pontoriero-1999" TOTAL_1="10" TOTAL_2="10" WEIGHT="13.226734329026538"/>
<IV_DATA CI_END="0.4935762297964359" CI_START="-2.0935762297964358" EFFECT_SIZE="-0.8" ESTIMABLE="YES" ESTIMATE="-0.8" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2" SE="0.66" STUDY_ID="STD-Silvestri-2000" TOTAL_1="10" TOTAL_2="10" WEIGHT="12.026860690512319"/>
<IV_DATA CI_END="-0.7728115249471825" CI_START="-2.0271884750528173" EFFECT_SIZE="-1.4" ESTIMABLE="YES" ESTIMATE="-1.4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="4" SE="0.32" STUDY_ID="STD-Zucchelli-2002" TOTAL_1="30" TOTAL_2="30" WEIGHT="20.038804260311878"/>
<IV_DATA CI_END="0.38598739458901893" CI_START="-0.985987394589019" EFFECT_SIZE="-0.3" ESTIMABLE="YES" ESTIMATE="-0.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-31 21:34:10 +0100" MODIFIED_BY="[Empty name]" ORDER="5" SE="0.35" STUDY_ID="STD-Silvestri-2003" TOTAL_1="49" TOTAL_2="49" WEIGHT="19.264632381322244"/>
<IV_DATA CI_END="1.22518667427982" CI_START="-0.2251866742798201" EFFECT_SIZE="0.5" ESTIMABLE="YES" ESTIMATE="0.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="6" SE="0.37" STUDY_ID="STD-Sanz-2004" TOTAL_1="35" TOTAL_2="32" WEIGHT="18.74578961970764"/>
<IV_DATA CI_END="0.6819837930430244" CI_START="-1.0819837930430245" EFFECT_SIZE="-0.2" ESTIMABLE="YES" ESTIMATE="-0.2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-04-01 12:25:58 +0100" MODIFIED_BY="[Empty name]" ORDER="74" SE="0.45" STUDY_ID="STD-Crea-2008" TOTAL_1="19" TOTAL_2="20" WEIGHT="16.69717871911938"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.02.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Split mouth</NAME>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="3.1018907888793277" CI_END="0.6615570105719057" CI_START="0.15429957949401363" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_SIZE="0.4079282950329597" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="-0.17943272394825385" LOG_CI_START="-0.8116352574992518" LOG_DATA="NO" LOG_EFFECT_SIZE="-0.3894161697736337" MODIFIED="2009-07-16 11:12:59 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.5409214627030188" P_Q="1.0" P_Z="0.001619657619917095" Q="0.0" RANDOM="YES" SCALE="4.0" SHOW_PARTICIPANTS="YES" SORT_BY="USER" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="104" TOTAL_2="102" WEIGHT="100.0" Z="3.152343238581986">
<NAME>REC</NAME>
<GROUP_LABEL_1>Emdogain</GROUP_LABEL_1>
<GROUP_LABEL_2>GTR</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours GTR</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Emdogain</GRAPH_LABEL_2>
<EFFECT_MEASURE>mean difference</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="3.1018907888793277" CI_END="0.6615570105719057" CI_START="0.15429957949401363" DF="4" EFFECT_SIZE="0.4079282950329597" ESTIMABLE="YES" I2="0.0" ID="CMP-002.03.01" LOG_CI_END="-0.17943272394825385" LOG_CI_START="-0.8116352574992518" LOG_EFFECT_SIZE="-0.3894161697736337" MODIFIED="2009-03-13 11:02:03 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5409214627030188" P_Z="0.001619657619917095" STUDIES="5" TAU2="0.0" TOTAL_1="104" TOTAL_2="102" WEIGHT="100.0" Z="3.152343238581986">
<NAME>Parallel group</NAME>
<IV_DATA CI_END="1.2839855938160216" CI_START="-0.28398559381602173" EFFECT_SIZE="0.5" ESTIMABLE="YES" ESTIMATE="0.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1" SE="0.4" STUDY_ID="STD-Pontoriero-1999" TOTAL_1="10" TOTAL_2="10" WEIGHT="10.465998782708553"/>
<IV_DATA CI_END="1.5083805516516293" CI_START="-0.6083805516516294" EFFECT_SIZE="0.45" ESTIMABLE="YES" ESTIMATE="0.45" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2" SE="0.54" STUDY_ID="STD-Silvestri-2000" TOTAL_1="10" TOTAL_2="10" WEIGHT="5.742660511774241"/>
<IV_DATA CI_END="0.9919927969080109" CI_START="0.2080072030919891" EFFECT_SIZE="0.6" ESTIMABLE="YES" ESTIMATE="0.6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="4" SE="0.2" STUDY_ID="STD-Zucchelli-2002" TOTAL_1="30" TOTAL_2="30" WEIGHT="41.86399513083421"/>
<IV_DATA CI_END="0.531192076598812" CI_START="-0.3311920765988119" EFFECT_SIZE="0.1" ESTIMABLE="YES" ESTIMATE="0.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="5" SE="0.22" STUDY_ID="STD-Sanz-2004" TOTAL_1="35" TOTAL_2="32" WEIGHT="34.598343083334065"/>
<IV_DATA CI_END="1.536862784610146" CI_START="-0.33686278461014596" EFFECT_SIZE="0.6" ESTIMABLE="YES" ESTIMATE="0.6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-13 11:02:03 +0000" MODIFIED_BY="[Empty name]" ORDER="75" SE="0.478" STUDY_ID="STD-Crea-2008" TOTAL_1="19" TOTAL_2="20" WEIGHT="7.32900249134893"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.03.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2009-07-16 11:12:59 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Split mouth</NAME>
</IV_SUBGROUP>
</IV_OUTCOME>
<DICH_OUTCOME CHI2="7.174587786495665" CI_END="0.8507974098310802" CI_START="0.017380736896000785" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.12160380722688316" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="59" I2="72.12383401643659" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="-0.07017384093407282" LOG_CI_START="-1.7599318145914615" LOG_EFFECT_SIZE="-0.9150528277627671" METHOD="MH" MODIFIED="2009-06-28 17:38:01 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.027673167031272428" P_Q="0.0" P_Z="0.03377443785225897" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="2.0629636430023357" TOTALS="YES" TOTAL_1="100" TOTAL_2="101" WEIGHT="100.0" Z="2.1227543995365066">
<NAME>Postoperative complications</NAME>
<GROUP_LABEL_1>Emdogain</GROUP_LABEL_1>
<GROUP_LABEL_2>GTR</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Emdogain</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours GTR</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="7.174587786495665" CI_END="0.8507974098310802" CI_START="0.017380736896000785" DF="2" EFFECT_SIZE="0.12160380722688316" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="59" I2="72.12383401643659" ID="CMP-002.04.01" LOG_CI_END="-0.07017384093407282" LOG_CI_START="-1.7599318145914615" LOG_EFFECT_SIZE="-0.9150528277627671" MODIFIED="2009-03-31 21:03:51 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.027673167031272428" P_Z="0.03377443785225897" STUDIES="3" TAU2="2.0629636430023357" TOTAL_1="100" TOTAL_2="101" WEIGHT="100.0" Z="2.1227543995365066">
<NAME>Parallel group</NAME>
<DICH_DATA CI_END="3.748016831490761" CI_START="0.13139194415653596" EFFECT_SIZE="0.7017543859649122" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5738015325378181" LOG_CI_START="-0.8814312612268762" LOG_EFFECT_SIZE="-0.15381486434452904" MODIFIED="2009-03-13 11:03:22 +0000" MODIFIED_BY="[Empty name]" ORDER="76" O_E="0.0" SE="0.8548109465758875" STUDY_ID="STD-Crea-2008" TOTAL_1="19" TOTAL_2="20" VAR="0.7307017543859649" WEIGHT="35.26548202542773"/>
<DICH_DATA CI_END="0.25347579149176075" CI_START="0.023344082401281104" EFFECT_SIZE="0.07692307692307693" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="32" LOG_CI_END="-0.5960635121633293" LOG_CI_START="-1.6318231924503441" LOG_EFFECT_SIZE="-1.1139433523068367" ORDER="20435" O_E="0.0" SE="0.6084103632936986" STUDY_ID="STD-Sanz-2004" TOTAL_1="32" TOTAL_2="32" VAR="0.37016317016317024" WEIGHT="40.49109003425997"/>
<DICH_DATA CI_END="0.3264602667718468" CI_START="0.0012757850502966856" EFFECT_SIZE="0.02040816326530612" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="24" LOG_CI_END="-0.48616966882013246" LOG_CI_START="-2.8942224912368952" LOG_EFFECT_SIZE="-1.6901960800285136" MODIFIED="2009-03-31 21:03:51 +0100" MODIFIED_BY="[Empty name]" ORDER="79" O_E="0.0" SE="1.4145021479413216" STUDY_ID="STD-Silvestri-2003" TOTAL_1="49" TOTAL_2="49" VAR="2.0008163265306123" WEIGHT="24.243427940312298"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.13536394823833997" CI_START="-1.3353639482383401" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.6000000000000001" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.05" MODIFIED="2009-03-31 14:47:29 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.10978089325772765" Q="0.0" RANDOM="NO" SCALE="5.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="19" TOTAL_2="20" UNITS="" WEIGHT="100.0" Z="1.5991787380129823">
<NAME>Marginal bone level</NAME>
<GROUP_LABEL_1>Emdogain</GROUP_LABEL_1>
<GROUP_LABEL_2>GTR</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours GTR</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Emdogain</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.13536394823833997" CI_START="-1.3353639482383401" EFFECT_SIZE="-0.6000000000000001" ESTIMABLE="YES" MEAN_1="2.3" MEAN_2="2.9" MODIFIED="2009-03-13 11:10:31 +0000" MODIFIED_BY="[Empty name]" ORDER="77" SD_1="1.2" SD_2="1.14" SE="0.37519258212844575" STUDY_ID="STD-Crea-2008" TOTAL_1="19" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2009-06-28 17:11:41 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Emdogain versus bone graft</NAME>
<IV_OUTCOME CHI2="0.0" CI_END="1.3369464581870605" CI_START="-0.13694645818706042" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="0.6" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.12611401505591185" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="-0.22184874961635637" MODIFIED="2009-03-31 15:31:37 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.11054580858197595" Q="0.0" RANDOM="YES" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="13" TOTAL_2="13" WEIGHT="100.0" Z="1.5957446808510638">
<NAME>PAL</NAME>
<GROUP_LABEL_1>Emdogain</GROUP_LABEL_1>
<GROUP_LABEL_2>Bone Graft</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Emdogain</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Bone Graft</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_DATA CI_END="1.3369464581870605" CI_START="-0.13694645818706042" EFFECT_SIZE="0.6" ESTIMABLE="YES" ESTIMATE="0.6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-31 15:31:37 +0100" MODIFIED_BY="[Empty name]" ORDER="80" SE="0.376" STUDY_ID="STD-Leknes-2009" TOTAL_1="13" TOTAL_2="13" WEIGHT="100.0"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="1.2759783907240325" CI_START="-1.0759783907240323" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="0.1" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="0.1058433194723081" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="-1.0" MODIFIED="2009-06-28 17:11:41 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.8676323348417962" Q="0.0" RANDOM="YES" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="13" TOTAL_2="13" WEIGHT="100.0" Z="0.16666666666666669">
<NAME>PPD</NAME>
<GROUP_LABEL_1>Emdogain</GROUP_LABEL_1>
<GROUP_LABEL_2>Bone Graft</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Emdogain</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Bone graft</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_DATA CI_END="1.2759783907240325" CI_START="-1.0759783907240323" EFFECT_SIZE="0.1" ESTIMABLE="YES" ESTIMATE="0.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-31 15:26:30 +0100" MODIFIED_BY="[Empty name]" ORDER="81" SE="0.6" STUDY_ID="STD-Leknes-2009" TOTAL_1="13" TOTAL_2="13" WEIGHT="100.0"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="-0.4612609249822286" CI_START="-2.7387390750177714" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="-1.6" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2009-06-28 17:10:57 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.0058894682908357246" Q="0.0" RANDOM="YES" SCALE="10.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="13" TOTAL_2="13" WEIGHT="99.99999999999999" Z="2.753872633390706">
<NAME>REC</NAME>
<GROUP_LABEL_1>Emdogain</GROUP_LABEL_1>
<GROUP_LABEL_2>Bone Graft</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Bone Graft</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Emdogain</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_DATA CI_END="-0.4612609249822286" CI_START="-2.7387390750177714" EFFECT_SIZE="-1.6" ESTIMABLE="YES" ESTIMATE="-1.6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-31 15:45:16 +0100" MODIFIED_BY="[Empty name]" ORDER="82" SE="0.581" STUDY_ID="STD-Leknes-2009" TOTAL_1="13" TOTAL_2="13" WEIGHT="99.99999999999999"/>
</IV_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2009-07-16 11:13:00 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2009-07-16 10:28:28 +0100" MODIFIED_BY="[Empty name]" NO="1" REF_ID="CMP-001.01" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of Comparison 1 Emdogain versus control: 1 year; Outcome 1.1 PAL.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAwkAAAGQCAMAAADSs9wcAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA
AMAAwMD////AwMD/gICA/4CAgP/g4OBAAAAAQAAAAECAgID/gAAAAAALCwsWFhYhISEsLCw3NzdC
QkJNTU1YWFhjY2Nubm55eXmEhISPj4+ampqlpaWwsLC7u7vGxsbR0dHc3Nzn5+cAAAAAADMAAGYA
AJkAAMwAAP8AMwAAMzMAM2YAM5kAM8wAM/8AZgAAZjMAZmYAZpkAZswAZv8AmQAAmTMAmWYAmZkA
mcwAmf8AzAAAzDMAzGYAzJkAzMwAzP8A/wAA/zMA/2YA/5kA/8wA//8zAAAzADMzAGYzAJkzAMwz
AP8zMwAzMzMzM2YzM5kzM8wzM/8zZgAzZjMzZmYzZpkzZswzZv8zmQAzmTMzmWYzmZkzmcwzmf8z
zAAzzDMzzGYzzJkzzMwzzP8z/wAz/zMz/2Yz/5kz/8wz//9mAABmADNmAGZmAJlmAMxmAP9mMwBm
MzNmM2ZmM5lmM8xmM/9mZgBmZjNmZmZmZplmZsxmZv9mmQBmmTNmmWZmmZlmmcxmmf9mzABmzDNm
zGZmzJlmzMxmzP9m/wBm/zNm/2Zm/5lm/8xm//+ZAACZADOZAGaZAJmZAMyZAP+ZMwCZMzOZM2aZ
M5mZM8yZM/+ZZgCZZjOZZmaZZpmZZsyZZv+ZmQCZmTOZmWaZmZmZmcyZmf+ZzACZzDOZzGaZzJmZ
zMyZzP+Z/wCZ/zOZ/2aZ/5mZ/8yZ///MAADMADPMAGbMAJnMAMzMAP/MMwDMMzPMM2bMM5nMM8zM
M//MZgDMZjPMZmbMZpnMZszMZv/MmQDMmTPMmWbMmZnMmczMmf/MzADMzDPMzGbMzJnMzMzMzP/M
/wDM/zPM/2bM/5nM/8zM////AAD/ADP/AGb/AJn/AMz/AP//MwD/MzP/M2b/M5n/M8z/M///ZgD/
ZjP/Zmb/Zpn/Zsz/Zv//mQD/mTP/mWb/mZn/mcz/mf//zAD/zDP/zGb/zJn/zMz/zP///wD//zP/
/2b//5n//8z///80TKWtAAAnR0lEQVR42u1dTc8luVX2+3K7T7fIMKB3Mp0ZjZKAlIhFVmQDSKwQ
YoEjFrBiP6yzZ4Mi8RPYscqaJAj5J0RZhV0WCIiSCZP5yHQPnZBMt7tFhnvry98uu8pV5br1PDNv
37pV5W8/9rHvOT43xAAAYLeoAgAAEwAATAAADSdUwQDe/CucuyLwtgjE4dznIinGhQolLumd8yU4
WzPhveUWTNAh5r7bNKPV8TuGbVqqtnuJnbTBJrkFE8LjkhiGbz60UDditc+779ZoL4YA/SvnSaG/
UW6gM7PJ1IeWKz5kpvmHq7wzqxxWHAtXao25xTrB12ztwM7bem+aSP8mhOjHeS68I34XoH3ekaO5
I0TBGULPZvMhtFSH7teNs0J0HanrU8LMpFZGscwkVntuMSd4pHyhjTTCqOhWeuXJ4tSiM7ywEhgy
JswMJ8t5h84tmJDfcXlSi22w2E/JGB9bwPCD5hZMmCLy1knhpIyJMeKLg+YW64SMUWl0CGpmfL7J
hBFIlcffNEN131YoQIW5BRPMyjXrtV3vNjuj53/0b2EqdG9yXaDlxtMFxliVqif77pue3HhzvtCM
UGVub6CBl7P7sZdNeQBMWFpSAhHABAC4YmCdAABgAgCACQAAJgCADf035mZ7V9jq9LF9wz7E+JuF
UE5/vcu63yYhFkYrb0LJ04K0+7NM36VVzwdVTWHFa/xUGy7IWAOKvjK4sac/6H7ObbGdZPRkZYTz
DJ2aPsSq3C2jv66yLnKS1lPlCwVh/q5ihxXc+n1jQlsocwrRdzH30ewG20dGT56Wa9TpBTOV9Lmh
d2+qBKqeyZUav6VV7tXn9wz2a+qviznjHNdyMDtIP/5wT5X1tcPSmtuuB+HcdNqAu5PWYGmx5Pxe
VUaNdQLXtJJV/zRzMiiMqxDGLM81PXNXI5+H1cnX1l+frq/SxtrmQKQpyKcEUcW0C6xZOYynJKx6
4Myyl/C1AV9fWaq2jN6aI6SbTtflvGO5E0KMDbYiLg5Y+uuOSJnSF9RkJUbeauPncypX5BMqK4iI
FNtuFm6q83jbQgRia/sfX6ar7SOjJ1cyyiwjK79OWEN/fci6mJnVbFuF0SB8eofLzJHg+p5Hs1nC
l7e9qDOjJ18e80tVfFG8gv56iaxPWLf7goh2lOwUKydzU3AueO6xBFvokNeY0dug4MzH96i0ENwY
zXh4nE/sLkvrr/ParM78ueMJ+1J8ygzTS4amuMZNTfJSlbSLjN6aAmwnwGmq+MKRcYUvRCfQGt+Y
rdnPWMpIsIr+ep/1KesEFXmy0J8RROXZLHDKFCbalaZTZ6F6EP1GMtd/vvA1dXkBqbaMpumiZiUV
VuOHcn/m7kpalU1aqHGxTYGqzegpiQd5Ih3U+EtJ00kVCSIUAewTAAAA6sRfbZDmCXMCUB826JXQ
ygYAMAEABunIXKg7SvGGkmD4qHRfQADY65zAo1diqVOUAaCuOSFOBP2O8BkqWF/ybRQAoJI5QUSv
ui4uNJsAfZowbAEm2igAQA1zQgoRLO8BkS4dVJrFhABUv2KOQnexZA/9AUkKAK6QCboxMXOuMdgD
17NOaLs3d6+Sp434DJFnowAAmzJhdGZQ3d1QMTf0xOfaKADAylhIFxU2CsDM7lPxOiFr5oCNAnC1
K+ZMISr3AQDsap0AAGACAIAJAAAmAACYAADXiTfABAA44xOTCsYuqmSNLbWky/8edHf7j9bw2vux
MVQuQvkZfyMpHcqOISGIkzfZtUp+uYcblyi0RL25UCnIIaxkV3vkw+0nb7wfYEJbfhotu+JDxxnn
Y2siDLkI5Wf8jUTC5caQEMTJW/N/EhE8Ift0jC/eXEjzqn1K8mp6/gvG7uvfP70xqHAKDVt9XWpj
i2wapG+UiscK8lylvZ9JOLlCkGLlJjsXVzfax3U7v2298N1Pb59pah2neK8wxhaqY8QvL0rR3I63
ZBBbcinKGC9J5V4nApH1wqs39IHwzwkktVoie0ImtxbrZYXq3aP9PLgq2mxGsxcR5xvn/5MIO1Ju
p6CRkpO8slnjvr1OePB+cMVMbt3IfdaK6t2j/by6crkzLyUTNqPcQU5Iyl/+7BH0fnDvyFduNRO4
TyVOklyPHbIQx4I3pL6ePkLTfmBNEZHZUW3IycVF18KykXt1CL7Eyx0lAlG/aaiuDoXgOsEQFnvp
yBxDmpvmG3WIUV0uJAXzM/7GDLl+ZhBP3tpryi63kU7XYDJ8w2jhq1snjAD+E44iXk15tNXMv4XN
GrQtDic5rRFs59IRcMUbJZMeHUk+wpwAAGACAIAJAAAmAEBkxSxja6ReObh/s1bLBKZn0JersAr/
5GRyYogHsc0GlrdPMDRUnTwm/YpxfUxIqO3qLROYnkHmUZ6JqfBPTCYnhngQGcziIvYJljqlEwux
7tfWbfHi8s/9NZlgjSyyGw960wTGopYJ9Q4dFL1NS8WfH6Sw2UDstzRpTALaPeZOEZtN6x1uzK+0
HhP6MUEJRK1pwj61snY0vdPIcF+s3MRc0ZEiota2lfFinYH2VLBhaqRKlMG9tDzVUmdQC0qOIS2I
1JWFsuwT0sqdJg/TsbSNTwmDy55BKa/MWyfkxJAWpH/YUiDHPiFLhtiJ3cb9WpiQPPrvbgCpP8MU
lOKB0kj6PUFeMRHm9zBZOMhq1hXyimWBInOCqZiumSYo0x2PZYKs6AeFiPWBemSWYkYyOTGkBFnK
PkE9Dd1gwbAHAOwTjgHYJxSRjoAroMKqwa5DOgKuELBPwJwAAGACAIAJAAAmAMCcFbMMrpHMrbQd
2CpIn5KZdaNa+wQ9+0pJKWk702NjoOwTPA4SjOOQfBVzSPsE37Goo7sKddoquLr27o1q7RP07KuR
J40I4XTI/fGa/DVlnY9ec++9qKneX4AJzNDIZlLZS6kvzDpItkpbBVNLZzH7hNKnxntMBGTBcvuO
hZdhrex65wLTdKGU5cIpNnzpFgq12aWl9rcd2icMHZVC8umkcnv8jOxT69o0XShVhFNkPcCGeXW/
tgoJ9gkz8jqBZhOCLGafMNJm8lB6R6es7it3PH4sE3t2dxsPIr2CygL2CQuUbmXcX4oJk+p3vyra
s6eE5eRgZ3heZOXqbAkeGbfeqpDG1kV0WjgwEeQyQTbyX+DKRseCcd5Ru8Hc2Qy2CvGGWrxHZb1m
W4Uk+4QZeV3IPsHTMxPtE5xy+9IJ+BNRzhRgnwBcMWCfkCMdAddMhVWD7Vs6Aq4YsE/AnAAAYAIA
gAkAACYAwJwVc9pJzePWCVv+suZ1AsDMQjpa+jQvtawYEoJoRgWs+31mhn2C0iV2vUqY/rWdVA9r
n8Cy9VoCZgnbbb35nQBYXUWdYMbYLP1aybJjSAiiHnZ1Od0+wTgL2/UqIUdSrd4+ocOLEhpI3lPj
JTk+FDI8KWyIdZ0ATPB3kB1E0nLFN17fgwpSiJU34Uc0hwn68K4bKSR7UtjuONssJwCzs0nLB7HM
OEsWP/KkVrUxCs8J83N88tQbqYhpr7VGqizxHBZRr5lQCdEg0s5irn3CaPFlSpYOpYQXWifIjMmp
Rm50ExqNZrM+O7zea4LZLnn2CfHiuylMfakO3C/OBKsmUyYnX+vIfahll8tm4SnB5w6zbKekFEns
YLqZt4kztPRPC74G3Ui/PmuNVTSbhYkgFy++TMkS/Cd4psbBVCHJk0IVolEoSyEnArO6W3YU0SAe
twZF7BNCXiVs+4SSC6gdAfYJxwDsE6ZLR8B1UWHVYNcjHQFXBtgnYE4AADABAMAEAAATAGDeijlp
C1n69P3r8p8g9eN2g48K2idkOFCIBbGMF7LsE5wym74TWMgCwQ0P/wmJOjjkCVKX/wQtfRl+VMo+
IYtJ0SC28UKOfYJTZtN3AgtaIDjha/Cf8KLsmae5TGhNO7p616w51ABBvfXC8Itn5SPGuL4OzY48
h0fRIL7MTtLkkGmDBS1VMdPGEw3fClkc0DpMUImZbog8o7ykfZx9SnN7TErkOadBxoJQRBLNqO0s
K88624h/e/0x9uSVNsmfVRomaRqr1T39Njm3W0yQr7KCTPGfMK/osj6+rM4Ecq1Eprq+uPL+P2fG
zufNvFk4qxFraL372zMhf/TyKmbvYiroN4+ofrbOlORC52XLqJu8YzlUuLXGf734krl2hJRChF2I
Rr19wuz2lqsEWW9alIckgmW9qc2iyotC1PTAa6GwtWq7R8M/+Gi+r4cJpY0GmWafMG54ESp6t7Nq
Wy9U4gRjNcA+4foxehTJKsupHMA+AVhqRbRB0D1LR8BVgmY8rlRkuHn0nN17/CnmBODIuHn9t56/
8+GHz56/8tpbz4vF+huYFIDq8OX/CD76/ndOv/jFJ5erZ+yT//2ff/z6j57/uviKmV/+EeqbsFcv
3PeQt4HawPxyPbzWPjq/u8UKaNklnSpyXwElgvQtwNVj3r4uUlaR3AilUuFmmkNTMT0Z/akwUq5m
xfyDP3/+4rF7+3MPP3pZVDo6l1y0FeY0jnOp7lxCdXV7vjDqTT3yBN05EVq0FeaptclBmkrk6rHZ
X9OS6K70VKw0L6mIJimnqYYrnp7wKnj+vbs//Pl7LRHuunvt5wc/oq+/ea/0iln0Y4Foa4WrcZ/r
U4B63R6OBkI3t9prwa+QCDynnyQF4cMQ7r43PiXw5KwI58rTolXhB38mb+6enLt++/fE/vynJ+z1
F9/9arEVM+d25XOhxpP2Up83uBmYF2imfUCkFHlKkO7x8FaWWClSWZOS74oE2i987ne+9OP32bnT
x/5+9vQrf/Hw80WYIGwuCG9th2qxZQjP7CB7JkKaWJQVpHtsv5VUq+ldd5B/xMhUUQc+/dvE7dIf
vvKdMtJR25XHxhNL1BFcFygbIZeLK2fCZDlCZD7uGiOzVkeaUCSttisiw0++wZ7//vOXSjjy/j26
9/Df2VfLMKHfYUgTMo2VBbDciiS/U6aFMprSmRGmpbwUXj3LSK8+e9EIQpd1gf35Bj1+Wm7FrC96
00XFbl08BFaBzrOFqG6mLdpLReEg3N166/cuREYSIpJQM6W7QtHQ/funojoh6R3G7v3ehQxPuhvD
5xv3n3w8P/5bcwlwKf2wdS26b+3iQLvU59nLDcH6V4zlsX7vCvmgaiW5z4wEiT/m0/LnfPNHz9Uq
vdp13suffvz4X958zbj3N1/8zMcfFPg5YaYuKk/e6b7amWH3sxcX9bVcPE83dy9/1lzcPfjXP3hQ
Ks15yhYid+sE2IgLYioRKsSnj9mXnr389YP7//Xgj8vFCvsEYE/EXQ7QRQUAMAEAwAQAABMAAEwA
ADABAEJwzsq2TgfOgn1iYXcwghmNx3WA72B/92T//kx0isQgrSN47VclMc8Bo/ZRc+7xZl7fAo67
COsc5UhOszwjAGszYTbI/e62MjlHhzgH+3t6L2nhwzFIJwz56Or2c/XIdyxewLeAfZB4m3M9cDCn
OZ4RgA2lIylldwhac6Vfnj/aYyL7B5Lp35h6346vP11SyvhZ7h6PGN2RtTIUQ+iYT8v9jy9rI7Nc
3ozocitcVhBgB3NC705FG+70AVDqozAZ7hWoP8qWWGhUl/rwHThm1T27Xj8uOhgDsbBYw7qckxwm
HqaLWyzuiCp9RqRuyB8pqyQwol4myDS5Rz+32eMPw53vyddhRjqVDHva8MUQODXUiojG/UFJpntj
KiMuWjkg/dtSnhGAOUwYnOHJcXLIHClCTupAeUGmnl4vA25Tljnn2Fn07Mc/0SFXzDTelyijy0ny
uP7zhgt2CUkBek3rQ4Z0FPEjUKaLBgRGUzYDKt07imym+g/Yl+q8+bBLBZnEHSMCCnnHpHECeSR/
V16J9fcyYzVG/L0ygYYdfE1CUL4RNL8KriAhydeZ+zDeATB09H/v021cSjFfkbY/h8FDQHz8De5n
Or4FYu4i4m5t7cIkeEYAVsEk+4RZB/IXS6Z8REUSlPitbDa2sE/I/mVt3CH9frtBiR+5QIJrWydM
l3mLdYX1I6JCaYEN+wM08AAATAAAMAEAwAQAiKyYvdYESi80ZxXoKBBIZ9dc18hjYYsF2wSA5RsR
6Fp92NkBxplAecoObA4zmJFsskFAfycrjNQewxgAyJCOpGZz0BkjWKYK6inzGzGYccnOqEFZOLSm
DEGeJeg95bAQAHLmBGtw1QdRy1SBmb+kukYMVlxkWDE0/+ta/DExaaRjJ4SxVAVBDCCVCcFe5N4z
bREoeQj3Gq0E7A2k3wAHP2EBizOhG2jT1fOl99L9LtPFF7WwIL8tNAAszgQaX0GHOqZjiUDpHXiK
vYEEMYBFpaNUOyqSjjG9jI759kkyul2DL8hILsABYDkmWFr30rRPYO4304jBsAEwAmkWDk28nW29
9K1r/QYBbIIRgfMYADzYn/+EeX0ZTNgD4D8haVEiQQQATJi5NgARgOthAgCACQAAJgAAmAAAYAIA
gAkAACYAAJgAAGACAIAJAAAmAACYAABgAgCACQAAJgAAmAAAYAIAgAkAUCnMsy04E9YVP/+pq+Hx
5fnllTHT6/NzFScA7GRO4M7VuRuL9svlSmhvMGZ99RIBFQzscE5wiWAP52KYDPqXmkmhnyDa56y7
NJ6jpoEdzQmCBRjQ0oNrEk//llD3mvtcnyq651xgcgD2xAQ/EboBXQxc8LFEBO4HaQUAFc8JflFf
DMsCCP7AYZmgi/gCgztwICZwrl1p26rcXViPcAgArkk64v3q4HLRrAcUPdyl8OW18z/dLw1YKgN7
QfZZ2dgRBRYHzsoGgK1wyg2AGQE45joBAMAEAAATAABMAAAwAQDABAA4LPRdVNtreOue3PQ93jtp
bp0bX+7U6MRPeWKWdgadR3J6EfqgGR4940EcP+99pSd6kg4X7hKFVtLOFbbRfCpRLaw8jJPG2O8J
ZNTTUFsdOy4uwIf7lRGBdFobXch5JKe7K++DylJBpPWpKl1SEhEihTO+yL59tYxIK5b2g7Zv3xeX
f+5vxITBn702OEkWG8UqBkVv0+yIZUZviQZx7spZ/ZAijJFO8zlpbd2wQ3ZujG+L5esUH1vG0q+f
CMtP71QqiDPq0IyKjpWbPLFW15BkzAnLZ+/kpWECVyXbBfR5LcTj6XSeQLMJQc7EOP+fFzBa7moG
kWrXCf2aONzN20bpP3YAWjj27O42HsR9Tvldm7Yp3RK4vwETEuqRLHl3z6PA7ClhOQnZzpNcZOCR
Rxrzx3A7umDZsWi0MBHkMkGIqAaxRB6MCaeADBRa1LVPSLKaZUga9r6cjKpHst8wn1yWCbWQEUSa
62VKkNqdchvJqaeRmSEQ9gAYsVnD/HklkDSxjTfpAfXZrIEI10MFyEhTVswldyCAKgTGiY18nB4A
DTwAABMAAEwAADABAOIrZjn8sm/CvGHqvs9X8y+IceuDkvYJps1GgSCr2ScMBgo+JT/YJyTq6pu6
7/PV/EsSYdT6oKR9gmmzUSDIavYJbcRmLqq1T+hx0Um9vw4TmlqhQQlBWZWYw9iVDBLz7RM0ZSAq
EaSwfUJOLehpza+Y0tN8ixu2qJnCKTqJ9yNS7sh3DGjDKZUIUtQ+IYmQWi6o+lp+sWwuT2NEaDJj
i7X1U4I0CXlEZp9dmgm2AFlBJtgnJBU/mIs+KXlY+wR3Rhq5Vy/koIm2ooRRJkgJ+4R48eWIAERV
cuD+Fkwg//aR3M2UkNPlrtk+gZJTSKLkNePWmlKtnRbfx55qSO6QCAXtE+SUFOQhiWBZb6r1ADUb
aJqlpppoO41+U429Dm32uIK++cZ8+4TQKqpMkOXtE3wGCyqsZMcyULjBdtAhAPuEHOkIuGYqrBps
79IRcLWAfQLmBAAAEwAATAAAMAEA5qyY/e4QZKLGkce/wnY70pJCGR5R0p+STGn7BI+VQar6o13u
gH2Ct3ls+4TuV5dD2icQG63wMBGG2qzAaMHjFUBr7oiS/pRkStsn+KwM0uwTnHIH7BO8zSOdKrrc
qe742xdLKSCdAhVKra5L8xssqRvUqR913/Tho6Iq0/0DjGWrjH1CkSDeh7RAuclzKes78tmboZvA
fVqCCYOJDjVGS6TfsB/3N6uaQ9O8Asxu+8I6qL6HMuss5mxvCFH7hM25QYE5YZm+5vhPoEhO0pyL
+D5qRsWicDvYTPGfkLSgCGp6H+10YO86Yeqs1cUQ0Nqrs5cxTYKuEmSs34pnk2JtWGml3F+FCQWm
ePJ91DoX7EfxuLSkIhPaUB5LMft2ci/au2jUKekfURCI93Bp1M8xpSM1PZr7zOYNw4rBr/5fh9GC
r71DSvpzKFXYPsHj/SHRPsEpd8A+wbQwCdgnHA2wTzj8LAD7hDnSEbA7Kqwa7EqkI+D6APsEzAkA
ACYAAJgAAGACAMxZMcthjWQoAQeOzvT7UNh4iSX1c3ZZJEuOrv605HL04zKCyAn2CeGiu2p82u8U
bqLG0wPbJzTlp6giHgvaIWxda5rGvYzk3qdZO5F3xmepINKp5XH7hFjRyUpT+QPwJGo+XVtv7MXi
558mMcE/4rcN0Q9OESXsmrRUOkWdRbNU2j5h4aLH3TOYT6lgVrOiac0PvpUegBZlgmvT1I9Mo2NZ
LWSgFbJE+d07KYjvYQalQ0WPK9mbx+FSwWrLiqg1P9jiN2bHPsFvhGAorwTbpkJnIylZqvl31M6C
cop9QrToU9wqrIH7m9X0KVJ3uapYtHGXoSlZmm9DMaHXyDT/CX3eRuwTxotuvTFS5mOqop2cjkFp
o0qFg//KAfV+lu1TZ2S8lpZLOzmv5xL6+ihuM6WG2OH6FUoZssAbo90sX5E/GkQ9lAsVXaLfJ6yY
Ke58oG4fCsnWBx4bgOpInGefkFx0p8ywT2iQbZ8A/5u7w0iTwT7BPyeMbmSgZ10bFZYVHncrHS27
uATq20zYh33CZ3/5bLsVMwBUgh/cvfv0IZgAHB3P/+Q9xhamgi4d8cs/Qn0T9uqF+x7yNlAbmF+u
h9faR+d3t1gBLb+sY319cSZKBeF9XYohhGBmrcYiF0YqXN0QeqROKkaTqmjEEMPGM8Kjn10+nv7D
N9aZE84lF6KrRrvx7Et15xKqo8H5wqg39cgTdP8QTYGzCjcahNv1JpJ7o9EQQgvM+vFo+Ganoudo
uG2Oi1vi83/0f+3F3y05K9grZtGPBd3AxdW4z/UpQL1ujijazNHcaq/FNTJBH1uLBhHuMJ+7sciZ
3VJJs1WVeOs/Gbt70vw9/cIH66wTuFkfvJ2S+/GkvdTnDW4G5vus6fmTQ7EgwyAyDCzxWh3r3v7A
XlKJlJe2wBs/PP/zpPt75+EaTBA2F/wVFmqaliF8buvtbkpgonwQTayZVKsdkTzCrtWSYgabV8JT
49tnVpkThEgYvO2lXkeNTv49zxjnwUQwYBKzRHB5UbBWuWCedUKtUwJ79sU7dnf+bP6++dFK6wSR
TQSWLylf2ZRQMggv0wdLpMKrocP7b908vghH53XCw7fX2TuyNxKSOjjnpszEhUErflCWTFtwtLtv
XZ3pVZfeJ0cqnHNrj894X31xNgI3xLvvfpY164QFZwRrncAbyXHYuhbdt16kHC514fJyQ1hSJ3cl
UQhMOcvpvt58tZom93sWAtHHY7c3xavPHjWbSG8vmci8s7JT64yDCdWKcVzU13JOnu698j775qJE
mKltIYq/CCzEhalEqAMvP35r2RkB/hOAKokL/wkAsBHABAAAEwAATAAAMAEAwAQA8MHwn2CdqS8n
nAAjrUMILzCj8RyQ4TgzsBxCD+chtomMxdA5HCcra87JotI5sdcpsDTOoRtOUtcPCwrnRtZ4UCyQ
wITZ8Bw6KH0nNDunl1vODEyfBpaHA4rGoDvBIPelQCBJBtm88Q5Uke6Rmd5QSW4PgLqlIylld85d
c6Vfnj+alh8eSKZ/Y+p9Oz7W/cnU3iFVB6Y+aX8MzoFu1uDvy9PUA0yk45cDvf1q54R2UCNtdDb8
50httBwcK/Q9lqTbzYwRWur+XJLP2tGPi47G4DnKsM0y9WE90gy5BAz54eiLyZLKA5LskwkyTe7R
z232OFFwRQKfy4oJXYRiMWjCkRyEdDfLVp8nz/qFJuXKVxGT3B4AFTBhcFQnx8khWRqHUh4vsVRJ
8YZB5vojRSbKzcuWXjmA+SvmhP5BGTK3dFeVKdLRSE80Yshbe1D+K3LEOWFA7MIB7bvfO4pspvp9
KAzfKOJbQeavVynUAf0eVMm/T+QJFOrUFLgp93GAKFCQCTTs4Gtn6SsnCc2VsTLVvvm6ogrjHSMd
ZwamL4CE8/w7dw6BGALpqniDe52OUwLfFkA44gS3B0AtmGSfIMvL1MvEkywzUX68EP+XQ/X+E4wt
lsWJsCIyfwADCY60TpguD2/jyHdeDJQfLdhwXYAGHgCACQAAJgAAmAAAkRWz15pg+H0ga4Xo6BhI
Z2Nd18hjPg1/5Z3bslgYtyUww1gxYAcUGGFCVJdgXteJad8QC1gxMK3fZtkSOMqzegyOrQ0AhKQj
qdkcdMYIlqmCesr8RgxmXLIzalAWDq0pQ5Bnmqf5FJ7lcRIA4nMC8w3DNOjjaxYJlozhGjFYcZFh
xdD8r2v4e8SksIKFDNptJmFQHQEjgDEmeGSU0D3TFoGSO6XXtMAyzDGU6sixbGaEMR5YmAnd4Jw+
2sqwpCLHxRhPZ6bAPOU+J4lfe4GlmEDjK+hQx3UsEWhsivFLR+mSPXaCgMVWzN0yOIkDjn27G84z
LUhfT6cGziSzoqITgDnB7N26ir8yEA5ZJDDTiMEwBTACaRYOTbydvbHn1wFlF9BZHmTZEpgFsIqT
zC/gWNif/4QinRhMqBrwn5AmkIEIAJhQZlkAIgBXwAQAABMAAEwAADABAMAEAAATAABMAAAwAQDA
BAAAEwAATAAAMAEAwAQAABMAAEwAADABACbh3t3dz8EE4PA8ePjL99576/XnYAJwaHzv4dPzv4//
+2tvLhC5ZtHPm38HW2plVc27m+c7vH2jeVXwy/XwWvvo/O4W5tjrQqsFoVfQnCBcezy8NVSqXtGx
REQgMSa0SNvvdib0wN3rXRNvUMG+RP/tTz8crv/677+64JwgRPun88JqTH55oa2j5m2zFbpHnqDX
RoSmqEOJeYEg3PfWcCWSCeqNphuihvbxZYLrHUH0H/UMavc++5UP2V335e6fv3JXWkQ6BYYvrk8B
fQ3Zw4fG3uZWey2unQnCrA5eIMh4HFykEiFxegoQgSdPc2vi+Rd/9e7dE/bk/Mfaz/e+9saPHiy7
TmgHD9FOyGpUsSqO8wJtcl3MmBVErJmPrvWEP3D3NN7E6+Lm0TuP2ZkE+p/48aPvr7ZiPtMgUBst
Q3hlFbaqgGTNhPOCiPFhfLSiha/1RLj1AkTopShtENwcb3zqu/vrv1xv78iuyY4a3WriPGNwwcTB
ibBcEF1wn1DRfFJnHtq2pvp+79lv313WCPrfa9/86KcLrxPCRFD7RsfGykQA2MuX9165rA8uglH7
+eZvvv32UntHSQKmKTOpZVwrLXEQoRwR9NrkYkqolMfGjfOX7nt1Tfny4189aq8udHj9wZOfFE7g
1r84EO2+m14honsmLAmUu1Lp9f+g0ArtPGORlBJEVX1Xlb6KTlk5W9GYUYXXD8HAVeDTD36320V9
7Qsfflp+VU6541qx94CVJ7HAQ1FfY4by9Pyty9LgracvF0gzQzoSxV8E1uPCVCJUhQePv/S5R1/+
aAki7NB/AnAA4sJ/AgBsBDABAMAEAAATAAArZmASprinm+TSbouEMCcAwAUnhyCKJtksu/hP1sN0
XjLNaKRzhylXyb0PaOMV0zG0pHAMWriuMNabl7vSzZAK5HEOHcmglawko9J8Oe3jH0ISPIHWx4TZ
IPe728o0MMTonnpXMnuU1b8oHIP2pvQF9fJbD0SmM/axDFrJtr1cD+zmtCOOCikJRKiYCc2IJZuG
6vrzcHkZxuQwqF2GPTUqXr7J4X1nTO2bP+wEljwsav5t4+tHUCcGdxD3eW1ug2cNwXnvSieYr6w7
7vlypTDrJTTChLbLkj7c6QOg1IbJfmBTPVa6fdMYmqU2gAY50fQgssfSTvhKiIECspvilOctGRTa
cmbESwKxso7NUTXj+lbMASbItCrQx1s3eXLne/J1mAgFnAWHGcQXQ0udsb475JzMe+RbxhToorGy
yjbtfhoFapKO+kWmRgmZNhfJUhMXDcJ6bp9z1hcZY4mxDAlQpOzgKtmwnPbTHqhinUDj8yFlTJvS
XTmOSEcpc19mDPlhi23r6Kl1MVJ0RQNUtHcU2UyV3gfDN+9miLQnB0qV9Sg00lO+jChzBd4yY/W1
rJpppTCbJHQKidPtvK1JCN1lN6+booP2TXqEbBXGOwDSsLWk0tAG5AQpxRuOWTcCyavog/uZoQya
H35pKxpjH+fOeJHF4wky5hSxdEoyRoCbBZb2pQa8YgNn8pRBhRK7brk/i7kTqmNKDU5JxizGaQL3
2DpE2GD2L5B1LH6XkC9XSOZUPkmqrhJpxRRpxebfSjaS11gMaOABVS0rNkvmhIYCslal6R1O1jw5
OsUAE4BMKVOmDr9U9ZRgFwNMALLpkLeLWicRnGKcDJJ4VnuDlnNm6W1lVHvXXNfIY15tUvWYFjQi
AJaWqLKFJJr0E8RcWeyURvaZXSemWkPe6K0fo5c0IgCmSUnl350RZn4yvr0jKeXwITuNPNnflr0R
TPuUWU+6sGZc5yf6wz5emcCzlC4r8zgJAPE5wRpclZFCO4ZqFgmWjOEaMVhxkWHF0Pyva/F7xCS1
2euzv5yxQaEZEQBA8oqZRu6Ztgjp6tTkG6cpfYFW1IgAAAJMkLnrFhmWVOS4GCNjqppjJmkkGexc
gIWYQOMr6FDHdCwRKH1ZY0hHOWljXtgErtfC8QDu6+ZhwFxMT8DyJ+5PIHz/lL/Zw0zxyB7FZXTM
t0+S0e0afN07JRcgwjbIPND60vXyDsEWS+bHfvvW17tls1PZfgw9u//uftOuSUryxGVH3MbbbiRd
dpSkDM0SVmYYC6p/da84YZwYsLwoPDfw3g1r7yC0/6Lu9GOwUF5EW0dWvPsv5lo0MQE1N/DB09ng
K6v/pqfPuO4z6uQZXcn9QvZD4yUyLklfO5O+lrbCRNU2iblhUhYPbhgrBnCgMBG0od4a9rlwJgKh
XmqeiuEqOGHkJdDdbbyJt1daavo3LXzC3lGNgBFBRQuFwbf0uUfzkJdpMSaeiDIJ9OsKoUcpjBlD
mGsVMb5OqJoKVUQBGB0w+A6f4W0sMwGRzuDEvSMAyJSOor1ZH8sn+I3KS2ByfLDUAUqIScySXbgz
/grOJjtQS0ogZQLg4UCYE4CZMhJXsngnqmi3dOGlu7QEpraDR6So5ATc3x+698xQenwa4EkEOJos
x7BOACDEBZ9iTgAArJgBAEwAADABAMAEAAATAABMAAAwAQDABABIwf8DySlnW3LTwhoAAAAASUVO
RK5CYII=
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2009-07-16 10:29:38 +0100" MODIFIED_BY="[Empty name]" NO="2" REF_ID="CMP-001.02" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of Comparison 1 Emdogain versus control: 1 year; Outcome 1.2 PAL &lt; 2 mm.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAv8AAADQCAMAAACnQP7aAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2009-07-16 10:29:59 +0100" MODIFIED_BY="[Empty name]" NO="3" REF_ID="CMP-001.03" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of Comparison 1 Emdogain versus control: 1 year; Outcome 1.3 PPD.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAwgAAAGQCAMAAAA9cbciAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2009-07-16 10:30:30 +0100" MODIFIED_BY="[Empty name]" NO="4" REF_ID="CMP-001.04" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of Comparison 1 Emdogain versus control: 1 year; Outcome 1.4 REC.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAwkAAAFgCAMAAADHIcUFAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2009-07-16 10:30:51 +0100" MODIFIED_BY="[Empty name]" NO="5" REF_ID="CMP-001.05" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of Comparison 1 Emdogain versus control: 1 year; Outcome 1.5 Marginal bone level.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAwkAAAEwCAMAAADLr83yAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA
AMAAwMD////AwMD/gICA/4CAgP/g4OBAAAAAQAAAAECAgID/gAAAAAALCwsWFhYhISEsLCw3NzdC
QkJNTU1YWFhjY2Nubm55eXmEhISPj4+ampqlpaWwsLC7u7vGxsbR0dHc3Nzn5+cAAAAAADMAAGYA
AJkAAMwAAP8AMwAAMzMAM2YAM5kAM8wAM/8AZgAAZjMAZmYAZpkAZswAZv8AmQAAmTMAmWYAmZkA
mcwAmf8AzAAAzDMAzGYAzJkAzMwAzP8A/wAA/zMA/2YA/5kA/8wA//8zAAAzADMzAGYzAJkzAMwz
AP8zMwAzMzMzM2YzM5kzM8wzM/8zZgAzZjMzZmYzZpkzZswzZv8zmQAzmTMzmWYzmZkzmcwzmf8z
zAAzzDMzzGYzzJkzzMwzzP8z/wAz/zMz/2Yz/5kz/8wz//9mAABmADNmAGZmAJlmAMxmAP9mMwBm
MzNmM2ZmM5lmM8xmM/9mZgBmZjNmZmZmZplmZsxmZv9mmQBmmTNmmWZmmZlmmcxmmf9mzABmzDNm
zGZmzJlmzMxmzP9m/wBm/zNm/2Zm/5lm/8xm//+ZAACZADOZAGaZAJmZAMyZAP+ZMwCZMzOZM2aZ
M5mZM8yZM/+ZZgCZZjOZZmaZZpmZZsyZZv+ZmQCZmTOZmWaZmZmZmcyZmf+ZzACZzDOZzGaZzJmZ
zMyZzP+Z/wCZ/zOZ/2aZ/5mZ/8yZ///MAADMADPMAGbMAJnMAMzMAP/MMwDMMzPMM2bMM5nMM8zM
M//MZgDMZjPMZmbMZpnMZszMZv/MmQDMmTPMmWbMmZnMmczMmf/MzADMzDPMzGbMzJnMzMzMzP/M
/wDM/zPM/2bM/5nM/8zM////AAD/ADP/AGb/AJn/AMz/AP//MwD/MzP/M2b/M5n/M8z/M///ZgD/
ZjP/Zmb/Zpn/Zsz/Zv//mQD/mTP/mWb/mZn/mcz/mf//zAD/zDP/zGb/zJn/zMz/zP///wD//zP/
/2b//5n//8z///80TKWtAAAfAUlEQVR42u1dS6wlx1mue+ecqXEyzGDfeTmexFaCQUGWIkh4iBUS
8ooSREkUlohNFmwwOyQWPFYGFiwQq7ABwS5CSNTCyJuwIZGABciWpUghtonH9sxcecZYnlu+M3M5
3V3d9a6u6u7Tj3O+T3PnnNNVf3U9/q/q/6urug4oAQCAHKIKAABMAAAwAQA0rFAFDVj5P3eu8kBs
HkjDuc54UopbKhQv7rfJF2dkzBsvLbdggg7eN27ZjJbiS4ZNWqpKvfhC2mCS3IIJ4X6JN903a1pI
9lhVuPxt9fa8EaijbAaF+sJwHZ2ZTaI+tFyxJjPlf0zlnVjlsNLYcqXOMbfwE3zNVnXsrKr3son0
X5zzup9n3NvjS4EqXJKjvML5gCOEns3yg2t3bdRP9rOcS0WSOsXNTGpl5NsZxOaeW4wJHiufaz0N
Nyq6sl5Zsjm11RGeWzdoMsbNDCfbeXudWzAhX3FZUotN4OynZIy1OTBsT3MLJnQxeedJ4aSM8Tbi
8z3NLfyEjF6ptQsqR3w2yYARuCuLxzSl5K8RCjDD3IIJZuWa9Vr5u+XM6OY//VeYCjIm0w1aZoRu
oY9Vd/Vk343pyY0351saEWaZ2wOswMuZ/VjKpDwAJmzbUgIRwAQA2GHATwAAMAEAwAQAABMAwIb+
jLmc3uX2cvrYvGEt0R5zIAy3fl1m3b8nISajlTeh5Gki1fws0WdpVXizVJNb6RqPasMFaWtAXlcG
M+b0m7WffVtsIRldWRlhLGNNTS0xKneHWb+uss5zbq3flW1JhPhVxZblzHq+0aEt1HYKXquYG9S7
wZaR0ZWn5crl9JyYi/SZse7eXBKoNJOpZfzWqnLven5PZz/m+nXep59jWg56i9T9D/NUWV07JK25
7XrgzkWnDZg7aDU7LbY5vs8qo4afwLRVyUo/zZw0C8aVhDHKM22dubsin4WXk4+9fr37epUq1SoH
PG2BfIqIKqZdYG2XQ/uduFUPjFj7JXxtwMZfLDW3jB6aPaR7H6ly3r7ckeBtnS2PmwPW+nXHpEzR
BTVY8ZZYVfqsT+XyfEJlifBIse1mYeZyHm9b8EBqlf6x7ajaMjK6ci2jzDKS4f2EMdavN1nnPbOa
vVehVYR1V7jMHHGmz3mUkyVs+3sv5pnRlS+P+aUa3CkeYf36EFnv4Lf7RHjVS8qFlZ25yRnjLPe1
BFOsIZ9jRg+DhjNrn6PSJJjRm7FwP5+oLttev87mtuvMnzuWMC/FuowwtWVommvMXEk+VCUtIqOH
pgErDThtKT53bFzuk5AGrfGL2Cv7CUnpCUZZv15nvYufoBJPNvozRFSezQKnDGG88jSdOgvVA68n
kpn++MLX1MMbSHPLaNpa1KxbhZfxY3F/5uxKWpV1ctQYn6ZAs83oKokHeSYdlvEPZU0nVSSIMAiw
PwEAAGCe+PoE91xhTADmhwm0EquyAQBMAIDGOjIddX0NublQPrKQ31hiiplSYPlMMJ50ONcm2IsA
AFMwgRG3X2eeEcDeE2AEGONE3h4FAJiJn2AunCVee6hZVs6tpfbGXoCOexQAYA5M0Be5BHf46stF
oktouuxRAIB5eMxRXdWPWLK7/oAlBQCLZkKsLzc3qHN09sAO+gnSRej+ZnoWHyHy9igAwKRMIPEl
30E/wRDqu0cBAEbGltaiYo8C0FN9Zuwn5AB7FIDd9ZjzqJAdAACz8xMAAEwAADABAMAEAAATAGDv
gXdbAPPCJ/Lz/Mj3NWdRRcpeakE9It6PGcDJiX5B9M1rVRWbFNKTiImo2pOBzQVqV3uspHYjCDO1
QDP5QwXZl65yZbeSaC059Yh4P+ZABDsn+gWRXuag8rk10l2kyQp1KlfQViI05XAbgbbGCIZSQfaQ
CVUryHqva8boIMprVQRCc5VgnqB9aCbcMbKHCPWNuZMVfZxcuMsx/zEYwkdjgqoBQf19vk4asXQS
iL79Hc2xKTNEfIFiR42U4Y/+GooJVStQf+9Am0GatjWSWBQlejMiN4mASDXSGkZLWe3FvwEtdip0
iykvdD/8BFL5SP5qyavp+duXgzUzHU6kHGmpU4+07ygs3L4rnNh8vLxJmZDf4Xm7lUUMBfXk0Xxz
Swey5Gin3mC/6HBo9f968YVj5XhmMPyD/BJcZUrJIEQQQ4kIO3Db9ThLIpzf4Gubv0nHBN0UkiOz
vBQ0kkQ18prR6GyeJzg5kRe0KYHeDz86lNYvYtaeoCpa9Z0mJClosBGcGELNCIZD9wZ4xrz7aOnc
ZzgyTLFnDeuO9oEKk4guDOdWUJSdnxVZdZ80WY2vHwc3zr351/99H9YRsM84uHry+Lj4cvX02lsY
E4D9xDMXVh9++PGD8vvHJ8dX/+qVx9OMCfqpCdpZCtzjyGiBzUsiSfVKC+1VR81Lsnf1ZfNMlXwQ
EaMu9Rr0HEbtEzSTqFPgLVEioWy0VQ8nXzj55K5z9br49xfG95iLd1q7r7GOvtWO6a/ILqSNetNe
ks12lAgVypIPIGLVpbrA2+klBeU3/f3kvD1KMHQsGvzb0cH/3LpLjuTv5vP9e89fvrYex5uyfss3
dsnj68tOvu73mT4EEL2WiXnkgn4YT/Pau50lQt6p7VERTsLBgw+rvEfooHjtRXFwtPENNn/Hns/b
Rx9dX3/qrXGZYDUB44zxmhf1V/1kHWY1cqT6dtI+4iyh5Fki8jrbm/dCPSvE85uP4+jf+xsz6S9+
/sujWUdlE7CWfiF8ZEI1vDKiH0Oy2+BGyQcR0U5psYeSwWpVvcDWN/jEQwfH2bfO0uL9cEQ/gXCe
YNHb9SOpIc3ejX3L+H69547zoUU4dyp3yFptfAK/FRYNHRxv/+m9k+duHEnfIPB35bMX7r+85SHB
8hN4NhHUXAewnWGHDaH7AZ3Pauht4fLGRrr88WnhE5TGkPV58JNX3/6/keeOmOPYpdQyM20m423x
Xc5gWJzfzAYTMc+tqA+y4MluVthw5W6U2gZi3gTGfaX5W+98cOfz5+WM0TFRn9eePbnz4O1R8uB7
ntCckMnUVBLRvzZHIFQvh6+dvLrNrCls1jYZvuTZI3tevp+INZevqpK1TKYaEtbzBO6PwojRkv7Q
URmx/vvfNR4pXPu9vx3xMXO/1Rap9YRDE6YlazQCn1PLHRyd3i4nUK88PDkb9c791qLywSMCW+BC
HyKMjLO795+/ef34s6/deTAuEbACD5gjebE/AQAmApgAAGACAIAJAAAmAACYAABtTBDa/+a3RAhb
JiNF4YaKjtkAgInHBO/ZGH3EAWBaJggh5EvQym/6181H9ZrIOkAQ/RdR8UvlFk6KtmydhHz7pJYc
aUKaCwCwJXhfbVEfp6LOTTDOyxGEWAHqNJj6VbY0lKIja7wF2kyuCdnT1zcDUzFBpBku+nubfW/3
1N8j7DsViZqf1AmlMJeASZnQHIaX4OOKRH/AR4VWS0f08jcAYCDrSD/MIs29zeq95fFtOREwOgCT
eMzxYUHEhwVrFPCegSE0CeFLXTghGBaA0ceE+tX71SGk1LhonqtgCZDGsRVWoNCOMmwOTZLHign9
JDftHiqECgwLwHbRaX9Crxfy29EwJwTYmGJ/QvYLgtsPpIdqAzvjMUdAB4hhxANvgFl7zAAAJgAA
mAAAYAIAwGNuHl151s6VgTmerb6orha3UlCL7rx3Vc8n5IMIFUUu8qO+u7oymMkCcpkQW+/ZU59E
RCOpJ3m19tRcs1pf8cmoh9CGDAUVgK7WkdA2CcjNCNZWBRVK/JsYzLSE3NSgdjhUWxkG4tmAiQAY
E5wOWe9Sra0KxNwx4O43sNKixraD8l9xifr6dJql8JpMcMwBRYBuTLAsl9g1ay9C8mMy6lPuDIUV
beoPAAMwQXa06avehPer+1sMZdaAAMAYTKDtHnRIMZ2dBTRdgUUHJRcgBrBV60gkTj9SQe2OXUT7
fOVlOMFd9BkcALbHBLURwZitDO5IIOYmBmNnjiGk7XAo0xXVpL/n6YCMWXjVZmbaHWBHBg4zkILl
nZ+Qq9lgwvKA8xOSDCIBIgBgQrZvACIAu8oEAAATAABMAAAwAQDABAAAEwAATAAAMAEAwAQAABMA
AEwAADABAMAEAAATAABMAAAwAQDABAAAEwBgpjDfbcEIl58b8PqbfU3GLCK3bb3ehDPCUc3AspjA
1FeuqMFKdS8Vmumazw0BPxFQwcACmcDsoYHY3TlvBoM6es2SkjI1OaqvRjhqGliQn6D0lTG3O68v
MV5zhquxoxo6WKH0TXAdrgQAYAlM0C0fpbyyQ+cNF3z9Ow9cJyQWAADzHBM0HjhOdHURfTuwT0wg
HiJYBAGAXWfCxgSSHgFjGhEYcxzrNg4BwNKto0LveeM7s/padZHrU0vMLyqfNMBVBpaC7HdlY0YU
2DrwrmwAmAqrXAGMCMD++AkAACYAAJgAAGACAIAJALD3WKEKgOXjk+rj/EBMsE8Nr44nN88erw9p
ro46Lq7M+0g/YWdQXRCkKQTtl3jG+Z5REaNyjQuJ50p7JOWFIolwaFhW7M2RjbExgVoVJRtQsqM4
Ary5Plsi2CqkXzA/uicuBhIxK9e4IGgSETySdWlpNDQoSwXZayY0p9trFSWClT9j0Lja9CsAjVdN
tojDTDpcaVujL6LrD1b0QUs47cgE4Q7GlCyRCCmmhOirBXQMERywHq23T/rTeZVEOU+kxYyaQR2S
dKc91KyDFR0VqQMNX41sBpDNv7R7pRZFuNGtG1CxX8e6rxzKiegoI6oaqj52oX+h/dIQdEiRQCAl
pqnau+je5qNhj2p//QSaqD8LqKklNqY5JOT4Iomlpbtmc53vn8RhnnOyNNMo0tb9iyIGFhFBIgxM
e0F8ttGeYxUYPQPDggxZjA0pbIeYNtNi/YvSQTQqUudNzuRTlfsquzSxtIHCOUVX0QeumEWiZc8a
pix2BJGGjLfxJBowvz1rIMLuUGFUsZ3xmNs9Z2BZoB0beX80AGtRAQBMAAAwAQB0HMAVAGYHuYxo
iAdmnTxm0fhIxiLghKX06mNiF0vYz0+T9if0WpcdrKJ8EWfzQs7+hHDRm9VM9g4E69ka9bTtnu5P
aJqB6uWngfZUK9ybJSpT15q2VkbYF5wYhHpj5PHO+Owp4mxeyNmfECs6tS4034QnZ9ifEOzxq4ao
Oyf5RDLW3c0B2kKd9gXltPc9BhGhnZPNLHpcqqUTHHYED9jsrV0MHYcJ7p6mZiNn28KZuZBBLd0J
ZqmxRTqvtshnRIpI314moeieXHiNNTpSI4X8hDG1yd2f4N2hYyxeCbbNDNfxRhYzU4Py88it0/aC
5O1PSCt6m0Enhl4HvkA/QS977hqsOVZb6/ry/rkWw+1As3Sv3kfQTS9pcLCW6bakt2ezivbzBGPU
phGHCUuSVFWI7OU5iSJ0oI0ElFJfuqFcTN62XztfYUomtI2gIlJZy5pmGCy3hZrRIUTEWBUq4hnf
z07O8ZhpZIW62vUnl7abEadf0a4W2YcMvDkvwzezorKYtD+hQ9F9iq92RWB/wvBWMTD5rEH34L3Z
n5D1NsjpnyEDI/n0y7R4t+Un+MxbEGF5oD3miGbU4OvPfebGU09eunT5yrVnDk6mt44AYGzraH39
0enj07Pj6tdR+Xnl3PrcuVsPLoAJwB4wYf3w6T/5g9PHx+GY137nH86tXqcXhmWCPHe5+cVtfjJf
IKuEKmFG6qOY6wSLCJzt6DmFTJV8GBEmL2snwleHWvM2L7JpEdUcXE/RuELqo7I5MZrKSYBNc8Qk
+84Tf/etTz986o3E+Eerw9W591anA/kJm7rk7lHizPtVXSmkZMtuvhj1poJ29IDyulRlyYcQYbLC
mBWfJ6cr61yr+kbBtXbiZuvoP8wERqfByeduXrv65HcPTr5575333ziqNb3lk7z/7v++efLRxSeP
nnj62XW3O9tzR7zuhWRlMdXvM30IIIR4RxBt5CgvVd/5bjLBLnlfEeYoPQuZzuH+KjUD3Gr2qXH/
lZcenV4/qPwA+Xec93lMju7dI0cX1ofrw9unfZhgtRDjbPNP8qL+WlBF6bpnYE/ygXbEmmUJJc8S
qa4z1XOk9iEL7mvW3xdfffjoF0tT/73N3/EAf8V4ce7cn/3R4fvJhDg0+wXGWjoKbkbRQ3hlLBWJ
7PAQECz5ICL2da3LidYq9zUTb/cpuHMxLrkVfOUb5ODse0OnekzO/vCM3O3iJxBpPuaN7JIa0uzd
mKCME74XBGBc1dqgIs74mV+rLIWePiIoB2G07uz07Nbt4w8/uvifz918+ieOStu/39/V6zef/fxP
0/sf3H73x5c7+gk8mwhq3mgP5/ryrb40kQ4Jt6XH3Tb0EmG6Zj39leL/D3/m9OLDR6WRVNj/eZ9H
h88crv6ZvtDXY2bmnFpiY0i/uBFWQoWXMcX0w2hGkT65MKSIJ1YaL0LpejXe4APzTd5O0XTVg4Gv
f+d18Wvnb3yFE2X3Rz+vrQ7X756Vwl/ueOeV7nRVcxeVn1x5YdWvMkT7qrtpvDIrZRTDk9av7a7B
ZJS8n0g8KZaRtJuSJ23vAwUtgQnbrNDpB+TVi99nv/3th7cjEa/86vdWh/xnLygWdUW/Z8yptcX2
xHWYpQnHk3yXWbWcs9rieGMy3akXWpSfR+vDj59c/WA2qy0SrVkGIkzozPA+RJgDEyq8Jn7j9Ozh
o1/6j4PVavXu6dD3xLojYIb0nd35CQCwLwATAABMAAAwAQDABAAAEwDAB+P8BPPl/fmvRLDfWFi/
YcqMRNxN5N5X9+sSlGgvK/akoC4FTkWo3sZOA7et35XrFNg5ckBYr2wM5cY4VYLi5TjLYkJvUPe3
qwHUfXWI/9X91kUl70mBWK+A952KIGjotvLMCL+IceRAfagAjZXHOVyi/fQDYKbWkRBCvueu/KZ/
rV+m2QQIov8iKr6dHpF/Iqyi1KOp1REl9a3bUvAfAOTLU6dumvroG0gIyr/8MUH1fIL6ujitt2wO
Vqg1lgpXDYweWugHx9CYylDre218uSn4Dk4yjTYiz0Dx3tZUZdGux+UrM4Pl8VcosCAmJJ5uob9A
m/q0xG546vkR0pnIu0ppOAXjJCXfyQ6itaMWbcQMaLWbG2ocY9bx9ANgSibUB9XpFnRMcVI4lBJs
ZMHxE7KMlu76NpymOo7N3p3KsTsec4Jm0Qw1EkEvmeZoV78UkoXiUQRNlxIDnZwGTDl3FHFC/Wco
NL9o5GwFEeeOT5KGRgia7DFr900gTrdXR1N4BzvIBNrM4GsWuzpvoPxmmPLaL+Ee9KvJxDpH50yD
2vJvf5F/6FQEeVBo/L4B7nrTFeqBQljPzbhJpx8Ak6PT/oReL+Qf7DYDpiDyD/NDj79FzP78BGOK
ZetEGBGZT75Agn3yE7pPsQymJnS8FDqcagk27BawAg8AwAQAABMAAEwAgIjH7N1N0DwfyPIQncUF
wplR11fkkciOhXpVtIqSvJcAixyATkyIzZH31KeYRvr2BTgLn7QJ/OS9BHLGF1QAulpHQttzIDcj
WFsVVCjxb2Iw0xJyU4Pa4VBtZQjyrMe+OYL5TaDnmGB1rvr2LGurgtlJezYxWGlRYxdD+U9f4e+a
SZEVgBl7CeTOSgwKQDcmtPSu5oIiai4/TlQ675LNmCx1djbHH29B+4EBmCB8yhd1A7xf3d+is9Z6
lvwnyQBADybQdg861MU7OxFougHfZb+BiJlQAmwA+lpHqdOPVFDHx432zfabZPR9DR2yTyOjAdaL
Av2YYC7xb7QpuCOBmJsYjK0AhpC2w6HyZ6uZThFUaUHddBL2EghjWz/YAKRgeecndNlLACwLOD8h
ySASIAIAJpBOewkAYAeZAABgAgCACQAAJgAAmAAAYAIAgAkAACYAAJgAAGACAIAJAAAmAACYAABg
AgCACQAAJgBAKtYHT1x98dLRjWdOtnqbA+xkAWaHZvfm+srD00d3q+9HxzcO6fotjAnAfuHk5hMv
XfrozR+/L4lAjsl7t370gxefunaw3vKYwMr/ucPLTQCvr7AqRhmVs+J7E60K2sSdYjv2RF1XUxm8
twjTrqvgulL1ig4kWydo3YGZSTUNze1MMDOedufxcfnT4up/hYOPDs+vX31he2MC59WfzgurtlkR
oarIMrbZkjLII7qrY3hRYq3gPUSYVocquP7GW/mlKt+5A7ejVK1nZYKZScmP8WmwPvj2k+LRj26V
RDiqVd/8PH78zpvPX3zpiZtDDg6rQP/C9CGAEGu4cEeO8lL1ne8JE7LGghYRlsChoTIlW49HMzDF
SHDy+q8/EnfI7x+T46Pjwi+Ifh7/zb175Et36OErL2yJCUVFMcaZHJCZ0nVnkO/ZajtiHQ0iMlz3
kTSElFGMmBP3X+t//erplWPpD6T/FSPH8zf+/I9X/R3pqMdcUCIQwitjqWDKvhhDoVoYQqS1G0+v
6IRMySh6TB4cO8bBZ75RqXYHHJ398PHW547sypDUkN7Extrc9P6cAFtnXG5Fh/sw3ReMSo7rJLx1
6/YHZ1947umrpS+Q/MeeefafxL2X3x1gbnWVQwQ1bwTMnTzE9IZ5ruQE3vKF4r+Llx5dOC2Nn8IX
iH0+vTp/+Cohv7U9j7mNGtqcgnIIOGPTzDXsshfCMz0vJaFNYBB7rpTV06vc6e3q0Amb8vQWebC+
9qnTn+O1seT5vLqmb9ALw97YeMbMakeq6hh489yA162hfK3qk9vz1axt5nv3Jo9y5pDCIu7zBKbN
+bOWyVRHQmsWHo5i9GoqlKuHS9MwotCgk58Sv/zdu07QFz9Yr//lhS3cM2O1RWqlYGSY68gS1Lq5
NWaTp/tfFI9+gRcTp4VXsFqv7p5u654Z1lHyPBuIMC8u8D5EmBaXN39/+cbx+S/dWr986TcvbPNW
WIEHLI282wFW4AEAmAAAYAIAgAkAAI8Z6IwuZ9Z1OuduihthTACAAiuHIKL7Scb2eebylEwzGeFc
0Y5Prs+ANqKYB0MLGk2hLoUVpbgq3JwoIf+p0E7OqoSolq7wlrA8GrouDM5IXxgTeoO6v10NoA1D
DC3V1czUNkv3aDQFGSI8t/b9bthlnsIezJnUcj2emxvJZVUYQUGEhTKh7M1Edd59pc/N16KLE02H
V3SJqhMvfokmvtO11qrRejIsdcaoKr26d42k4O3cKzlbz7vZlcIhli83O6r5YiSZ8W7UwoRKZanW
O6uvFSWsgKbvpLWq0EDvq3rLdm2kdj8rja9YCjRgtCkyeWI5tA3mTF4t0oqVp204Wip2z2MOMEGk
VQEVsbqhri1AfcoUz5uvXDSWgnDSob4s02DtNfY+7aQdvooorxajpkgYCIEZWUe1r6mplUgbi8Qw
A1elNR36KleO5nYSg2tqPRJSz1wCsBA/gbbrR47NLaivzw742P4hwaNHegrJWhY1Ytqto7SEXeNI
QNMWO3cUmUwVfvOaKvMobPTEuSM8KkoFjRtLKcQRvtsKOuDgsA89Ph2rXqa40SpgbMgxnQrNS9TM
XkKNCXvtl/B0i0rG2znSZmqp/iYnr6ideMQ6MqdsjQuB+4rmGUFwktPJmW8KoCVTtfgOUSXL0BOd
xtfs2upyG0PgYAuu/VAWcf90UlPIvZPY62dlWazuUFVdarfLbcxirDpwj4xDhDGH/bw8w/mdndXY
/zar4W9J51M6up1b0RGbeI62kdjFYmAFHjArt2Ky26zQUECWVypoVvTF0BNMADKNTZHa/dJZDwl2
McAEIJsOebOo8ySCU4yVQRKPJ9gsds4svb2qzZ5R11fkefxP58GefiFtL4G7gBqYwqLKNpJop0cQ
fW2xVRrZe+pTbNmNb1+Au/BJGFlJ2kugLSEHtmAlDR+3h0z/2/jmjoQQzYeQK/JEfVnUe2GqUGKF
SFkzrU2IHlinK4I8i4wIWSUEC4AOY4LVuapNCpWNoe1IIOYzPXcTg5UWNXYxlP/0Ff6umeSsAAwp
d3y1nLbJBwCymdAy5pgLiqixrzJ1kPLuEsh5hE9aHm9B+4EBmCBy/Rbh/er+FkNpLfQcGIMJtN2D
jhnmIqizNIFPuauovDL2WzqALUAe65wl4EY3XwbMePcbWOeJ+28Qvr4KWhdJekTdHQUi2ue7Oiro
4LMMoMAoyD2Cl+e+BJtvMz927EOfdotyprL6aDS7/u3+0r5TIagnLTvhKt1qIqmYURKizerSUgyS
UsgRSRgzWKDFtscGVh/DWh8QWv9QV+o+mKtTRBlhMo4Zr/MN1NhQxq+OdmcqhfKXfn8Z0zsmUHe+
Rv1v+rV6JGp8pbrvTHVf2pKJ+bzUnkeirSMBtd12UGAUImhdvdXtM+4MBFxFKkN58y04YOTdQF6t
DjmrDuVSd9N/afIJc0dzBPYSzMhRaM413Gi0q8g8arXwVrMm8wa1X8H1JM2ToLjpq/B2P2HWVMA0
06z8hOgJVJz1OG0s8wY5xz6mzR0BQKZ1FNVmvS/vcG5U3g06p4edOsAQZhKxbBfm9L+ckc4HqCXd
IGUAYGEhjAlATxuJKVtcmiraJd14kV8tg6lS8IgVlXwD9/mDjGdK6elpwEkiwL7ZcgR+AgAjLhiK
MQEA4DEDAJgAAGACAIAJAAAmAACYAABgAgCACQCQgv8Hpn6eULQ1e4UAAAAASUVORK5CYII=
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-06" MODIFIED="2009-07-16 11:02:32 +0100" MODIFIED_BY="[Empty name]" NO="6" REF_ID="CMP-001.06" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of Comparison 1 Emdogain versus control: 1 year; Outcome 1.6 Aesthetics (continuous data).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAt4AAACwCAMAAAAPK5luAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-07" MODIFIED="2009-07-16 11:02:50 +0100" MODIFIED_BY="[Empty name]" NO="7" REF_ID="CMP-001.07" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of Comparison 1 Emdogain versus control: 1 year; Outcome 1.7 Aesthetics (dichotomous data).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAArAAAACQCAMAAADHqaibAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-08" MODIFIED="2009-07-16 11:03:07 +0100" MODIFIED_BY="[Empty name]" NO="8" REF_ID="CMP-002.01" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of Comparison 2 Emdogain versus GTR: 1 year; Outcome 2.1 PAL.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAvEAAAFgCAMAAAAFNNaoAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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=
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-09" MODIFIED="2009-07-16 11:03:30 +0100" MODIFIED_BY="[Empty name]" NO="9" REF_ID="CMP-002.02" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of Comparison 2 Emdogain versus GTR: 1 year; Outcome 2.2 PPD.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAvEAAAFgCAMAAAAFNNaoAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA
AMAAwMD////AwMD/gICA/4CAgP/g4OBAAAAAQAAAAECAgID/gAAAAAALCwsWFhYhISEsLCw3NzdC
QkJNTU1YWFhjY2Nubm55eXmEhISPj4+ampqlpaWwsLC7u7vGxsbR0dHc3Nzn5+cAAAAAADMAAGYA
AJkAAMwAAP8AMwAAMzMAM2YAM5kAM8wAM/8AZgAAZjMAZmYAZpkAZswAZv8AmQAAmTMAmWYAmZkA
mcwAmf8AzAAAzDMAzGYAzJkAzMwAzP8A/wAA/zMA/2YA/5kA/8wA//8zAAAzADMzAGYzAJkzAMwz
AP8zMwAzMzMzM2YzM5kzM8wzM/8zZgAzZjMzZmYzZpkzZswzZv8zmQAzmTMzmWYzmZkzmcwzmf8z
zAAzzDMzzGYzzJkzzMwzzP8z/wAz/zMz/2Yz/5kz/8wz//9mAABmADNmAGZmAJlmAMxmAP9mMwBm
MzNmM2ZmM5lmM8xmM/9mZgBmZjNmZmZmZplmZsxmZv9mmQBmmTNmmWZmmZlmmcxmmf9mzABmzDNm
zGZmzJlmzMxmzP9m/wBm/zNm/2Zm/5lm/8xm//+ZAACZADOZAGaZAJmZAMyZAP+ZMwCZMzOZM2aZ
M5mZM8yZM/+ZZgCZZjOZZmaZZpmZZsyZZv+ZmQCZmTOZmWaZmZmZmcyZmf+ZzACZzDOZzGaZzJmZ
zMyZzP+Z/wCZ/zOZ/2aZ/5mZ/8yZ///MAADMADPMAGbMAJnMAMzMAP/MMwDMMzPMM2bMM5nMM8zM
M//MZgDMZjPMZmbMZpnMZszMZv/MmQDMmTPMmWbMmZnMmczMmf/MzADMzDPMzGbMzJnMzMzMzP/M
/wDM/zPM/2bM/5nM/8zM////AAD/ADP/AGb/AJn/AMz/AP//MwD/MzP/M2b/M5n/M8z/M///ZgD/
ZjP/Zmb/Zpn/Zsz/Zv//mQD/mTP/mWb/mZn/mcz/mf//zAD/zDP/zGb/zJn/zMz/zP///wD//zP/
/2b//5n//8z///80TKWtAAAf3ElEQVR42u1dy84lN9Wt/vjSu0FRlKibRgkBpAwYMcuURzAjBrwG
b8AEhBgxY8acCf8ED3gJZggkJJRBlABJBwUpCb3TQf2fU1Uu3112XV111lJ/XRe7XL4s79r2WeV6
QA0A3BDuUAUAGA8AYDwAnAL3qIIBov1femdlJLaMJyNVYuE01y6HFF0OrreXFdf3HvkE403IBeK2
jSikVF3i8t/lcPuCdGSS1Vf41vkE4+OmRw6GXAyN0xulLrw/9k2/3CJnjd4YGem2QuVaSOOZI53o
Vhq3kk/48aEWa630pYZF55ZcNuaRlMppUQ21S87ajcqLyogwHCkpe9r0DDL2rTQauXgpKs4nbLzv
greGRBkTadVx53CKEdfG8koXtaDSSWzIi7TzmO2SrfQ0qjifYHy5Hy/GGssKXuspIPLyMsT099Mn
z5pPMH6Kl1rYj1YZucrsvMixPi1XtyIV5RN+fIHhybEyGzr2QmTk2ItpX9UfCXEz+QTj7Xq1q1Q2
ovNIxdVImUdJyrsWbYVeoLMkmkCOI/mx82amsZaZry+fD6AkK5mAqH+GGwDjl/VwQHgwHgAOBPjx
ABgPAGA8AIDxAHA8mL+5tjOmsnFmSlPzceqK8ZgLYTlJdZ/1Iv26E1mES54ZSyr9zXBahw8CQ+nc
3foBM573sTaTqvzCmhkfFItzKrXyLJqMF72UW5Twb3vx9zKSap11WXJr4UjEpscKlyzUw4wIwvlJ
YEL19/J9dTuztXXQjNapPov3geZqxCBv1iJxrWeW9ry0xUChZeSO0DmmJ3eN95aSajnHlAkjB1Ni
KdMiArWkKqTJa1y36NI7GZbx2w+hNZX9FWXR8uOFoZbVPLQzMWiY9RXWo1oY0mfpaZoTevKtJdXT
JRpdql0OZPQGObF0ydwyCnVtTn6kU3RhpjnUq1f+DZX9FWXxzrZ4/i16agVts3eFHDOeMv1MdyTV
nheYQwD98JEjsbr0xZx6lVkdR5Z0L5koqdsSwhatBKtfRlLr2CaWJlb1Wbz3PZrC4jXL+/FbSKqH
rMuZWc0Z94zGEtPplZ2JwdE2GNfOU5QM3Y6fxftQ9soLtPjgdANJ9RJZzxs/h2LJzvb1csDJ3U4K
IUXpG+mbvqhYWxbvoo6tGJ8OMq4QlqkScbudyaS1JdVi21YvKLHImC0SU54Yyomz3Swh7aeemG+u
6s7ine1t9j6XIQWXnkMqQ1f03qd11LjK8qbJ6eybSKpV1qf48TrxlIeeF8vJu11GmfcGip28rekP
3ks6wSLYuks6NhVlMU87WXSXuIwc4vLpdefHm5T4tkWpMYv3WXwv88IgI5/h82bVHQi/to0HAAAA
FsGPt73dPWw8sDO2pSDUwsBtAYwHbguuPl46e5bOLTKNYEkiMQMJHMXGWwo+af7m2kHKjRfSBYBV
bbwM7AUo7mvSvUdEM00jDwAV+PH+iwyGJt00+5YWfaJGHgC29ONDb1pKvweI4L7fVURmHwKAvRif
Hn+an4ZxTXnEAwKAmhk/MuEivSDhv8oCAIfx49U0pDD2CiHSFr9MIw8Aa49ctVQ8Lho3lc6W6tmS
Ls/VyAPASlhJOwmNPFDClb1GrssBGnngACPXRSlfHAAAm/vxAADGAwAYDwBgPACA8QAAxgPArjBn
J/n6n/eLFFP8yA/hLgV7szn0fbkJZ8GKMTmPVpmnxXIDh5qjVGVHijmc4CGAGiddIxeBu1423NCt
ML4rdLq4lKj9/urLn73ZnvDGfWkkxpw8cpOTQjIWh7PT/hslvFtM4wSZyXsN00TvevkjXrt9vrz8
PayC8Xbfv1R52+OvVaFOtK2gjwyjsn49TTfCY5hK+KwyJ2P1gTQzK7Fi2vemNSohhpRe8P/s8NA3
C7ZlvOr7ba8nwzLYVtEyGbU+CDN8lslPcZofi2b31mQxKbuYi7syMjt8T12N4/RSun0o9RB3Nrth
3GfpO+7uPZNMpl8fr1xAw9xiUnw0kQg9tx+f7b6Ga567arM2O9p0yiJLBXC7HaX74ngxXfJScsxB
WSOSpfCwGsYv8DSn0GZbm35wMGX4/3QDFbESJs7Hc3MEl6aGHJRmc5KNZRB5lo133LluvopCwZ7j
15+wN9sbejWbFM3BeIziu82JpbPDw9R4mzUqKmbCS7dj9LMNudefClg//pQYH8ZOv3hpbDxXA5XB
SSl/ek9wy5ErUD1oRvDJn/qw8cBtAYwHwHgAAOMB4IQjV6Wyjv26zWRtQlL4OmZ0E+r3sCZ86n0q
0sdbZeGGMkprHvAt6uNZ/fKRNREQlMLvpYj3WRRRv0c04ZM7VlOFPt4vC2WU1jxgfWI9KdSuuvig
jXeYr5XxqvN3Cvm69cElmCf/WUMfv0r5Nn24JvAgGOP32+b4Pl1JzssxVVjwBZuHTA9gJT5too+f
/1TkDbrYl8EYO+rjydTHk/tUDdjD+tmfUorYvlgNnpiV7xJ9fKKYXtl4hpE+3cg18J4rjxKnNrvd
hN32pV2aDfytfH18oJjhFou8saCc/5XfZ3hYG+PjrwqEJw5qNPFH9blCtbuEPt5NN96D2levmvPj
LvGk1MN43tvPPDvWqks33UgnIqJ+8Y/zI+rHWw4ise/y9EruOhTxQbc2pH5fQRO+gD6+r0szw4vo
4710I/r4opIcHNDH3+IzA/p44HSU3+XSo3k1wGkAfTxsPACA8QAYDwBgPACcdOTK0YGLt4a8/gG8
TpW8kWFeTx+fl0IylheYrY93i1iojW/sS5pOHNs0o78ClOAqHatDWxBmfMby8d6Qvk6VPAd3jfw2
S+jj81JIxvICs/XxbhELtfF2DMtY0bmnJ+/DhOiWiafGkdR6L82EzcHe81tZ2tf5QrKV1cIzi0hl
97Lfb1vE2HSCeMfmUGWMD/kuptk5hpqGCslfJ5g2LOJShLcZ/WUVHE8xnkMrxFMz4c2FI3QMbuY2
c57Ly+XVV7p+fF7SjBWH3Te7xz+nUT+L899Zmf8qSF4KU+6T0MePF5Gj3iYv8Lm3AjysnfGTfNK6
THzgjZ+cF6Qr9F2izsp4EWm0YLSWU1M/7oKVb63/zkkzX7dP0wu/U8+rOT7N/FgLOM6xImZq42/Y
q+F+Ptb4pI0zOxvQTwdV8lzHsjUcfu3N1pTPyGuewj4Zy66+Qn18k9S2p7Xxdl3cEqCPPx1maeN3
eEJDHw/MH73vePmh5mqAM4BmBUMfDwBgPACA8QAAxgNA3SPXW10/fuYC8pylS6x6/Xh7CektWnA3
6fzNrx8/q4dy8B4lsepYP95ZQvp2bLzD/Anrx9c2s0WjQXuraniJCqT1qmnJ564JLZ3//bb5uOX1
4yN+zwy+FseqZf347Y2Pls4fff342jTYnFrtkZpllCULaMrYylWxPj4jKqdyweYbr7fj1Syxfjzt
/oYr5eaHcgYt40Z4ZNX1nFhmIA3rWuevHx8ophPDkAdyvC42fMn1YQ2Mx/rx5d0rY9X1nFhU6DJR
cUVkvdaL9eOHFsv1M2t7KPLEh3xe78padT0nFs+sQM6NwWvVxTG9GqwfP+duc2JN08ePlyUWw10/
vqrWWxnQx58SWD9+glcDHJryu1x6uLka4CzA+vGw8QAAxgNgPACA8QBw1pFrWioeEcLX+MurJfx2
l3GxNeE8Y7CWp7BPvzng6ONVdsr18X1hitaQ18LhzfXxIWyimQ/p4yPVGxbC1ziXZWo8KRbU780o
Q57CPv3mgKuP77NTqI/Xv1oVrSHPwTzeoD5eWb/2N7/BBh5y0ipr6cWpT6k8hX1S0BISz0zIDucu
yUHhm89fS3/qM7Ix9fGB5eaXz1RIH298NuHS49P1Wfv67Bm/my+hFZ6aBCWyU5KvSVnY3YZ1GdC/
uW6y3HxIV0OxGjngOwqpDjvfYc1T2I+vUx8SxBTp43NE/kypQqdDz+rVDG/7ZfO89j4w8uPiIuvH
U1asbI/cagqe/OWd8TXk16mSOXi4NePZcEw5QOqIPPjgb6dtlv28GxlODS/a16tSj+2Iu9SYYrxS
Euuz1+LGTwgqS5zzsrAmpzi3J/Gk0NN6NYMfb778xXquNqCHr9SXKdDHz79N3vrxyXXqAyu5L6yP
9xaqt+5kh54b0MefEtDHl3o1wNEpv8ulR/NqgNMA+njYeAAA4wEwHgDAeAA47ciVi/Xxdc7gZq0f
b8idpy+12ozXwUb6+OD68WEFfPr6zbQ1+ywhf+/Wfpk+vs7VhrPWjx+m4WhOx2pG14/fQh8fWz8+
ooBPX39D+vju7QZV2a5ROOSkFWX1jskdi+dmwUiCZuSIZuWw2aB9Q/no5fC/3zYr98Hb1W7EF3oS
cIZPsi5HjNeRPFn8AtVOBYxct5Ep5tXQnuvHh/JHaXt4ACUGj/8as/b68Vkfhmd/8esSGuaVgeKj
Cb4RXc39WCtypitZ3Zg1kyILGNIFVl2nxJN2WjE5+oJVfNH0jVvzYSWMt1+JNrXyR/BuCmThi0n7
F32tME8fP15MKAQjuHMeec6C2aaVP6Q7n3jTLmv19/kuzSb1xiD4JBtv+nFack2K+NWuFx/xVrXw
OxS02EhkJIUc7flcffzIPbB+vDlDBONwRkAfn+XVACei/C6XHs2PB04DmvGFM1rfxL/90zfeeg7G
A7eB52++/vdf/fO9pztx/mt4CQrYlO+//eUHn193vvj0N3ef/fyy8/2/7TZyFdf/pD6S7sBChAJF
d1F3sbjuD9G6oEvcjQcnG4y2dJFVBYzE0nXmB+uNUWlmRYYT17ftkx42bsAQWVgN7MQz7rwa37/7
/GPj8MlXX73YceR6KbXs2s+tWH9Xn7le1bfqZceqLB0UuPTghO/QVVig1rxYgSoQRh3pRNSeHO9z
w22F2z7SyYGKLIysegn0J1bk3ytPf/R+S/jH/YmXn9KTVzZuO9epkV1/F8oqCW3HhWnSnao1a0r1
2fZUty/FCQnfF1lmxYoQPn0buVDHDFn1sqwswvfX+P0vrnT/pPnk8jds//Knd3cbuQrh1riQvV8y
7ErLTFgXi4LKPzakVWQRMYx2LBkJXqADylgH8c5EGmkDv+LB488+vFD8suf+/fUHbzzYh/HS5bwM
1k2M2P1zc5T75yG8cgsiXo0dq5TwS1SkjDRSOJ6Mdt0l8LuX8bAfvrWTjQ+7m6HRmN8FpFQu68XU
yOYWIOVysQKXZVdk3MQXj8bles/in/z70bdb/937E3/+wwe7+fGymPB6ngbYchwh3ceBVJtglBrw
8tmrj548a3331qHptm//8WebuvHWXI3wBl05tS9sX0ebms7LOW9v6Is2UsKiCjAjJ2y21A8OIdQc
mT1VZkdJZGnLBnrx7KPXRUv3pvPhH3/n1Y/f3bjZ7mz/5GrCh3lg2R8pD2/YNf2/6wnpOIGi8RzD
Ezo6ulZS7m9esI4VqsgJ6Y5n1UtgXT++w9f/++vvfVMdPP4Ff/Ri82abp53MrSFxI659LU7P2KhY
7tlYz9/5/H8X+/70G+89WmYAMn3kusRkwNyIwEKO/gzCr4xHH/7ntTe/9c6//vFol7qBPh7Yu3tC
Hw8AYDwAgPEAAMYDABgPAGA8cKvwv9nN0xe5dZeNCy5XHVivPbSmO3nBrFZJC6347q3kPqwN33iL
accz1K8D5q/4FVmonZ3vugfz5l5CWFCpFsbPRmAlOA6tqMg+W6013e31D53VEIMriXkrufOQIQ72
jWC2r0EUiBJbqF2tt04ZpdOb8YXhgc29GmbuF9Nq98zdy6Zt0yGAG/Oo0fHd9Jr+j3MbXNO4XxeN
Yymwuxhy8EEVzNpce+t9miC+kClQrY3XtktZN9tIGWZPmS39vQX229j+MoW5fKvvnHCYJ+Zau34K
3jLsQcJ3X4HQ7o7+EA0FuM85XOVu8TpqUqXz3Ch0gFoYz3n+SoyVKtR7alPgYEKr02gKifWn7ZxT
1PdirxcVDFyCeRsicTNlYXhgRcYP7cLjnYCbvL6SE7yY9aP519Di9yPV2YZh7VjHBDYfudJ4m1JB
03N0rEn+2TAXoh8Nm7akaMa1PLkPhS+moOcGVDNXk5ikDC8oz3odbopaeU73kdDkDqW/azGBiPa1
sU4xywjT4o8vYE3G0zADbqwobi8oby81bhxxYBSorwmat9ia7kxu4mM843CnGZZLD91eJx+dNYwt
tG7cj8fWhh9uk7EwPLAiJunjZ61Ovthtlk9o4g0ZvynNQRXf+htxDLYh/PaY9tMQyH4OP3769MRi
BNg+IZqcOlh/FEBJBoDxAADGAwAYDwCHHrkG1exafVv44WlXluXOQZvKsiamd29cdXkXNCZiN9Xy
mEkBYoxPzSrP5E1KSBISpBviW0u4qc6kReyWWh5idGDUq2FD896L4R2pvA5twiJ6Oy3uRfVaYd9J
6aP9yfj5dVr/mnM5cCs2PmhWScneTUV847y3RCFb7NhZ5zUgU1PuuzeUReeYS2Sr5WHkgRHGh7gT
OWdr4SnbpgbfkIjKHMl2dJpcETtEuUAe43vDmS3gMsnI8aCYTJ7Hvi/da6+4KXRWwHYgj/E0PpKN
UctTwlM+BZOC9Ok6dwDI8GpyHQJicg01J224u0KIqatPPABWEbEDYLzpzpC9TExcEd/YInpLg25d
ZCjs23T7d6w5RXdXXZ4jYo+dAIAjrh9fymAwvnJg/fhRRwqEB26J8YW+OwgPHJ3xAADGAwAYDwBg
PADGowoAMB4AwHgAAOMBAIwHADAeAMB4AADjAQCMBwAwHgDAeAAA4wEAjAfAeAC4IZhrGYjLn0zu
NVLHlZd/o2/lXsJFI1HNQI02/kJN2fE6ttfv9nAOg4RHBQP12niZ3FOHvXFXdG6NvDL4XXjT71rh
qGngcH68EIanojqA1Ofa88I0/X24kDD2QJ2M18bY25MD50P2WkbON00qAAD2ZXyC8K3bDsccOBXj
k4RXnAeAszBeDUiFv2d48dl2Ho8DoEbcuySNTchLofeGbiCFOyHfRpNtgAiFA8C+KF5bGDONwLLA
2sIAsJVXkwNYeOAsI1cAAOMBAIwHADAeAA44cvUU8N1Wj1VFKLCfpu8ubifjhTQSbHWUp56VF1nj
+bxYMzIhrZnjYI3H3lYYxLC3MC3h6ON9laMI7uozWix5vdqqM0NHKc5M+IwXBTJjze14iaZSne7m
59rc2cneUnTdvdW9D3ZcmCZdR7eNvmFehFYTS0gONn3iCNUKxgO4O9m9yuC8zWA+tJuzT0Db2knh
PQRl75cMu+ZzwDYrQuRaIGA1I280lX6y2CfNtxlUawrvnbdbYLx0OR8WwseI3VWVGOU+sA7kqFNl
RZVWa96Qr3Nnc7bJeHVVhrpAX6EXm3ExF/hddj8j755Tfo3Ias1oxLP68bKY8HqeBtjbyIuo5e88
mJzWPL+1ugv27oIJlt6IDBfriu28HPSGvS2/uP4bW2Xldqz8ne2fXKtmmFCX/VFHaGPX9gdFP6Y1
X5zSDo88u+mQGYTKjTXfkzeayjoyToZGZVIYjv25zXyxPn7sqTgrHnCLD6Ej6ePl4hEBoGbG5zIZ
hAdOwngAAOMBAIwHADAeAMB4AADjAWAlxrPxv72XCXavKUiR/VCemA0A2MjGU4jHcy4HgG0Yz9ya
XO73zN3LpuXxEMCNedTo+C2J2UvRvVYl0fTJ6gjNEDKcAICZCK5JxnT9o8um22v/9IaHKMOZ/ujC
8J7jFEvRu1ZtVDz/rvoKAFiU8ZzncBCnPJEr6ck8iiZGwSTIiwAAKzGeBt9ivBNwpr8eovyoh8Kz
xgMAUOjVGMaV8oaZRda49VHKIsDaA6uOXNNmntNm3rHqxLHUw7OP7EWAmQdWtvFXklLTjTW1u93t
XjbtHltPAn3U052dwCHFZkii3eqNikteBPduADAdk96BGpk2yZxV8fsGcIvY+B2o4i8m8KhXDQoD
hxu5JkALxLDioX8AVYxcAQCMBwAwHgDAeAA4AuO5gxNB/UxU9AOQL5RnNwW2d6ChB7aBMVeT0ifO
nHE05ZHz0sbMDrC8V8OGSL0XwztSeR3ahEX0dlrci+q1wr6T0vckhoYe2MXGmzZ3EKmTkr2bovXG
Vqz7encnLbJk7+2/6ylo6IHaRq40cu5intnSWWYyzhFecjwGNPTA6ja+dysK1FvcRMedWfJHaOiB
XRlP4yPZmMn2lO00cdgJDT2wqVfDmSZzsM4ZcnrjgL1kYkYcGnpgdRuvhfBa0t4kFPGNLaK32Gtd
ZCjs23ShoQe2x4O6SQIN/flxqG+EAMBJ/PhaAA09ABsPAGA8AIDxAADGA2A8qgAA4wEAjAcAMB4A
wHgAAOMBAIwHADAeAMB4AADjAQCMBwAwHqgUb//0jbeeg/HAbeD5m6///Vf/fO/pTpz/2j2aANiS
77/95QefX3e++PQ3d5/9/LLz/b9tmgHjzW7R/j+8ZqtfuBX9ycsZ0cVoo0px3R+idUGXuBu/qbsL
hK4FVScjsXQ1+sF6Y9SjWbfhxPVt+6SHjRswRBZmA7sJGHdeje/fff6xcfjkq69e7Phmt5Tdn8l/
p4rFNULXhG1su/n6oMCl5yO8qjJpFjwRK1Arwqg2nYjak+N9britcJtMOjlQkYWRVS+B/sSK/Hvl
6Y/ebwn/uD/x8lN68srGbXcfMR7CNOlOPZrVojpoe6rbl+I2CN/XgsyKFSF8+jZyoY4ZsuplWVmE
76/x+19c6f5J88nlb9j+5U/v7jty7bq67J6qlk0wIwlRUNOng7RqQUQMox1LRoIX6IAy1kG8M5F2
28CvePD4sw8vFL/suX9//cEbD2qZq5FNjNj9Q3KU+6cmvHILIl6NHauU8EvUrYy0WziejHbdJfC7
l/GwH75VC+M9r67vAr23f3kCXOyKbG4UUi4XK3BZdt3GTXzxaFyu93j+yb8ffbv1370/8ec/fLCv
Hx8nvJ6nAXYeR0j3cSDVJhilBrx89uqjJ89a3711aLrt23/82aZufOEvUELYvo62K52Xc1O9oS/t
SKGL6sSMnLDZ0phSE2razJ49s6MksrRlm7149tHroqV70/nwj7/z6sfvbtxsd2HnXXZT62Z9yD5M
Oh6faDwv8DYcHV1RKfc3L1jHCtXthHTHs+olsK4f3+Hr//31976pDh7/gj96sXmzFawtnFsd4nZd
+1qcnrFRsdyz/Z6/8/n/Lvb96Tfee7TMAGQ1r0YuHhFYz9GfQfiV8ejD/7z25rfe+dc/Hu1SNw+w
bC+wc/fE+vEAAMYDABgPAGA8AGDkCkxH8Tfnyj9St/EVsPHAbeHe6wi6O0zp39Y1/Zdd7WTYO9OY
X2JtE7A/zWp/WJYpkILKuw5Q6dhRuy99RzPUpe1/aE2nq/JibNj8ZHm8dMOG8LXOWhg/G+Qf+23r
f36ejXjsnnCPLtcHPmDPbkweMsSjj0TrThSIotPt96yN+SXmeOn0xvp0M1AH4zvb1TZPz9th92qk
OkvZBxgG7HrEQ3zPzKlGz/1YpfHMITbto5cC6w+Fk3PCtMAdHx2+zaQfOakES3dghvPqF2xyxQjj
te1iChkpw+wps6WZyX4bW1aalW/RBJ0TDvOEDKfJT4Eah28hz6zvtNrdach2WbxeOs7V9n7XJFOl
89yoI3WAk4xcI4znvHLHWKlCvac2BQ5oeuXHU3AHEn7ewp3JehC4vahg4BLM2xCJuxyoByGwv1cz
tAuPdwIueczwap13vvdAM5Kg/Egd1e2HFVCNH0/jbUoFTc/RsSb5Z8NcCJzlzDvHuyCN99KJxOTo
s83x3IBq5moSk5QcDBiOglMR7Bp7inQj72LiyHQeTSWifW2sU8wywrT44+sgbvyEatv4ivuYu9s9
fUnPRPe7/dOZrClz44gDo0B9TdC8ETtct0/Yt2pG3PRQ9+hORG6vk4/OGup0dSUYG07OsNtxVSpH
439+h+VCRnIxg4vvYMWepDJgWqh2mk3SyU5o4g35/L8p5XfR0soor7ziO9h5vy8v+1Tf+QCPcKY9
O+YpQLXf4X75+1F1lUer3pG2aeh9fRo+Td6hJAP28/n3uAOWjwdGR4mZBOMaH3Ve3sF4YNzP4yyz
SlWaeDfvYDyQQ+WC2cm6CO/l/d7qDIEx2KC+pbI8ubIsdw7aVJY1Mb1746rLjaFIQsRuquUxk7K1
G1Tm3FCxL8Tz3Kf7vJ48kzcpIUlIkK5/HLWFm+pMWsRuqeUhRl/Qu1ky4l4XhOZqmHnYcK8sY3Wa
FZ+60MYJ6a+107qEmIEqXY72J+Pn13lPPbAdGB+5Bl7wcaTyjfPeEoVssWNnndeATE25795QrhMX
dIlstTyMPJA/V0Mj52wtPGXb1OAbElGZI9mOTpMrYocoF8hjPJcOKTi46x/zlDECKe0Vl7pyYDuQ
x3gaH8nGqOUp4SmfgklB+nSdO7AGwh9zS1+gPzAjnW8HT0gxkEJ7OpKCPn8/zyEg9n524KQNd1cI
MXX1iQfAKiJ2YAYKFwS+Mq77sJXQ3wS16SnXzIBMzdUQczsD2G0GBqtj/8jYJ2YKpOUmTHrS5zqP
407wGJ3HyUzTRDVNfRT2TqBXrGnrhfrmo/o0oTrQZxS38z70m5mitvVi+B7T8J0idaQ/mChUTMfG
k+PVWP/b40szElm7ZI5hyRzTOtfQmBfjXpO27BTMELAq4aXxEWtpWW0h3TNZZrksxf5s++1h8+tv
3pG+/ngqA+IZL8AACzryxlfapYh9r1Y6V8S99sIUVQrSTMh+jEj7i4cy5cdXTfkVYwOFjnHSUbEZ
Z30s1rfVpSnK/K45OlcDACVeTbJbxL95I4NBc1LMyiHeCAFmuzcueYVnXqVo8qmalWKOQRehk7Dx
wBzfRmjXufc4jFOmDxL4iHjQyGen6I8E+nj2VWZ6LfDFBODcTlcDPx64HW8rcB42HrgtYOQKgPEA
AMYDABgPAGA8AIDxAADGAwAYDwDr4/8BqE4foyHyUU4AAAAASUVORK5CYII=
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-10" MODIFIED="2009-07-16 11:13:00 +0100" MODIFIED_BY="[Empty name]" NO="10" REF_ID="CMP-002.03" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of Comparison 2 Emdogain versus GTR: 1 year; Outcome 2.3 REC.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAvgAAAFQCAMAAAD9W/rPAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-11" MODIFIED="2009-07-16 11:03:59 +0100" MODIFIED_BY="[Empty name]" NO="11" REF_ID="CMP-002.04" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of Comparison 2 Emdogain versus GTR: 1 year; Outcome 2.4 Postoperative complications.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAArcAAAEACAMAAACeZK4VAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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==
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-12" MODIFIED="2009-07-16 11:04:13 +0100" MODIFIED_BY="[Empty name]" NO="12" REF_ID="CMP-002.05" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of Comparison 2 Emdogain versus GTR: 1 year; Outcome 2.5 Marginal bone level.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAtQAAACACAMAAAAccw4KAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-13" MODIFIED="2009-07-16 11:04:25 +0100" MODIFIED_BY="[Empty name]" NO="13" REF_ID="CMP-003.01" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of Comparison 3 Emdogain versus bone graft; Outcome 3.1 PAL.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAzcAAACACAMAAAABKGe4AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-14" MODIFIED="2009-07-16 11:04:37 +0100" MODIFIED_BY="[Empty name]" NO="14" REF_ID="CMP-003.02" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of Comparison 3 Emdogain versus bone graft; Outcome 3.2 PPD.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAycAAACACAMAAAAmhuZQAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-15" MODIFIED="2009-07-16 11:04:50 +0100" MODIFIED_BY="[Empty name]" NO="15" REF_ID="CMP-003.03" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of Comparison 3 Emdogain versus bone graft; Outcome 3.3 REC.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAzcAAACACAMAAAABKGe4AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2009-07-16 11:06:30 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2009-03-25 14:18:45 +0000" MODIFIED_BY="Anne Littlewood" NO="1">
<TITLE MODIFIED="2008-06-20 10:15:48 +0100" MODIFIED_BY="[Empty name]">MEDLINE (OVID) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-03-25 14:18:45 +0000" MODIFIED_BY="Anne Littlewood">
<P>1. exp Periodontal Diseases/<BR/>2. periodont$.mp. [mp=title, original title, abstract, name of substance, mesh subject heading]<BR/>3. intra bony defect$.mp. [mp=title, original title, abstract, name of substance, mesh subject heading]<BR/>4. infra bony defect$.mp. [mp=title, original title, abstract, name of substance, mesh subject heading]<BR/>5. intrabony defect$.mp. [mp=title, original title, abstract, name of substance, mesh subject heading]<BR/>6. infrabony defect$.mp. [mp=title, original title, abstract, name of substance, mesh subject heading]<BR/>7. or/1-6<BR/>8. Emdogain$.mp. [mp=title, original title, abstract, name of substance, mesh subject heading]<BR/>9. (enamel matrix derivative$ or enamel matrix protein$ or dental enamel protein$ or (teeth and enamel protein$) or (tooth and enamel protein$)).mp. [mp=title, original title, abstract, name of substance, mesh subject heading]<BR/>10. or/8-9<BR/>11. 7 and 10</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2009-07-16 11:05:19 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2009-07-16 11:05:19 +0100" MODIFIED_BY="[Empty name]">Cochrane Oral Health Group Trials Register search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-03-25 14:26:15 +0000" MODIFIED_BY="Anne Littlewood">
<P>((periodont* or "intra bony defect*" or "intra-bony defect*" or "intrabony defect*" or "infra bony defect*" or "infra-bony defect*" or "infrabony defect*") AND (emdogain* OR "enamel matrix derivative*" OR "enamel-matrix derivative*"OR "enamel matrix protein*" OR "enamel-matrix protein*" OR "dental enamel protein*" OR (teeth AND "enamel protein*") OR (tooth AND "enamel protein*")))</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2009-07-16 11:05:50 +0100" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2009-07-16 11:05:34 +0100" MODIFIED_BY="[Empty name]">CENTRAL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-07-16 11:05:50 +0100" MODIFIED_BY="[Empty name]">
<P>#1 PERIODONTAL DISEASES (Explode MeSH)<BR/>#2 periodont*<BR/>#3 (intra next bony next defect*) OR (intrabony NEXT defect*)<BR/>#4 (infra next bony next defect*) OR (infrabony NEXT defect*)<BR/>#5  (#1 or #2 or #3 or #4)<BR/>#6 emdogain*<BR/>#7 (enamel next matrix next derivative*)<BR/>#8 (enamel next matrix next protein*)<BR/>#9 (dental next matrix next protein*)<BR/>#10 (teeth and (enamel next protein*))<BR/>#11 (tooth and (enamel next protein*))<BR/>#12 (#6 or #7 or #8 or #9 or #10 or #11)<BR/>#13 (#5 and #12)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2009-07-16 11:06:30 +0100" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2009-07-16 11:06:12 +0100" MODIFIED_BY="[Empty name]">EMBASE (OVID) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-07-16 11:06:30 +0100" MODIFIED_BY="[Empty name]">
<P>1. exp Periodontal Disease/<BR/>2. periodont$.mp.<BR/>3. intra bony defect$.mp.<BR/>4. infra bony defect$.mp.<BR/>5. intrabony defect$.mp.<BR/>6. infrabony defect$.mp.<BR/>7. or/1-6<BR/>8. Emdogain$.mp.<BR/>9. (enamel matrix derivative$ or enamel matrix protein$ or dental enamel protein$ or (teeth and enamel protein$) or (tooth and enamel protein$)).mp.<BR/>10. or/8-9<BR/>11. 7 and 10</P>
<SUBSECTION>
<HEADING LEVEL="3">Filter for EMBASE via OVID</HEADING>
<P>1. random$.ti,ab.<BR/>2. factorial$.ti,ab.<BR/>3. (crossover$ or cross over$ or cross-over$).ti,ab.<BR/>4. placebo$.ti,ab.<BR/>5. (doubl$ adj blind$).ti,ab.<BR/>6. (singl$ adj blind$).ti,ab.<BR/>7. assign$.ti,ab.<BR/>8. allocat$.ti,ab.<BR/>9. volunteer$.ti,ab.<BR/>10. CROSSOVER PROCEDURE.sh.<BR/>11. DOUBLE-BLIND PROCEDURE.sh.<BR/>12. RANDOMIZED CONTROLLED TRIAL.sh.<BR/>13. SINGLE BLIND PROCEDURE.sh.<BR/>14. or/1-13<BR/>15. ANIMAL/ or NONHUMAN/ or ANIMAL EXPERIMENT/<BR/>16. HUMAN/<BR/>17. 16 and 15<BR/>18. 15 not 17<BR/>19. 14 not 18</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>